var title_f4_47_4848="Trans-urethral bladder catheterization girls";
var content_f4_47_4848=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F50955&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F50955&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Catheter insertion into the bladder in females",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 395px; height: 303px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The catheter is inserted into the urethral meatus until urine returns. Catheters that are inadvertently placed in the vagina may be left in place to serve as a landmark for subsequent attempts.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from King&nbsp;C, Henretig FM. Pocket Atlas of Pediatric Emergency Procedures, Lippincott Williams and Wilkins, Philadelphia 2000.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_47_4848=[""].join("\n");
var outline_f4_47_4848=null;
var title_f4_47_4849="Urine sample with chyluria";
var content_f4_47_4849=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F60451&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F60451&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Urine sample with chyluria",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 363px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAFrAbADASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwDkLZSgfzCRTfI3ncGOKjupjMrEcYpLLzfILEfJXXJpWVtDlinvcmwPu7+adBYqGLmQ5+tQIqFt+eKsGWLaNrc0NJWQ36jZk3H7x+WmxylpAMnApwkiYFSeTRHEqHPY07p3ROvUlluSjBRnFCzYOc80x9hbrQkak/MeKqPLygSSSll6mqpuWV8AGnXLhTgVFvAYFqaS6u1g9C20uY9zNg+lQNNvXGTSTlGjyDzVVQ2OKd432FZ2GzMyODk16B4E1IeVsfj0rz7l2w/bpVnTr24tL+FY87Ceawr4enUpNNm9CrKE0e4WkwJ3E8+laEdwWfBGBXO2EyyRwvn+HmtZJkc7VPNfMtW0PooKLV11NT3HSneYQMVUhlx8rdKeHPO7gHpUg4Epk+RgvOapyARRNI5xUsR8vO7qelVNUINsxmOFpopR3SOQ1S5865bHSucjhM92wyRitm42ea3lHK81hNOYbw7O5qkWlZHSabAkhAkfaV6c112nXckUHkImUIxmuGhPzRuxwOprtdMulNgTFg4FK5Mo3LENvsn8zd+FdLaR/uw+a53TWM5+b1rp4F2xAUIwr6WSFkNR7wvBPWnHnO6onUM2TVoySHhsU9n+XjrURoHrTsJpDWG/qcVVncsjKelWj3qlMwGQ/elImyKMVx5LEDmr00nm2XH3vSsDU5fIYsh4p2nX5lTrU3NHBaMvxTbk8tuCKbDeCGQg1XJ/ekniqWokphhQrvYT5L+8W9SumeVcD5fWqV1M23CDK+tRCaWWI4Hy+tU7jUobS3YTEbe5zVRV3Yl90EkqopOea5/VfE1vZpKsrBTjjNct4h8UtPcm30dmeYnGBTNH8H6prk0cmrqyJmuuNJQTlN2/Mle+1GKuY6zal4nu5oYrciFjgOK7Twp8LvskBnkuGDnnbmvTvDPhqDRrJFiijPHXFabQLgtgAD0rGeKlZRhojpVKCbc3dnDx6Z9gjzuJIqdvFdjZQlb2ZYwB3rcvrZJgdleQ/Ffw8lxZDZIyv7VNGMZS5ZEYhtx5ol7xB8WrO0Ei2pWX0968g8Q67e+NNWUiDYmeorS0bwTbyBWu5Tz611Vho1vpYC2qqw9cV7lLBctmtLnjVK9m77k3hyzOl2AiLkkr61ou4K8tUJ6jdxSsiMvJr04qKVkcMm73GeYM4LcU9CIvutnNVJQudoNPVQi/MetU23ohIsF8NlWzU8UzB884qtAqhTk0CTa2P4aShGOj3Hzt7E0rnzC4JqNroyMAeMGoJZfm+XpTAoYg96ppPcWxAjAbgQakW9SOExEcGrUUcYYgjJJqvc2yCTBWuNJuyvsbt7tiWjRu23+Gi6hCsSh4qS0s8y/KcCo7iN0lKs3BoTd/eE32Etokc89atsRGQG6VELV4E3A5zVfLnO85pxTlK9tAvZassFPMk3J0qSRCVwv3qS2OxaV5MtleKi11qJ6FeRMD5uoqIFWByOlXDgjnmnKsSqcjOa05r6saKCxF+V+7T2+Ram3hOg+WoXkDN935auLcde4nZ6MqiOV5M/w1NKHUq69Vp/mdlpqbpG68UlKKurbhrp5HeeCdetniFtc/60jArs4bcpOGH3TzXjGngW2pxTIOFr2TR7z7ZaK/sK+fzCh7OpzJaM9vAVU1yt7Gmm3d89SJ+8znoOlVgeam2smCOhrzrHpuzJIf3jHd26VDqkPnW5D/AHauRqDgDqafeWbG2Iz1oWpnzWZ5hqXl2kpA+5XO65qdnZKkjj5m6V0fiC2L3DRZ5rzT4jMtnbQlxnac1tRipzSZdSThByR2enXwkgVpPusOK7Lw+sn2Jyh+TFeK6F40tLhba12AMBivbfDURlsFKyAKy5xSqU3B6oIzjNe67m9o3HSukiLke1clYboL0JnK11anMeVOKzSMaq1J2wB81RkBxle1JDljhuakdcA7eKaZgRDkc1EGPmYpS/O2o4+JcE1V77APnfyxn1qhdfMuTTrx97EA9Kht51CsknJ7UnqxXtuY9/CXBP8ADVK3ZYziPiticbEYtyvpXM3sn78lPkX3pG0J3skaq3ID/vKbfTrLHwQAvXmsG91W3t4vmmQt9axr2+nvtPuTaNjCnkV0xoy1vp+pzuUVbs39xY8Q+NrLRIHjYqW9jXmVzquqeLbhotLDqjGs/wAOeHL3xFr8jX0haJH5Br3bRNB07RvKFpEFcKMkCt244f4VdkJ86tJ7GX4A8E2mmwLLfrm/4JJFen2TQ4EbBcDpxWCLgPNgD5vWr0TFeT1rgnKU5c0tzsVSMYWjsb0rl1AiPy1UlU/dHQ9arx3BKnDYxSpMXyc1L1IuMliWNcr1rg/H1vG1kXJGQM121w7sT1xXkfxq1OTT9KVo35bjFa0P4iCUl7NnJ6Re/abp4T0X0rcVWHI6Vx3gdmdRPIpy46muuLkHAPBr62ilyXaufN1n7w4gsdx6UyRgBSKzecF/hqd0UHJHFaQVpXM2VQFGCe9SyqAoJ6UkYWSQjHAp+8YIYZArXSxKuRRncfanylAPao85BKjFCDcMt+VQlbQfmNaMFcrRAMNzSyPhcLxRbn5uabHYfDEYpssc81duYPOTzCNoHemXNtKJQWGDSyTSMvkyLhD3rjSsrrY2bbIoFx/q2yahmgMr8nBFXltWtYfMh+YVULs8gOPmPUUoxTXMxMkiDCPa/OOmaqyRE5bFX7vKqmRiljAchSODTim9bA2ijbP821hxUVwWSXIHy1emhCz7EpsyBl2d6pRSd2xNu9kQQHzFNCAqSDUqKIh8vJpJGc9qqDs9ES1fqRPwduM03cCPL2Y96nxiMn+Ko1YMORg1XM5a7CaIjEFFRRja/Wp2O47fSo3j+YGj4X3YX6C+YY5AcZr0bwhq6zQi26NXn2QcdzWz4TLprCtzj0rkx1JVabu/M6sNWcJXR6zHEd2COlWo23fKR0qGGbzPvDFWFINfLM9+nPSxYtog53Zxird0f9HOfSqtsrZ46VauQGtyoPzVUdgbXMjynxM72940m07eea8n+K7iTT43PcV654umkd2twnIzXiHxRui1vFAeq1vhYOU7roaYqajTd+pw1m7W88VxGPuc17f4A8YT38cYkJjRBivIdAtlmVRJ36V6J4esJLeHYq7UYdRXpToRqK8jzI4iVL4T2fT9Xge6UiQMa7S2mEkYZWzXzbaazHp2trbmZjz617J4b163mjVI5Nz+ma82vh3T1WqOqFb2q13O3inGaWWXdyDWcJAo3A9aXz1Vgc8VzbjZYZix6YNVppCvAPNE1zuYFOlZ93eJFlpTgVRN2PmwvzF+TVZ51QZY4HrXJ+JfFthZRsWmwQM9a8n8TfFS43PFZElexzXZQwkpWnPYyq1Vbljue2ap4n06zUrLcqG9DXkXjn4lqha2sxk8/MBXl9/qd5rLNcSzuHByADWHM0jOfNJLe9ddOgqcOV6q9znlUu1Jb2sb174iv59shmbGc4r1P4XeJEvtJvor3CFEOCe/FeaLpqDRoZyBlq2YbWW20svbZXcvO2uiVJzVmQp21Y/RvF95p+q3v2K3MihzjaPeujg+J2qpKDJYvx/s1T+FEUZ+0maJHYk9RXdXVrb7ci3jB+lbwwMJpSluzCpimtO2xHpXxHMmJLmHyj7iuqh8e6U8Sl7uNWbtmuBvNEt75CCRG3tXJ6j8Px5hdLtwPrWFTLofZVzRYyT62PfY/EOmzIGt7xHz1waRvFGmWgLS3aKfQmvnd9J1PQl/0GWSbPvWPd6frepS5mMi+2TXK8rkjo+uK259EXvxM0uJyq3EZGK8O+JXig+Jb5YLd96BugpuneAzPBvubl1k9M1s6R4ItbGcStL5jDsa7KWXSi7pHNPF3Vmy9olt9n0e2UJtYCrzKwYVbAVVEYAAXpQ3I+YYr2XFRsjzr3GBflz3qYoPIzn5vSq4ba1Lk7s/pUh6E8caom4dTVc/f4FSsdq5z1p0ajGe9F0Go1VDEHGBTZIwr788elPLkPjFNlGWy3AqW+ZaBsQNH5jFhTNpRh9ald/KGV5FNRi7AvwKpLSwamxDO1yGMoG4dKp3Kyu23FJbXSwbldTuPSpI1kaTzM8VyN8nuo1VnqOiuHhi8qTpTHjCES44NSSoC4Z+lW7uNZ7NVj4wKlR1C+lyhPMtwox2qPLCMsnUVNYQLuIPbrTp4xvBjICDqKqPvaJku25HYfvvmb79JMm2c+tDyLGd0QpzfPGJD1pOPK7DuRvGuNw61GrfKQaej7jim3IAxtrSPM1ZE2RAXweaiDDzM9qkxvOMUNblOT0q4yXXcGKoGdwp4VT96miNlw3anMc4GKSdtJoW+wCJd4YdBWt4fk2aorHhKoW67ThuhqywMbB4+lKpTU0+bYqMrPQ9ZtWDoGXoa0WQ7VK/jXEeGfE1tCqw3IGc45ruA6SQCWKVCrdADXylek6UrW0PapVeaOopuCrKsf41LJOEGWPOKpfZ3ckocUyezl8kyNOuR2zzWaKnNW1OO8QSIb2Rz97Br55+IG+91Rki5INe6+O5xo+nNeygsCCMCvC/319fPeLDJsfpxXpYOCs2jKtUcviZFomnz+ZBntXsui2gWxQTAZxXnelRXAkDeVJx7V6Z4dE0tnvmicBR3FeirWdzkm2rHj/jCFYfFGYic5qodf1jRJ1uIWYRk+tdN45hifU/MRcPnrVG90l9Q0mNQcmonT5lZmiqSjax6P8AD3xpd6zbAzEkryea3r3x7p1mxjmb5wcHmuS+F+nR6dZXCuvzbTXNa54Ym1rUJzbE/e7GuFYSNSbWxu8S46yO4v8A4l2UUTCF/m7c1zE3jG/1R2CFvLwe9czN8MNVj/fOxKDnFdR4as7W1Q2sqjzQK3p4eENEjN4jm1T3PKfFOpXNzfPHKzYB6ZqDQtJa9nQyDEWea7HxZY2Rv22x4YHmqsONirafLgc1socr11FdS1LFxothAESy5cjmudvdKX7d5cvDV3ml26Nalmx5gHBrlfEVwIJeRmXPWtpRtFMxvdvyLWphINHhgTsRW3GjpoY90rEuk+0aJA5+/kc10lpmPRQJjkbeK2gu5ErW0E+GMTLNMW6Emu+v4yQDHXE/D6QK8/14rtyWYZzgV0037sdDlqq8jNjiO7J+9UMspDlWrTZM/MDzVQwh2JPUVUKco6xIckyFDtHzKDnpkVG7BXG5V/KrHytkY5HSoxFubL1rzuT16EpW1IJcn5lHNQSMUAY9auS4XpUYjE3HpUTTa16j6jJtojRh1NBw6Z9KjkYbxGR0qcx+Wo9DU2totx3K6gFuaG+9x0pZBwSvSow2RxT12Y/MehBOGpQzK2B0o8kkZFKwK4zzisvZ63Q7jmyXBolQvwelPRS8ZI6imfME96ceZvUTaRGEX7rdBTJRuICdAae0ZC7jTEcFsDitFLWwdLmnfxRs4CAZpsE5tnELLkmmQiR5csO9TzEpKHKciuSzbaiarTclmtSy+YWwPSqi3JVvLB9q0XIng3OdvtVCGzLykjoOc0la1+oeQ9rd0Qup61VCucoG61oRSFw0bjGOlQxwbZN3aiHeIn2ZB5RjXa4zTlkCrjHFW5MSjafzqp5P7zH8I71ootRbuTfW1hrx7fm6A1E479atSMJUKdNtVYw24g1CXu3W43vqPgQSc4xTbkHOB0qZFwcHimygA4610KDUbsgIIiyjPSrC2yyDgdKSFgVAFW4Ux93mk3C3uhrfUrfYyAeeakSJlT5gauKmGGafK38IWp5dnIpPsZU1sZgRF8rDvVe01vU/DkpeZ3njHRetbaJjnHNKFjlOJY1Ye9ZVqcK3QcakolGT4y3CARJYPn121HpPifVda1uOXEiQHkpWkLG0H/LrGc+1bWhJb28ysIUXHoK5fqcLOyNvrDJ9X04aunkXSfusZwaxZ7XRdJhMe2MlB0rb8Qa0fmjjTb8vUV4rrck0upvmdvmOMZrH6suVNqzN6VWTurnpOheINHa4I+zIQvtXolpquk3ejOYoEiwPSvD/AA1ou1ldXJLda9Gj0pl0d1DlQR2qKmFSs29WEql9jyP4hX1vLqjRQFc7j0o0Fj9mCFs47VjeJNHZddLeYW+at/QrARYZW3N3FdsVKTdyW+VabHV+FLoxQXoMZPymq3gyZpby7YknDGtbw7IkdlegqNxU1keAlzc3xAz8xow0IOrpv1M6s3ya7HWXMzyQ7SxxXnunws/iuQB+OeK9Ckj3QEEYNcjp+nCHxA827J5roxCSfuoxoN9Tk/FdoZdSlVByKwWtpLWVAO/Wu61pFGoSMQMmue1FGaRSiZFcsY73OtybNO002R9KaZHIwM1yGr2+bdmkG5wetehaVIi6Q6sfmx0rjtX5BUDPNaVIqysKMu5XnRn0O3C8HIrpGjI0OMdTtrJSMNp0atxzW/EP+JZtPI21rT1bXkRLoyp4IQxzSfWu8cHyww9OlcX4PIiuZAe5ruHO1Q3bFdFK8aUZs5azTnZGeZmU9PwqQfOMjg0/YJH3AUmNjHNaci5uZPQht9SIoGzjtUJB3deKkWQ7iO1RTEKDz1qPaa6LQOWyuRTkbs9qjVSnzqaTG/jPy+tDDYPlOacn73LcF5EcziRhhcH1p8jnaAaVsKu5hilgHnKc1Uo9ZCT6AigREnmosAfMBUoQpkU4KCOOT6VMnZbalIiSRiCADTYWG5t1PMvlEjbyaaIg5LZxmlF9bi66EyqPLLBqRZFKYxUYjwMZpyJtFWnJ6WsLQQyDoaqTEbxtGOaszIMZFVym8jFJpJlX0NOKfFypI4zV6/ZZMeX1qKOFEk/eDvT5kBkAi61y3es0rGi7EM2RbfPwaWwuGxtI4qe42rDiXk1HYtChJYcHpUNdXsNPoJIVeT5OtTONqbT1NRi1ZZTIh+U80y4ZzKp7Cru3qhabDN2G2nrT129GqVxG0W8D56gYZj4HNCimnLqHM9kRyIqEkd6ru2w5qQpIx56CpDErpgjmmnKXwqxOxEh8yMsetRlSRk1Zii2jB6VGzBZNp+7Wig+X3mJtLQkgj4G2rkTCIgHvVOOZUYYFXwiyBWFEuSy5BK/UtoFYjNPkVU6daZGMDPpU+5GTJHNS42d5hddCvGCzUEZbFKH2tkdKcSCRt601a/ufiGvUmjUDAq9CoVcr1qpDgY3dasxBvNBB4orTbjZ6BBalPV9iQM8h5xXmFza+fqLOvTNejeKJo4bYtJ0xXkOqeIY9PuCwGQemK5JTjon0OylF2uel+F/3DxrL0rv7yUHSG8n0ryP4e6wmqBnl6DkV6X9si/sKaRSMKPWsKt1y32LcfvPGtdaRdZZnAxurR0OXbOXHQ1x3ijX0l1hkT+8RW94VZ53GWGK3pyvJpBNWiel+H7eOaxv5E+9sNYPw5mC3OoK3UMcV0nh4CHSr/bwdhrjvhwd2o6gW/vmqw03Ku1L4V1MaqtDTc7zzAyndWUlkwvTMo4PtV2565XpXYeHtOiu7IEjmozGt7FJxDCw5m7nlOu6a8js8Iy3euG1Fr+G6WOJCQTg8V9GaroChXMK8454ri5dBQ3DF42yP9mvOjj7u9rHfGhdPU4i2gdbMbshiKx7hIt+2X72a9b/sq3EB3RnI9q53UfDcVwS0aHd9K2hj4yV5aC+qzTtucBeuvlIkXY1uQZ/s3nrtp+peFrkxqLdHDg88VJJay2lh5cqtuA54rrp4mF9ephOk3ouhn+GQ32tiOma9CG2SAL7VwHhcN9uK5wCe9d/MFh2Y9K7qb5qaijhqxtO5WUGNtq1BdlhzViWVduR1qqN05I9K00eiI82RBgoy1RToZYyy9BUjoC200SgxRlFPWlyyStEd0ytAjFMHpSFQGwKfEWj4aopdxbKVSilG8VqS782oSBnGHHApsRMXFSBvl+aoWzI/y0kr+9Lcb7IsBt7Dd0qCRmjmyvSpfurSDDDJq3zPdi0WxChMrndTy4Q4FDx45SmyBVHzdaTSWtrgtB+9WOF6mnDcvD1HDF8pdeop8bGRsN1pWch7D3VCnvUUSFXyKlkTZyelCfMRitCTRuSGkwODViO2Kx792TUCxNcSYxippi1qPLznNefeXMrG6StYZxM+16mNqkKFjgjHFVyjOMrxUkkrmIIatv32mh2VtCGxutrSK/I7VNDEHfcTxSWtku1mByTUa5jkKZpJTlqhNIS4+SbCj5aSCRUkJZcg1cxHswSCarlAjk0ezT1b0DmsNIG4sOh7UJhgeMVLBAWLE9Ka3yE8YxVJ6WWxLXVlCcMH68U3Zt+ZuasToZBlRx60kcPmLszR6giGPa5HGKvxNtAwaqvFsO0VZhTAGTWiunaRO+xaS4A4IpWuFPQYqHbtcEcimzAO+BxWUYczG7Imkb5MioluQDg8Gk3hV2mongEvzA4xWtXayFHzLaznFaOmNvlCvIAPU1lQgbdp6ioNW8y3055o3II71hXc7e8XTUW9Cl8TJmNp5FuC59RXnun6PDexqt5jeeOa2bDxrE921pfAEdNzCo9Rs7O5uPPtLwKc52g15kZy2md9ox2Njwx4QlsCVt5vll6YNd1D4J1JdFlUzMVcZ61xvhfUJ7S5hiLGRc4zXtVrqwXTkjfoy9aVSs04qLFLms+58w+IPAlxaX7Sux6mq3huO603VF3sWjLYxXrPjAfa7kwxc5PWsKx0S2jdTPIAynPJraVamnzQYQTatI66WB7bw9JcKcB05rj/AIe3EfnXoA5LGuj8S6oF0Q28ZyoXAxXI/DkHzbkkYyTSwEmpNsjEJcp3S/OOTxXofhVM2aqjc15hLIyyACvSfBoP2ZW3c8Us4uoxRODfvanY29uj/K4ye9Ol0myc5EQz3qa2QAbgck1ZiTc1eKlc9LVaGRPolq/CxVny+GIg25VwK7JUUJk9arSrkZzVSp9WClJXOZk0S0WDHlfP61zfiLRLKPT7hmiy23iu/mTapPWuY8Rxk6fdE/3aV+RpxGlzaS2PmVi9rrziI4Xf0rtZLgvbrk84rib47fEcik9XrrWQgIO2K+swMVKDTZ4+Kdpi728vk1LDNlSE+9TVUAUxV8ly45BranJxVktjBq+4IWMhzxTZwzTKc8CpHG75hxShC8Zc8EVSi5Xb6iTSGTMMYxk01QEG41Km3yS561Wclzx+VUrP3V0E7rUaDliccUpYN90YpRjGO9HAGaFabuugNWRCd27npTsFTntTg25TxTgMLzVe63dBqNcM4BU4pGAcDPUU8CkKBuhpryQIASU2rxTI4yp681KgBOM05gF4FFr6CWm5HISwwTmnJxjFRqhD5JqWP7340k7aD3NOOeRSSi0ok845k4FMt45o3O/7hPNTXXlmPEdedHllK5tK6Vh1u4Mu0fcpb4eUuR0NV7IgHb3qzd/OoVulF2pha6CwIWNjnrSRQpIxLnBpYwohO3riltCjQuH+92qrtRabsg8xhtSZcqflpVgLSY7CiOZ0fYelPVnEh9KE1HRai16gz+VwKrXGZD8g4PWpbg72GKR3WLA9aq7a91WFZX1KxcovljnNRplDx1q6Y0K7x1qEqDz3q4xjFXvcG2+hI0ZaMNjmmgdqkjckYPSgRNu3dqOZX1RNrdRu/wAsYPeoyMtuzU7IJWB9KGQKfan73RlaEciI0fB5pkZI4PSpW2YyvWoF3bjnpQ3GCv1ErstpGrcg1X1xx/ZTofSpInCHB71Drig6a7HrWNaV4+8XTWtkeSp4fXUtTKI2Gz2rpdP+HV9FIrwsz89Kj8MB/wC2wyf3q+gvDTFYFMirn6V49etKGx1vQ4bwz4QvIp4PPiAAPXFei6z4dlj0wGEc7a37KbzbiNdq4z6V0usr5em4wORXC5upq+g4u6ufOUmmXyXDMI9xz6Vh3+lzNdb7glOe1euyXCR3Tb1GMntXNeJPIuCdgANbRq6rQItvXY4PX1SLTgitk4qr4BhOJWYYGat+Kogluu30p3gkjyZB3r0MFFuaaIxNuS5s3aMvzAcCvQfBBLWyt2rhZckbD0Nd74N+SBU7VpnNvZxv3IwLak7HeW6qACDyavRqFGe9UbdCAD2q9GCPv14kEr6Hqu9iZRlTuNQuoxz0qwqgqTUTjcMHpWrWhJSuFwme1cx4hBawuBjjbXTykglW+7XN+I2xZzgdCtc83ayRVr6s+X9aiVfE5553118pO2MY4xXJ+KtsfidT3L11y4eKPHXaK+rwE37N2PGxKTkARdnXmnRoGyDSpGR1oAIb5K64x5W7I573RDJlHwOlTMQEwO9LtAB39aRB8pzUr3JNsbVyAqMYJ4pscYVye1TOm5MD71KkTBMHrSVo6tbhq9CtMoByKYMEgVYaMc5psaphg3XtWi7LS4aETAD7tAXAyacsTBuelSsVA2mrS6IVyscEcUioVyWqcxggFac+0gBqOorlQfewDU4j4yetKyKpGOtSopx81O6JSZAEYnpTDkMAPWrRcDiqzZ8zI9aS8ymbcG4EiQ5zTi0QfZjrTImJl2N3NPuLbZOozya8+KlKW2humoogkK+btjGDViRlWEBuWot4B9pKtx71Ddho5SCMr60RTlOzYP4dBLdsPg9Gqa5gMS71NMig8xdwNPdWERUsWq7+1lZbE6pXHwSRyQEnHmVWnZsYXrTIEMbb88elSk+cTgYpR9xtWBpSVyGBGYkk08xGVSfSkjjYMeangbZlcZzRFOY9hkJxGUbrS2yDzcPyKkkjBHB5pIlx1qnGEdhXk3qOZR5hx0qb+DAqP1I5piMSSKdpW12CyXqC4BOKQozNz0p68dRU+9fK4HNLlX2RXtuUpEHQcVHHIuSGFWHUt7UkkC7QR1oWj01AbAUJ5HNQ65Cx01z2q7a24Y8mma98mmsM1FSTSd9iofEcJ4RgY67143V794eQGMK1eE+Fzt1cH/ar3jw4m+JTnmvExW1zqmm9EdPp1vuu4inABrc8Tsy2YA9KreHbbzG3NxtrQ8QqGsyMc1yKFoMpbHncUMLSFpQDXGeI4wl25QYSuvuo3i3FQSc9K5LxHdLPCYyNrgUUl1HG9knsedeMLrywik5zWh4QTEW4DqK5nxXNvuI4zzg12XhMBbFRjkivawOkkY4lvlNO5G0b/Su48FyB4l7HiuIdOMGu18JxjylAYCjN7Kl7vcMF8Wp6HACFBJ4q6uWAqhZsWjCnt3rQj4rw6buepLUkAO3PamZyc9qsIdw6cVDKMNkdK2fcm+pSuCMnPSsHXtkljOAP4a6K5UOnArntbYGzmUDkCueehpHU+XfF6BPFSq/OXrrinlJGR02iuS8dH/irI/8AfrsAN8EYP90V9Tly/d3Z42L0lZDlbcuRUUTbJCWHFTRfu+oyKRirMTiu2Sb8kcqaW5HI4duBUgTin28IlyxGMUjt6dqUnz6W0Q9iPgNgdaayuDnNPOfvYqJnZugqOaLd+w7MaFLtTZioYYHNWXXYg9TTfJGQTRGLqPmYaJEWaayqeakmGDwOKFj3DOa2vZ2F0uMRewoEYc5PaniLnrSiIjvRdkkWwE5PanE1LxEOmaaw3DOMVTVh3KjxMTnPFMI5Aqw7EComTBBPepWu4zdkRQ/mL1FMEjz3AZhwKkfCPhu9SSri3LR1wOU21fY1srEUhZpvlHHrTrhw8YRxjHeqsE75w3WrE0LBQ0v3T0pxdOM7WCTfKLCFSJthzxVdJHCOAMj1qeIxxKRng0nCRMF702+j0BRIoIg/3jUZMkUpCrlfWpwpW3Ld6VmkFuGxxTjJR0uJ3exVjZy5yOKnj3D7gyO9IG3L8n41JFcLFGyjv1pQjfRyC9hEUNKCTSXXBwOlRRo+/wA0/wCq71I371ty/wCrq0qcXZ6ibk1oPgZlTkdacgXJYnFNZwq4PShYzIOOlJq2twu2PMgYYWljyG+YcU63hVFJP3qccHg1V3LR6C0T0B9rColUFsE8USKV6dKkcK0Y29ap3TtEB6RDGQeag1uLOkuW61LEx79RS6uyto8m/rXPiFywdy6b95HnPhiVjrewj5d3WvoPQIsWqMhya8J8MrD/AGvz/er3Tw45WIBORXhYpM7JtdTu/D9yzMFI24rR8QN5dmX9BWPojASrnqTWl4m3GzIH3SKxWkAicOk3mytJtyOeK4HxPFvvJG+6MV0l1emzkYDO3Nc7rJeYGY/cNKk2m2uoRTPIfFyvFfRZHBNd54ZQixiJH8Ncf8SZUW4shF1LDNdvpJKaZbbRyUFe1grtpx3McStNepewWbkcV1vhRd0wUHiuTDkR/NXWeDv9aG7VOawl7LmfceEtz2PRrI7hsx071fUfpVC1yvI6GryZyCK8OKtseo99S0hyuMVE42mp0xj3qCbIatk/duJbkE33TXOa5GFtZvcV0UucHNYGukG1kHtWE7MuB8sfERvJ8YQKvIZxXbRqBFF7qK4v4mDHjK2/3xXaniGHH90V9PlycqW542K0kNmJX7ozS26buTUYZt3tUobaMiu6Sc7RT2OZWWpJLIqfKDimMo2ZHNRsnmOCandQkeBU2m5WWgOyVxiP+724qNGKv864WpYUGM0yfLnaelKKd3ET7jJyZCNnIp6fKnz8Glj/AHQpro0pzSvJjtYbjcORSSLhMCnkFRSYyuTWnNyrzAYR8gzxTyuVBowGHNCg9KtdxXBcY9aikk52rUpTYMdjTNqjlaXMgSsQPkDpzUIZnYA+tSsx35PSpAFOCKdpPoN2RsX9s5Oc02FmSEo1StKzvhuKdKF8navLGuSUdVzFp9CO1ijZ+RzUd9Ixby2+4OlWrcgQbCMSetV58E4PJHelTlaTdhyV1YbBblh834VNHEqNh+aTc3lYUGq6O6Ah+TUcrlJzlsDfLohL/dnCfdqUuJbNY14YVLYxiSXMn3feo5Lf/TG8s4WnZ1PgWwr8u5GgVUwv3u9VAAJfmHFW9370rjHvSTxrkYpx5ZKz3DVajnO5PLX7hqJ1KxeXHQSVbbircYULlutVJxj7qBX3ZWgiIX99yKkjzuOzgU98odx+7UscqYwByaJw5EmJSuNUjv1pHQr856U9oyJQe1JKD5mM/LQ3yoSGl1KZNQgkHI6U4Ll8dqk4AwBTlU05YjS7hGhkPy0usxhdEkLcmlhyregqfUgG09iwyvpWGJTUfe1uVSa5tDg/CqRvqXI53V7p4ci8uIE9K8V8NyoNf2rH8u6vcdI+aAbR+FeHidLeZ1TZ0uk/8fCfWtTxKxFsFHTFZehxsZ1PXBrS8Tgm3AHpWH2WUnocNqFnby2bFh89cBq5khBRjmL0r0SaAvasC2DzXmmtQSwXkhkfenpRRs7oqDR5d8QWH26zI/vCvRtKGdLtT/sCvMfiFE39pWTA/LvHFepacQdItFAwdgr28Ik7HPiG7K5Izbl2113hENuCg965ELsQ5611Hgp2N6AeRmqzKzo2WiFhb8+h6ja/NGF7ir8OAMHrVG2Hl/N1zV6Ibua8GNraHrvfUnjB6mo3I35NSqabIQOcVV/dJTKlxyDisDWQGt5AOuK3p+eRWHq4/dMBWUrlR1R8tfFKMxeMbYsf4xXXFi0EW3rtFcn8alMXjOyw2RuFdfbgNBCQONgr6HA1P3djysUldMNuIeetRFi3A61LKefanQxAfMa9aS5EutzhTu7ixLtXLU+MiU4qFmJfA6VYBCDIHNZv3VZPUrVvUJAITURXH7w/dqTPm8mnY42kcU5RbdwTISRIOKkgG0YNKAB0o3DBHep+F7aDIZciXnpQCu7npTXRupzTlG1cmiMo30DUawG7jpUh2qATSqn8XY1HKpAOa21JdmJMc/SqbyfNtWpsFVOTUJQbdw61XK3uTdIHUkYpyIVxmkRiOSKcQQQc5peySHz3NyeIztjG2nwWpgO8ncKsXBCt8vSn/etyVrzqji2r7G8bpMy7qbfPx8tTSRjyVbPNRRQq1xmU4FWblQQqw8gVcZTUuWOwNJq73JbcqITvHaq4jEoY4qzIm6JQOoFQiQRDDfeqFGUr8rFdLcjlYRW3Bw1RWqu+GfgetOeFppN3arMr7YPLxg06cXrFMHLTUZcxxlQFIzWfKjrKuMkVOIZC4JztqW8cBkSIA+tNW+G3zFZ7pkbsNwCrk1FITn5vlqw8bRDzEGTTERrg7pRir/d/CmCvuTKvmwgHp61GEEbDJqfBC7V+6KgmRiwFKHLLSb0Bq2xMWDsAKklXEWO/rUaReWuW60b2c7e1VJp+70Er7lfdtHy8mpo1GNz8VCqlZjnpTbl3dgo4pcrl7sNgWmrLQYOfTFN1mZYdFkYHnFOiiIiy3FUNe2/2RIWbisMRL3VcumveOc8GXitq/mFQTur3Xw7KseZOu7t6V4P4Dhil1bO7jdXuukwrEvynrXiYqylodU2dpoapHNuU53Hp6VP4mYLDk9KqeGYHD7n6dqu+JkWS2KscGsVrDUune2h57qMpELMr4X1rjdZWHyWkMgY46V6P/ZtvPYvEW+fmvHPGimxuXiRiQKmlZysmEY6XPNPHUu7VbQdRvFeoWbY0u02/3BXlPipPNvbJhydwzXrGnIBplqD/AHBXvYNpSRhi7uKuO3lxiur8Fyf6YExXJysI2wnIrpPB7kXobvmunMpfuGkY4P8AiJnrViWc7SOBV9V2nk4qlpDM+Sw4q7JkvzxXy8PhR7bepMgBpHAB9qcq5WmEZ4qnsSV5mxnA4rD1MAxvu4rbk+UkHpWLqKeYr1nPWNjSJ8s/GmI/8JtZAHcCwrsFxDbwqOfkFcp8bgbfxnZD1YV00YZ4Icf3BX0mVNcilI8fGr3rIZuLSY7VK7DYAp5pWVUT/aqIRkHdmvS5W3zP5HG7JWRYt1AUlqA2Wx2qOV/lAqe32+ST3o5Iu7nuxp9h4Tau4U9SJBg8VGjs0eMUnUYpRppLla0G5CE4Y4NNwGIOaRvl6UqID3oTafIthWXxXCZzjAHFMLDy6kYjG003YuPan7y0Wg9HqxqzYUA015d9RyEAkdqiRsE07OxNx7oG6nFNKhBnOaY7EmjBxk9KtqyTuIkR1bqAKQkKw781CquW6fLQm7fhvWqbTFY7FYwAS/SqckxSXbH9ytS4xyBWXPDtJIPFeaoqUW92b31sPuIQ8W5aZajyQS9TLuSDcfu1Ckm48jIpq89HoFrCrNiTB79Klmtf43pIxHDl5Bk9qd5rXjhVOFoqKN/d2CN2QysVhzH1qK3Vm+aWr02yKPycZb1qvBE27k8UudbLYVmtSNZTIxROlMkRYWy3U1eiWKHcTjNVQBLIXbkCmpSaemg1ZDsO0e7+Gl6xYFPeQPF+7HA7U2FSi72+76VKtbbUfoxGysYx1pkBLfM/ah5hI+FHFP2cDB4qufmVuUXLbqRzS+b07VNEoMXH3qRtiHAFQu7FtqDFUo3WuiD0HvgDB+9UcURlbI7VJJGWjAz81LLm3iGOp60OV7QghW6sGkJO3sKzfFcaroErVo2qGZt3SoPF4UeHZRWOLcVFRuaUk+Y474cNGt6Hbpur6B0Foiu5/u9q8A+G4T7YAwyN1e86YBsAAwO1eFiua+p0SaR2nhx3ldsfcHSpfEkTPCdnWmeGUNuDu/ip3iSUxx7gePSskv3ZrfQ4mOY2kxefOK8x+KhjjQ3a/davUtRUXdixVcvzwK8W+KMz/YVgcEY7GpofEUrL3ked3Z8+4tX7ZFer2bA6dAB2WvLp1G2xCeor1G1AFlbAD+EZr6PAq8m+xx4rVq4ioSdx6Vv+En/4mYA6ZrCucgYXpWt4MVv7SBPTNa5lFfVpSW5lhXaqke1WT7IRV2I7xlqyrCQSqEHGK1IvkGK+Vp6xue49SeM5HtSSHA4p0eBxSSYHWtUtBehVcbgd1Y9991sVszNgHisa/UqGbPWsqrSRcVqfLPx7Zh40sQ3UsMV1NixS0h3ddgrmvj4AfGlgT/eFdHAN0EP+4K+gyqPNSPJxr94kf942R1omOyMA9akyEX3pGjMoB9K9lzWiZ577kUMZKkv+FGcZValGWG0dqZkR53DJpKOnvbhzdhyM0a/N0qQhiodelEcRdfMP3akJyuFHFZSblsy4kNwRtXb170isNvHWpNoPWlVVHao5JX5itCONM/f602ZlUYpZc5yDTSAyZat10IKzEEc9KhOM8VZdAB7VCYz1pp2JvcZ1PFOOfu0BTjPpSqD941bWmjC+oBmQYqKFXaQ56VJIM/NnikQkEYovzAdjO+w81TkUyNw3FX7qIN9arhUiHzHmuBtOPu6Gq31I3k3w+Rj8acqrAgwNxpMKDvqOB2WYs4+Ws3D3brc06k0y5TLd+1QQozHCfLU14/mFQvSnA+WygDg005OKJ2ehFIdp2Ny3rTonCZGcmo7gM9xtjGTT44whIY/P6VF3sh6FdoXllJDECp1QRRlQc560sLFnZUGc1J5XkxtzljVTk9hWvuMiRUQt+lRPKZjsAwKdAGKnPWnxqEkywxUXuMjwsYwoy1KImIznHtT0RUlaTOc0iuS+49BWtNzSfKJ2vqIsZH3hTJJVT7q5arE0/mLgDpVeJAjeY/NG6stwV1qySJDt8xjjPaoPmklxjIp0splfC9KtKwt4s4yTVX5Xyx3F0v0ECiIALxmsXxnIw0GUVqozO59TWZ4xwugSiTiscUnGCgtWXSd5XOd+GEQ+0Byc/NXvtqFECEDGK8F+GUYEwZTxur3q0dWgUA/WvAxStOyZ0Tu0dd4bkFwmD/DUHieLJyX/AAqz4XREjJQ5PeqvicblMgP3e1RZezubX905yyuPslyZJk/c+9eP/HTyXiF1b42t2Feu3cwvdKaHAVuea8M+Ke+OyEBJYL60Ya3OtRr4bs42wUXSWm7gjFeoWqbbOLPYV5X4dJnmgRuNpr1xVYWkQx2r6PBSV2zjxO6SK0r7hyK2PCLbdQB7ZrMMZKHcMVp+Gm23oVfWrzDXDysZ0NKiPXNNAZdwODWrEeMHmsbS0xGpzzW1ATjgZr5altY91liFcHJpZhuOAKIvvCll4atSCrJjG0isbUlKqe4rXm5JrK1P7nNc1RuzsaR3Pln4+/8AI42P+8K6Sw/48YvXYK539oHH/CY2AH94V0dgMWkWeuwV9FlV/YqSPJxj94kWNnFTZGzaOCKejbV461GYzuLHvXqxkqjucTVlYiB8sk9TSEebyRihkw3tUhIGCK0eupOyJYW2R7afGBuJqEHPIpwY45pcqWxS8x4XeTzjFQOxBIFPnfYBtPWoWfBBHNDpuWqYuZDNpLYJqRgAuM00sGfcTUM7/NlTT20ZOr2B1JPFNYA4GaejFVy3emGPc24GqhJgxr/fGOlLI2TtHSnlcrg0xEw3NJzX2lqCTGFdo61GOGFWHRepNQD749KcVyoHroddcz9+9QRgTtuenPE0pOOKmiKQwFX5auNyjFKMTVLqRsqMdi1JNsMQQfeFVEDiXeM4q7JGIo/Mb+KpnBKaUWNyfUbAqBD5nXtVWSRvN2DqelOCu7g9quBIlTew+cVFlTbW5W+pFCRbNvk/1lEgWVzKPvGkMJkbzZDlRUtoyeYcj5aTjbW+oNobGBACV+8ajyTuM34VI8yPIwA6U0DzW56URbWrQrJjUYeWWXrULeZJ161JOVibCjiltgzyZ7VbjyLnEpX0GyREItOdlVAvc0txuLEA0kMPBeTtT1jZrqAAJEvz9TVe5LNHhelTSss4O0dKkgRRF81JThDWO4avcrwR+XCGamO5dhnpUksnmHy16CkiQbvm7U1aOrV2Fm9i1bqBgnrWR45iM2gSk1pSS75FWOqfi1XGgSKTyRWGKhywS6l0dZHL/CtgLkRn+9XvVrCFjBX8a8P+Fkccd6C4yd1e9WUfnD5OBXhYt+9sdEtWkdF4cwEPk/jUWvvGFKP3q7oEaxxuFHNY3iNC0hXuTWf2Ea9DHuoBBZNMn3Oa8O+K8iSWu9PvGvariV4bVo5uY+eK8P8Aii6MhEYwtLDW572LtdHH+DgrXMZfrmvWy5MEWOgFeT+CVEt2oA6GvW1TZAm70r3sLpujirvXQrySErg9Kv8Ah8ql0CvXNU5ChU8Vb8PbRfDPTNdWMS9lJ2M6T96x6zpALwKe9bttlVrD0ZW8sFT8tbkGR1r5akrHt9ETxnmlm56daIxlxinTAq9apC6lNuCc9aydTGa2JF5JNZGoqWBxXPV1RqmfMX7QkKr4u09h13Ct7TCptIi/ZBWD8fQx8WWIb+8K2tMIS2iD8/KK+iyhN01GJ5GO31LnAO4/dpXfI46U3aXP+zQuEOD0r1lZ7qzOBPqIwyKasRIOOlS7lkPyjpTZWIGEq1dMJDMbeKTzATilUNty3WmNHs+c9DSk7bslXewvEn4UxhwdtSKABkd6XAwcd6zbV7XNFsQrGDESetRrGDxVheG2Gm4CzY7UaIZFw3yN2o6cVIyAMW9ahbNbc0VsZO9xQaTeC2D1pEBA560YG73qbt7oexHLkn2pkeNwzT5XGdvenrGODTd7aoR1LHccR1XeJg/zHNXrFAschfrUQbcxGK4qc7XSVzaWtiSHaE+ZeKr3GZWC5+X0qaZzs2Yx71D5LRqH65ojGOre4XsPlTbGu2mRsWUqealhOVIPOaWNFQE/xelZtMe25GQUTbuz7U3/AFi7V4NIEJuNxPPpUjqFYkdfSpTlF2RTREAICB1J61JKxUAKvWmQrtctJ39aklnERAAzmtIu26JavsMWHH3zk1PtWNNynmowpcbm4FQlWD5BytZuzd29B7kfzyS8VPODhVB+tPUeUN2OTRDAZ3Lk4xWvtOb3mtBW6DGAhjwByaQRs0G7OKml+eQccCo7iQEeWOBShG71BsijCqM45qLJDnA61My7Ixt5NSxoEXcw5pttO0QuraiWUQX5361i+P7sxeHpWQbmFbEkjO21BxWP4piK6PJvXK+9ZV6VleT1LpP3roxPhPcGZQ7rht3everCYrECvFeMfDK3V5htUBc17jp9srJjsK8HFP30jpcdTodAug0ZyOaztfYSTcNg5q7o0IVXEZz61lazCDPkPxmsm3ypIsx9SmW2tGMi7+K8O+Irreq2xdvBr3PVYx9hYj5uK8O8agF5ARtGDVYaPval6dDlvhwgfUHQ9VNepsjFAM9K8v8AhqA+qzhDnBNepRKzjBGAK+kwisnLsefiPiIjFhc9as6H/wAf4z61DIfLGF5qTSAWvAx45rXE8zoSlLsRSfvpI9e0XLQLg8VuQggYNYGiA/ZkxXRRklBkYr5Knrc97oTW/wAjAHnNSXK85zUcJJccVLcLk5rZbEv49ChKpIPNZl4OCK1puFyKybzJrnqRsaReh8x/tBjb4rsj/tCtXSk32UbE5+UVlftD/wDI0WX+8K0dGcrp6D/ZFe/lEpKmuXc8rMFdq5eUMB7UKpZjQspKYxSROwY8cV7ajJq/U85uOyJQoipy7dpJGaYT5hweKTIT5c8Gpbtq0GjAgueOlJI2V2EU8OqHA5pwjVjuJ5ovfSS0Hy9iNIjtyaRULAjoamlkMYAxxTAxdgVFZuo1qkUoabkRPkjawy3rUQy75q3MoY5PWqzPtPSnGcm9h6IibduIxnFML4OMVOJtoJK9arKd7kniqvU20J0GyEs4ApChDYzUjNhgAOPWnHHY1paf8wrpdBBGMc9adHEdw54oIwuaBuyKm2m4XXRHTSMWDeTSW6MqGRqls4jltvTvSXLEt5adDXKnzS5Fokabaj2w8e81HukddoHyinjCxbCKSRvLjGyojFPRbh6kUIwTmnOMfP3FTW4V0JP3qiVG87a33TSv0GiOMM8vm44qbyiHMj/dNSXTpGuxKgWZpFCN0qXBpc9h36DJsSuNvSnywowUjqKe6pEoIpQA4ylDva6BbkW59mGGE9aRGTGFOan4MRU0QRRjgdaT5eXbUepDMrOFEY+tWmXyoRs6kc0RfK7AVDL5khISqV5fE9BPTYj3EthaJYAv7yQ4FWLZFgUmX71V7pmm4H3KqMud6LQVuUjhdGf5DkUk7sXA7VOLdbe3DjvVRNxkyehrSFrucdkS30L0CqHT361k+O326S6KPlrYXbGo3dT0rJ8SIZ9PdG6VwV0+VVFsdFJ62KvwuQhFbtmvbtKwykGvLPh5ZeVbqAOM165aW4SFWXrXi1/4j1udF9TQ0pPs4kxyGrH1tQJCF6k1vWKF42I7Vn30Ucgbj56mS0Q09DnJoJmtWGPlwa8T8dQn7TMr8DBr3e6llhiaMjjBrxvxlEZ7mfI/hNTh3aWhafRI4b4TQpHrNznpk16jcSrESqd68w+EylPEF6JugJxXpxRGdi3Y8V9PhYxa5nsjz8RdzZAcBCTVvTcGRSOuaglePGKbYMRcLt6ZretBzg7GcNGj1zQGP2VNvWugiYsOa53w9xaRkda6RCCox1r5GO7TPf0sie3JB9qlmwR7VFACTx0qWXA69KtbE6cxRkJ/Cs682itSbpx0rLvwoGTSqbGiZ8w/tF7R4osiv94Vf0PLWKem0VV/aJEf/CQWrDsRTvDUjS2C7Om0V7WUu1NanmY7Vq5qMVUVIjrt5qFYzv8A3nSrBjUqNvQV68m27XOC0ew0xktkdKlWFP4jzUXmEcelJln57VSjUlvoTJxQ9okEvBpkwYH5aIz+85pXfL4FWouWl7gpJCtlkAfinR5hU470kp+Vc07epUZ6VjKEt0kUpJ6DGVnBao3RWj96sFsxkL0qA42+9O0pLUTsiN1URjdUTKmRipXG7ANO8kLg0uSHVBzNsryIqkZ6UuxCvyHJqd0VuG6VHsCNlelVyx3SCwcbMN1pm8kgDpT2TfyKRIyG5p+pJ1qKbbILZzUO3fMG6CmRBpJfmJIzVu4QKmB1rkbUXyPVmtr6igox2459arvFskO48VLaxnGT+dQyQs8xyxAojyRdrhr0HgCIcd6VMnk1JHGET5jnFRjLSjjC1F+ZaDt3Gyqr8HrSCMIo7065XLYT86fEpCfNzWijJRundk3HLBlcv0NRuArYj6U+WUuu0cU22QgEtzWc6bSvJlxYnlHPWnxW7I+9jxThES3mk8DtSuxk5HSolNy0BWQxpFLkKOafEvlKxbqajij3OSeMU15jM2wdqrk5n5IV2IQZASxyKihG6fb2qYjy0wTyaUALAXH3qrnuuVIVtRt38vyk5Wo1RWTI4xTFjMhLO2Ki8wlyg6CtOWyUUxLUmiy0mHOfSk1mDfYMVNMwQw5qPV5zDYM2c1y42T5VyvQ3w6Vzo/BFtsslJPOa9RtICbdPmryLwNePNAp5xmvS7a7nVFCqSK8Ga5Z2ZurNnSxW5VBtPB61Tu7L96Cpq3YSM9vls5xWdfTygNtBJFEmrGtgvLKFrchiN2OteJ+K7ZVvrhVOflNen6ne3K2jEBs4NeLapqxGqXImJztPWppaz2K3Wm5x3w9iI8SXuDxk16UIiQxzjFeb/DgmTxNfP2JNehXExyVXpmvpsM5OCUTgr/FqRFQJMnkURn/SVKjAzTI/lfJOac8w3jAwc11zTk3G+6OeL1R6v4dfz7KNEOCOtdPbcLjOSK4LwZfLsClua7a1mVcndnNfF25akovue/FtxTsaMTbTUrsCOaqRvuHPFI02Gx1Fa6Deo+XGOKyr5wVwavTthcg1h6vdJHbySK2dgycdqyqS6IpWWjPnP9oeVI9dt1YZyRT/AAkwOmhVGCR1rk/jb4hj1bxbbwwEPtYA12nh1DDpqDZglRXvZQuWCUkeZjnc0TCxXBPNQszRcE5qdI2bnJqOQYPIzXtLax51xuwyEEHFPKlBjNJFlge2KYGLkg1UYzu+dku3RE0K/Nkmo2X98SKNrdAamhTHXk1VlG7BDym9RmmfKhwaWQ8gA4psgwy9zWLTa3sWEiEfdOBUJcL1qZyScHio2hA5JqeWSaVx3Qg55xSK7MTmpRIAuMVFgAk00rPYlsawYtkdKVnA4NO8zaMY696jYhjitn6EoYdw6HinKrnBzTXBAwOaTeSQOlZehR2AVYs4qrNKxbirMhVm5oaAbd4rn9pBPVFpPoLFKTDt71UklleQLjAFTojMcrUpUKMt1qFKHNaxSvbcY+cJRIW3BVHWmlssAKsoyqBn71U7wWgt9xUjVV+c80k5VEBWmzAsm41EgLYB6VnCK+JspvSyHoq8EdTT5W8sAIKdMiRIu3qajkYbfeiCvLTVeZL2GNK5XbipBvSDpSwjKYP3qkaT5Nh+9SnJuXLYaXUZGh2EvxmoYEw7MnOKmmZ/LVe1SJsgj92pXlGLj3HuVWHnNvbjFV5pG34XkVPIduQOhoCosO49apNrW24nYgfJQetR7QMFetSRhnY+lKwVM46mtk29EJ+ZCzFiPUUy+ge5tyrDipY1IkyelXo3V5Qp+7UYiMnC0VsVBpS1I/ClxFaSiAH5ga9V0fUEZQpUV4L4geSwvvOtM5z2ro/D3id2jhUt+8J55r5+tQkpc6+47tOh7gLpo1+QcGqs18qf6wDb3rDh1JhaRuxGCPWud13XQ7FIya51eeiG7p6lvxf4lWyhZkA8vnmvnbx1rBgk+3ZwshxXa+Ip7u7kaBt3k8mvK9Xgm1vUU0tQSkbV106SjK0dX1Li9Ls7L4c25VTeH/lqM5rtEDMWyOM1W0TTFsdGt4AMMgwavqdoxX0EE6VJKKPLk+eTkyts2v7U2XAOV6064cg+1QqQeRW8abdm2TJluy1ObTpUZc4J5r0PS9aju0hNu5Zv4vavLJ9z/Keldp8NrWOKOV3Jzz1rxc2wceX2y0Z3YKs1LkZ6UtxvRdnpzUu4hcnrUGhIksTH0rSMKHg14qi2rnpJ6XZg6letbRlz0NeO/GHxmfDWmSfZ3ZnuFxivYPGFv/xLm8vsua+RvjTctqOpWtoCeGANOjT56noTOWhyPhHT7jxDr7X0uWw+45r3aJhFFGgA4UCsXwdoNvoukwtEBukTJ4rdRARuNfW4OkqMLy6niYiq6s9NkRmdt2AKUMASWpVCl+KbIgzg11OUdrGPK2JvCkj1qSKMEZakWJQMt+FIpZjx0pOz2HrHUsIEHBp8iqFytQfL0PWpFwBSslqw3KyqzMS3apI+Tl+1OMgzgdaifcTk9KXI5vm6BzJExXzHBFRSI+6poWAGVodmDZbpWL5ld9i4pFUoVOTSSBWxtPNTsGf6VXlj2HKVdO71ZMrLRAxGMGmFFxjPNP2grlutRbgOa0jK62ZLugG5D04pQqbgSeaVH3nFChWfmpHfudTOAHBHSleRnTYppmSFYMOTTrWIspHeuSpG1pGkXcYpeIYzzUrI7IGJ4pzoF4Y5NLIwaMKDjFHtG2pWC1tEJBsAORzSFC8g9KgUNnAH41ZVhFEQT8xqZLX3BrbUdIdnynkUkPytk/dqFHycNVhELjA7U2uRWkCd9gYhid34UwEIDvHPaiEbpCDxtp13iQfKORUqUW+VAr7sliT92XzzTbeItNvbpTLUsPvnA9KfLLubEdSrpuP4iv2JHKlyPSq0p85vl6LUkhwg55NQPmNSO5qowe6YXI3+eVdvTvSyLlto6UsB2Aow+Y96cHETYbk1estug9hnlso4o2AEF6eZhnJ6VXy0z8DiqjGU9ZaIl6bFzMbR8CobfHm0KRGNpNPyqjg81MXbRIYuo6bHdQv6hSa8SudYn03xM1uMhVbivc3djaHBwcV5B4z09F1SGVY8uX5NedKNpPm3O6nK6t0PZPCOqPd6dEZ87cUzVbu0a+VEUZJqXw/bAeHYGjTB2c1zE6M+rBi2ADXD7qlOUVr+BuldJM09WktghjCYcjrXJeG9ESHxDJdMOCc5rpvEk0UdjlceZjrUWhxF7JZO5716OX0eaKm9LficuKqcvu9y7cuC5CCoMbR83eppCFPvUNw2Fr2LW0PPTfUpXPX2qMY28Cp0AdTupXChMDrV82trFIjEeQDXVeDpNgZM9a5FyxAAOK6DwkxFyqk9TXn5lByw0jfDO1RM9X8Ojy4GB71tAfL71lafH5Uae4rVyBHmvmqfwo9mW9jn/E0mbCcekZr4417F14zdZOdr8V9ieJPmsbgqM/uzXyDOiyeNpyTyH6Vvgv4sjKtpG3U9NhO2xt1I/h4qYRnZntSrIjWsAA6Co5JSThRxX1mySWh4nchdSvK0BGZcmrMYDH5qRl3ttHAonW5dGEY3IoozKCM9KcIzEpyafs8kEA1DtLHBbrUwlzO7Y5RSFiZS/NTTMuOBUUdvtfrxT5AA1aS5ZbELTcjKDgimTOFIFSFuD2qvGDJLz0pxjffYbZPEyjgVIrAvhhTZISHBXpUqLj5iKxnGnGPqVGTvYjMbMx2nAqF0YZyamkDFsrwKPujmqS5FbcTfMVVI/iFNZFPI6U+YDPyimHjirUI/ZZHM3uMBXOFFIylWBFSYAGahyS4z0ppJjR1U03mNgClSUxLlaigG5jUzRkNj+GuaXKvcfQvzK7yyO+7FTRxs4ycipF8tfrTZJHUcDg1Lk5q0VYLKOrHLJg7VXOKeIBK25jioLcPyQKk3lR83Womn8MSlpqxZIkVutIbgxDCDNRsGl+lKVVF96rluvedx3tsLLISAydT1pUl+dSfxpiNjp3oCMTk9Kc4xasySe6bzSAnAoUC3i3E5NNV0UbQeaa4LDD/dqErNRew3YljXd+8Y8UjESMM9qRG3rsToKSNMBs9ah23DUiupdrjaOlNRTK+5+BTkXAJlpQ4PH8NXeKXLFfMLMZMgzhTxUlvIsSEY5qCR1B+SlRHYZPSrlFcq5mTd9CKQszkilwQM559KkLrHwetREkPlulaKTWwdNS4sn+j5fjiuI8RR+ZeRELkbq66dvNh2pXGeLLz7GYVX7xNcFdattbnXQ1sey+GFjfwuSOqpXD20f2y+lKn5gx4qGw8QXGnaIqKTiVPWq2iXwsYJb64ICgknmvN9mqaknrc6r3sznte1dm8TLpLkgk9K7qyDWtisQHQV5DbXUevfE5L+Ikwg/hXsN3J+9KxjjFetgrumrrQ4sX8VipJICSSeaq+cWbaelWpYlIyetM8gL1r0PaRVkzlUXuQyHavymmA5TJ60soCtgU9EAXcapuy0AhjYSMVPGK0dFuxaXaHPANUBGPMJTvTpojHjHU1nVhGrekyoycPePcNDvY720V0OcCrpuudoyRXznP4q1zQLhRAGNl/Ea17z4x6ZbaOW80/aQOme9fLVsHOlLlR7FOtzx2PSvGniC20fTbh7p9oMZAzXyDoFy2seObyaM5jLkg1D47+Imq+LZvsyu/kE4AB610vwp8NS2JN1eLjf0yK68uw7VTX5mdeSjTPSraEC2QE9BTDlX4GakA+bA6U6RdrV9DdX11Z5NhEG9qSYshAAp+5UG4daRWDnL0nzp6LQYGHcmSahEXPWrUh2jC0wJkHd1ojJoCPBHANNBO7BqYgKnPWkRBjLdKYMiYbhiljQLn1qWMBifSomB34XpRd7AiSI/Ng9KfI4BwKZ93rQg3PWbinr0HtsMMpPBGBUbHIOakuB2FV239+lUlpoDRCzlMqBnNCg4yakKZ5HSoXY5wKaj0RDsISWOKVRvIB7UoIAy1PBUYNXrblJXc6NXWIkdzSZkduvFMMJ8zJOasSqVhyvWuTmjzJJas2s0IpjQ4fk01syHA6Co4fmGW5NT+YoBAHNEoyUvdEvMUShFwvWoN+6UBu9NwdxJHWplChCxHzCh6aIe+rGzMYhhaSFg3L01jvGetPIVYwe9TJS0ikCaRCZPMlxHxg1JcSnKqv40xtsYJUcmoo1Yhmato+8rsl6bFlIwGDmpArO+SfkqGIkxk9RTJJm24XiseRybVy07al0lRxF97vTZHEYyx5pkSmOPe3U1VliklfOeKzUYy9EVcbNIzyDrtpWDSDbHVlYljiO45NQpkNuWtXPS8dCdtwiiCDD9aV5jkKlBjeQ5zilwq/UU1OO71FboMn2phpOtR+YJjwOKmaP7R16CnBUhTAGTVJqG2rJ1e5Ch8skVxvjrSLm9RZrfPycnFdo7Ky8DmpZfL+zgMMg8EUVFzx95blQlyO6Z4tfeNI7K2FrdROZIxjpXLya3rXiKY2Wn+YsEh6CvdL7wxot0S81oCzd8VJpmgaXp8ga1twjdiBXAsBJu7eh2fWopaGF8P8Awsui2AN2P9JIBya7WSRFTI+9RLyKijwW+bmvQhGNtNkcU25O7K6F9zM/TtQheR/apbiRQMKKiiBHNayV43sSnZiuFRh5nWiQb1wnSopwXfGealQiKLB61MrpK24IjVHQ8GluFd9pHakVzv69annHyAg0m5RqK6Ho0RGNLuLybkAxnrXD+JPh9p93ITaKRk5ruEhYqTnFGHUZDVM406jvJlRlOPwnGaD4D02xRWkj/eDnJFdbGqxRrEoGxelPBZzyeajBy22tIRjBNRVglJyd2TblJBXtTj8xz2pBHil27ee1JNNqwiN1B6dKUhduB1pTzyOlMAOau4IXJ/KgPlhmlI2j603aSw4qVYb8hZCC9PILKB2puArc0jMSeOKLt6ITRJhY1PrUSnJOKf8AdHzc01HCnpTi3YWg9IyT83SiSWOM4GM1BPK38NVwDncxo9nf4g5rFhpAeTUTMX6dKkQKy1Hjy896UJKOiQO9iPcV47U3GaG6EnrUW4kYHWtOW/vEkjKGGKauGIX0pocrx3pWOMEdaT1Ejq5cwNjGc05VMgwelS3ajeOKeijy+lcUneKfVmtrNopmMK+0UiJljntU2Bvp6qPm4pzctrjSVyF5EjGBgmoS5kBHSowB5xqwFGRxWllHVEiQx7OW6VWmYmXg/LWnMo+zdKzMDj61VBuV22JomVchdw4qO9k2FY0HB71adR5a1BKo9KzguV3epW7HRR+Vbk9RSROJeNvHrU5UfYGqHT1Hl9Ki96bmNauwksjH5MYAo80IuKsTqNvSqTKOaqNuwkmMJZ2xk4q3GRGu0io7dRjpTpQMU5pVJcvQa0VxhuQzlBwPWmhMNnNQgDfU8YGDRK0LKIo+9diPKWG1Rio0Vzw2SPWp0Uc8VPtHkHim6nI7RQKF9yqI1HeliHzHeeBTABipJANgocnbUfKk9COd/NcKoxilOY8ZFLCo8wVPfKMrxVXTmoEWsrlUuWOAM0bPLG7PPpUtqo8zpSTgecapSu+UTiVcYYsxppk7AVJOBimIBitenMxbEeCBuphcuatFR5JqvCo3dKp6akyVmJ5e0A55p7McDNOIG6nSqMDis3KzsaKOgwynbgU0OcbTSqo3051HpSbTlyJAl1IydvSlUA89KUqMdKVgMCpnpF2LWrG5bPHNTFiYuafbKD1FPuFGzpWfteZpIbjZlRUDL1ojYISOtKgGKZGB5hq2r6XCK6j1XdlielKJcjAFOUDYajhUbWp2Uk7kN2Gghn5NMZsSYHSkYDzaeFGelaOCjqieZ7Em4SLg9qFA2mmADmpo1HltS5bKyHfm3KbyBTioWJf7tOnUc1JaKMdK0a5VdCS5nYZgooOaWM5zuqaZR6Ux1GBxSXvbg9NCJox1zUJTDbqn2jNBUZ6VN7MLaXIG4+bHNR7ixGRjmrIUZ6UyZRkcVXNyiSuf/9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from Photo Quiz. A woman from Britis Guyana with recurrent back pain and fever. Clin Infect Dis 2006; 42:1297. Copyright &copy; 2006 University of Chicago Press.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_47_4849=[""].join("\n");
var outline_f4_47_4849=null;
var title_f4_47_4850="Patient information: Chronic fatigue syndrome (The Basics)";
var content_f4_47_4850=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?42/20/43329\">",
"         Patient information: Fibromyalgia (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?41/11/42161\">",
"         Patient information: Chronic fatigue syndrome (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?24/17/24854\">",
"         Patient information: Fibromyalgia (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Chronic fatigue syndrome (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/chronic-fatigue-syndrome-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H19817603\">",
"      <span class=\"h1\">",
"       What is chronic fatigue syndrome?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Chronic fatigue syndrome is a disorder that makes you feel very tired all the time. Sometimes the disorder is so bad that it makes it hard for you do your normal activities.",
"     </p>",
"     <p>",
"      Living with chronic fatigue syndrome can be tough because most people, even many doctors, don&rsquo;t really understand the condition. Plus, there aren&rsquo;t a lot of treatment options.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H19817610\">",
"      <span class=\"h1\">",
"       What are the symptoms of chronic fatigue syndrome?",
"      </span>",
"      &nbsp;&mdash;&nbsp;The most common symptom is feeling tired all or most of the time. People who get the disorder usually begin to feel tired suddenly, right after they recover from a cold or an infection called &ldquo;mono.&rdquo; Even though they are over their cold or mono symptoms, they still feel very tired. Plus, being active makes them feel even more tired.",
"     </p>",
"     <p>",
"      Besides feeling tired, people with chronic fatigue syndrome have other symptoms, such as: &nbsp;",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Sore throat",
"       </li>",
"       <li>",
"        Trouble thinking clearly",
"       </li>",
"       <li>",
"        Pain all over",
"       </li>",
"       <li>",
"        Headaches",
"       </li>",
"       <li>",
"        Trouble sleeping",
"       </li>",
"       <li>",
"        Tender lymph nodes (glands) in the neck or armpits",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Chronic fatigue syndrome is hard to deal with, because people who get it were usually active before. They did not tend to worry about being sick. Then, all of sudden, they feel tired and can&rsquo;t figure out what is wrong with them. Even the doctor often can&rsquo;t find a cause for the symptoms. And to make matters worse, other people sometimes think their symptoms are &ldquo;all in their head.&rdquo; This can make people with chronic fatigue syndrome feel angry, helpless, and sad.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H19817617\">",
"      <span class=\"h1\">",
"       Should I see a doctor or nurse?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. If you suddenly feel tired all the time, you should see a doctor or nurse. Lots of health problems can cause tiredness. It&rsquo;s important to get checked out to find out what might be causing the problem.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H19817624\">",
"      <span class=\"h1\">",
"       Is there a test for chronic fatigue syndrome?",
"      </span>",
"      &nbsp;&mdash;&nbsp;No, there is no test. To diagnose chronic fatigue syndrome, doctors and nurses have to go by symptoms. Often they look for other causes of the symptoms first. If they can find no other causes of the symptoms, they consider chronic fatigue syndrome.",
"     </p>",
"     <p>",
"      To be diagnosed with chronic fatigue syndrome, you must feel tired all the time for no reason, and you must have some of the other symptoms listed above.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H19817631\">",
"      <span class=\"h1\">",
"       How is chronic fatigue syndrome treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;There is no cure for chronic fatigue syndrome, but there are treatments than can help with the symptoms.",
"     </p>",
"     <p>",
"      The most effective treatments seem to be cognitive behavioral therapy and graded exercise.",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        <strong>",
"         Cognitive behavioral therapy",
"        </strong>",
"        &mdash; Cognitive behavioral therapy (CBT) is a type of &ldquo;talk&rdquo; therapy. During CBT you talk with a psychologist or counselor about the things you think and do. Then he or she helps you change how you see your situation and how you react to your situation. This teaches you how to cope better with your condition.",
"       </li>",
"       <li>",
"        <strong>",
"         Graded exercise",
"        </strong>",
"        &mdash; Exercise sometimes makes chronic fatigue syndrome symptoms worse. But not exercising at all can also make symptoms worse. That&rsquo;s why experts recommend that people with chronic fatigue syndrome do gentle exercises. As they get used to that, they can slowly increase the amount of exercise they do. Sometimes it helps to work with a trainer who understands chronic fatigue syndrome.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Researchers have also checked whether different medicines, supplements, and special diets help with chronic fatigue syndrome. So far, none of these approaches has proven helpful. &nbsp;",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H19817638\">",
"      <span class=\"h1\">",
"       Can antibiotics help me?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Probably not. Your doctor might offer you antibiotics, especially if you test positive for Lyme disease. But antibiotics do not work on chronic fatigue syndrome. And testing positive for Lyme does not mean that your symptoms are caused by Lyme disease. Plus, taking antibiotics for a long time when you do not need them can cause health problems.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H19817645\">",
"      <span class=\"h1\">",
"       What will my life be like?",
"      </span>",
"      &nbsp;&mdash;&nbsp;If you have chronic fatigue syndrome, try to remember that you have a real medical condition. You are not imagining your symptoms, and your problem is not &ldquo;made up.&rdquo; Scientists have not yet figured out how to explain or cure chronic fatigue syndrome, but they do know that it is real.",
"     </p>",
"     <p>",
"      The most important thing you can do to deal with your condition is to find a doctor or nurse whom you trust and like and who believes that your condition is real. Only that way can the 2 of you work together to figure out how best to deal with your symptoms.",
"     </p>",
"     <p>",
"      Many people with chronic fatigue syndrome also have depression. If you are depressed, get treated for your depression. Doing so can make your chronic fatigue syndrome easier to handle.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H19817757\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?42/20/43329?source=see_link\">",
"       Patient information: Fibromyalgia (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?41/11/42161?source=see_link\">",
"       Patient information: Chronic fatigue syndrome (Beyond the Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?24/17/24854?source=see_link\">",
"       Patient information: Fibromyalgia (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 14, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?4/47/4850?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 15916 Version 1.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-200.215.4.194-8300F9CC1D-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_47_4850=[""].join("\n");
var outline_f4_47_4850=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19817603\">",
"      What is chronic fatigue syndrome?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19817610\">",
"      What are the symptoms of chronic fatigue syndrome?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19817617\">",
"      Should I see a doctor or nurse?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19817624\">",
"      Is there a test for chronic fatigue syndrome?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19817631\">",
"      How is chronic fatigue syndrome treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19817638\">",
"      Can antibiotics help me?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19817645\">",
"      What will my life be like?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19817757\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?41/11/42161?source=related_link\">",
"      Patient information: Chronic fatigue syndrome (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?24/17/24854?source=related_link\">",
"      Patient information: Fibromyalgia (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?42/20/43329?source=related_link\">",
"      Patient information: Fibromyalgia (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f4_47_4851="Retapamulin: Drug information";
var content_f4_47_4851=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Retapamulin: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?29/4/29763?source=see_link\">",
"    see \"Retapamulin: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F4599865\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Altabax&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F4599868\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antibiotic, Pleuromutilin;",
"     </li>",
"     <li>",
"      Antibiotic, Topical",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F4599955\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Impetigo:",
"     </b>",
"     Topical: Apply to affected area twice daily for 5 days. Total treatment area should not exceed 100 cm",
"     <sup>",
"      2",
"     </sup>",
"     total body surface area.",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F4599954\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Impetigo:",
"     </b>",
"     Children &ge;9 months: Topical: Apply to affected area twice daily for 5 days. Total treatment area should not exceed 2% of total body surface area.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F4599958\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ointment, topical:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Altabax&trade;: 1% (5 g [DSC], 10 g [DSC], 15 g)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F4599866\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F4599956\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Topical: May cover treatment area with sterile bandage or gauze dressing if needed. Concomitant use with other topical products to the same treatment area has not been evaluated.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F4599869\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of impetigo caused by susceptible strains of",
"     <i>",
"      S. pyogenes",
"     </i>",
"     or methicillin-susceptible",
"     <i>",
"      S. aureus",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F4599938\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Central nervous system: Headache (1% to 2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Dermatologic: Eczema (infants, children, and adolescents 1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Gastrointestinal: Diarrhea (1% to 2%), nausea (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Local: Application site irritation (adults 2%), application site pruritus (infants, children, and adolescents 2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Respiratory: Nasopharyngitis (1% to 2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &lt;1% (Limited to important or life-threatening): Contact dermatitis, creatine phosphokinase increased, epistaxis, hypersensitivity",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F4599933\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to retapamulin or any component of the formulation",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F4599934\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Irritation: If skin irritation occurs, discontinue use.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Superinfection: Prolonged use may result in fungal or bacterial superinfection, including",
"     <i>",
"      C. difficile",
"     </i>",
"     -associated diarrhea (CDAD) and pseudomembranous colitis; CDAD has been observed &gt;2 months postantibiotic treatment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pediatrics: Safety and efficacy have not been established in children &lt;9 months of age.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Appropriate use: For external use only; not for intranasal, intravaginal, ophthalmic, oral, or mucosal application. For treatment of impetigo covering up to 100 cm",
"     <sup>",
"      2",
"     </sup>",
"     total area in adults, or 2% of total body surface area in children. Concomitant use with other topical products to the same treatment area has not been evaluated.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299993\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP3A4 (minor);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F6222744\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no known significant interactions.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F4599870\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F4599871\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Teratogenic effects were not observed in animal studies.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F4599932\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/use caution",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F5736763\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Ointment",
"     </b>",
"     (Altabax External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1% (15 g): $116.17",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F6038893\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Altargo (AR, AT, BE, BR, CN, CO, CR, CZ, DE, DK, DO, EE, GB, GR, GT, HN, IE, IT, KP, MY, NI, NL, NO, PA, PE, PL, PT, SE, SG, SV)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F4599946\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Primarily bacteriostatic. Inhibits normal bacterial protein biosynthesis by binding at a unique site (protein L3) on the ribosomal 50S subunit; prevents formation of active 50S ribosomal subunits by inhibiting peptidyl transfer and blocking P-site interactions at this site",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F4599948\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Absorption: Topical: Low; increased when applied to abraded skin",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Protein binding: 94%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metabolism: Hepatic via CYP 3A4; extensively metabolized by mono-oxygenation and di-oxygenation to multiple metabolites",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Parish LC, Jorizzo JL, Breton JJ, et al, &ldquo;Topical Retapamulin Ointment (1%, wt/wt) Twice Daily for 5 Days Versus Oral Cephalexin Twice Daily for 10 Days in the Treatment of Secondarily Infected Dermatitis: Results of a Randomized Controlled Trial,&rdquo;",
"      <i>",
"       J Am Acad Dermatol",
"      </i>",
"      , 2006, 55(6):1003-13.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/47/4851/abstract-text/17097398/pubmed\" id=\"17097398\" target=\"_blank\">",
"        17097398",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10271 Version 32.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-61.234.146.186-A1F0AAE071-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_47_4851=[""].join("\n");
var outline_f4_47_4851=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4599865\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4599868\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4599955\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4599954\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4599958\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4599866\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4599956\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4599869\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4599938\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4599933\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4599934\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299993\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6222744\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4599870\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4599871\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4599932\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5736763\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6038893\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4599946\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4599948\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10271\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10271|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?29/4/29763?source=related_link\">",
"      Retapamulin: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f4_47_4852="MRI of Chiari I malformation";
var content_f4_47_4852=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F68681&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F68681&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Chiari I malformation showing descent of the cerebellar tonsils",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 453px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAHFAbADASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD5UooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACipYIJbhwkEbyP/dUZNd/4M+D/i/xYiyWOnNDCTjzLjKD680Aed1JDDLO+yGN5HPZFJNfTmjfs66RogF3431+GKNBuMSMADU0/j74WeAmaPwvo6ahfJwJCmRn60AeIeHfhb4u1/yzY6ROEfo0qlB+tep6R+zibaJbjxTrttZIOWjVhmsjxN+0D4s1VHTSlt9MgPA8vG4CvK9Z8SavrU2/UtVu7pz13McUAe9/8I18IPCrCTUNRN/On8Ct/hU0vxe+HmiRldD0SSVsdSxFfOK24ZS21M+780LA+MfPt9loA94m/aLkWJoNO0FAP4WaQ1TP7Q/iJNrjTIFA/wBqvGWtJldfJVyPcU6eznlZQV2fSgD2pP2i/EROZNMt2Vu2+tSy/aRXy/L1Pw8rY6ssleADRbqR+MAduaY2mXUL4LcmgD6PX9oHwtOALvw9Jj13mpz8cfAUzqZNFlTHHc181G1uz+7YkEcjAqFYp95EhYe2KAPptPiJ8I9UZheWU0BfqSGqYeBfhH4si83StRS0lbpmTBP4GvmN4B5ZG1Cfc1CjqgBCNE46NGxoA938R/s1aisL3HhfU4NRTqqEgHHpmvI/Efw+8T+HSf7T0q4QA4LKpYfpV3wx8QPFPh+dTpGs3CqOscp+U/nXsXhX9o6U4tfGOkxXNvjDzQrvOPpQB8zspVirAgjqDxim19iyeEfhX8UYXuNGuIbC9mGSVIV8/wC7Xk/jz9nvxHoUks+ij+07BBkMOH/KgDxKirN7ZXVjMYr23lgkH8MilT+tVqACiiigAooooAKKKKACiiigBVIDAkZHpWt4dvIbW8JuFyjd/SsilU7SCKAEpTzSUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFXNN0y91ScQ6fay3Mp/hjXJoAp0V6z4S+AvjTxAA0ln/Z8Z/iueOPpXrmi/sy6FY24l8T6229RllicKKAPktQWICgknsK3NK8I+INWcLpuj3twT/ciJr62trf4O+B02yNZXFzH0aX5zmsnXP2jvDukxNb+G9KLSLwrxqFWgDy3w7+zj4z1aOKW4W2so2xuEzfMB9K9M0z9mnw7pJiufEmvMVj+Z4wQoNedeIf2hPGmqZWx2WUZ/iVea861LxLr2tyPLqerXlznqI5On1oA+nL7xR8Ivh2jHTLG1vLpRj90u9ifrXnfjD9o/WtRjaz8OWkOm2zAgSHhgK8URIYRiREkL9yMtUkdgJQSwbyx0ZugoAdrXiDV9akZ9W1O6vHJyVL5FUDvlKpawFD3Kjk1fiFlasN585/SLtVpbsqrCKMIn97HzCgDNGiT8PMwXd2PWrsdjDGQmG3eopZJ5iAZZVYHoTUDtMFKlw2f4loAvC3tohvkWPI9arzanHGSkKkn17VQmMkoCSceh7URRBfv4LDpt6UAWILqV2JuJXVe22tC0uM5LBnUdCaz3wyqYl3P3WrSW8hh3Fio/uDrQBYS4cSkncN3QCrKRNMT/AAkc/N1qiXFvGCwbd2zT45ZJFyu7ce56UAXYU2tmQOQD1xT8J5hLBG449agRroKE+/H3C9ae6kDzCAAO/cUAJ9nhkVnaAKe+RUMlhbyKNuE/3KdHcIzlVdpHPYdBUE969uD+6ymew5oAZdaJMwUxhGXvvqm9vNa5ULJCD6D5T9a17XU/tBRNwx/d7itVRFIDvdW/2X6UAclal7WZZ4Znt5l5ElsTmvWPAPx28T+G0it74rq1kDhmJ3SqK4e90/TpTuUyJJ6RHArEurK6tAXt0LKf4ov60AfWVrd+AvjHZkvDbR6iykMkuFmU/wCyK8e8dfs+6xphuLnw6/2y1jGRBIcTn6DvXktncz2l0tzDLLDPHyJrU7WU+5r2b4e/HXU9Fmgh8SZ1G1XA+1RcyAf7RoA8HvrO5sLl7e9gkgnTho5F2sPwqvX2rrcPgj4xlbaxtopbpl3PdWygSRn/AGjXzp8VfhHrngK6kkkjN3pRPyXcQyoHYN6GgDzWiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiinxRvNIscSM7scBVGSaAGVu+FPCeteK79bTQrCa6lJGdo4UepNe1fCj9nm81OODVvGJNnYcOtp/HMvuf4a9e8ReOvBvwo0lbHSLaAXYXbHaQ4Lk+7D+tAHDeCf2ZbS0QXfjXUkdMBvIhbZt9iTXWaj4/wDhp8NrdrPRoLaa8jG3bGgLn/gVfPvj74p+KPFtxJDd3klpaufls4iQce7CuI8kwqZJStsT1Mn7xmoA9p8W/tGeJtUzFoVsmm2h43yDLY+teR614u8Q61O73+r3U57rHIQKqW1pPdsDDG3l95WOB+Vakdnb2ki+bKsjegFAHPLY3Ux86RHCn+OU7qlt7fY5xtLew61vXN8gBRBtTuOtUhdxAboowcd6AGRWkzNut1IbuHORTZbaHJ8yUCQdRHwDQv2i6YtCxXPUA1p2ukoyDd82fvL3oAwmulVsNGIwOhYZzT7eWS6k3TsYrX+ddJFpVs8TxiPIHc84pf7Hja3CbNvo1AGNMkUEYeGAbD916pNJJK/yDc3fA4rej8NPHdDfOWU9u1a9ppsNsxSOMOO5oA44QSSc+Q6jvmoinkkiPJHcV3MtqvcfL2A7Vl6xpaTQb7ficdh3oA5hZGXDBNw7g0u1HnG6N1LdOa6DRbBHQidfnHUVsx6RbJMshG4jpQBiaTpCqpZ1YZ6EmtM6ehgO+QDHQ4rUAUBtq7T+eabsLKFOBntjrQBy13DG7CItux6Vcs7PywMA7e+aq3OTrHkCPBz0z1roYbYNhGB3egoAp+SrnCA49qp6lbyPGVjyH6Yro4rLCtubYRVe62B41UbYx949zQBj6ZpKQwDzGG5uoA5p+owQBlRWDFR90VuuqkfKdi44XGSaxbq2mWTIG1SfqaAOV1a0lSQzwDyx6Ck0+V2T96xR/UmurvLBvIDxR7T6nnP4Vzd1p6M5aMmOfup6GgDVsriO0BeTEwP8Q6CtC01OKUsIgv4jiuTtGeAN5hLsOq0t1cldptn4PVcYxQB0N/ocd6Gmt5FhuuuOit+FYP2UPI0bKYrxfvD+BvwrU0nUjdAQyvskXp71f1G1jubfCHbdr91x3oAxNP1nUNGvYprC5fTrlGBEsJ2o3swHWvobwT8aLfxFaR6D44giVnXbvcZScew7GvnaGd2ma01CMeZ0II+8PamXCf2c/lvmS0Y5Vv4oj9aAPS/jj8JI/D8Y8QeFVkm0OXl487mhPrn0rxCvqT4L/EmHUbD/AIRLxbLG8Ey+XbzOvDA9Aa8s+OPw2ufA+utNFGTpd0xaFxyB7ZoA8uooooAKKKKAClAyeKSigAooooAKKKKACiiigAooooAKKK6z4c+BdW8d67Hp+lRHYDmacj5I19SaAMnw14f1LxJqkWn6RbPPcSHAx91fcntX178LPhP4e8AWA1jW5IbrVI13vPNgR25xyFzwa2/D/h7wn8JfCE73EixRov8ApF24Hmzt/dUd/wAK+e/iX8SNR8dTrYwRtY6CGIgsozzN/tSdx60Adt8Uvjvc6mLjS/Bj+RbqSkuongsOmFWvBmhubmdriWRwjnMlzISSx+h6VbvI7awkT7ZskZPuxocqn0Peg291qRE92xg0/tGOGb8KAKsM7CQ22kIZJDw1wwq3Dp1vYN598Rc3HXBPANNl1BIAbewjCRDrjvQlm10yPITj0FADrnULicYEe1ewUYxVc208pGMk9q6CK2VECqPl7tV21hjZTt4x6igDjpLWeJC8qYYd85qrDGZmIxnPc8V3T2kb5JXI71VbSI/ODp17Ke1AFDR7NYoSmSWPr2rRKCKRfbvU4gaJgXXHbNTXVvmMDbyfu0ARwhQxcN8vpirLo0kYYkY7VkWUxS6aG6kw46ZrYVomjwxOBQAAbiEf/WdjQIv33znJFOxnawHA6HvU/l5G7kNQBDtDkg/u8dD1qGWBw3Yg9/WqYvXnv/Kjb5V+8a1WUPCc9F6D1oAy7WEQTPGflZucVpZygVgOOtUtRBTybgAoVPJ9qtxlZFWaM7kI59aABVRQxHOf4j2prbcKd3P971qYgOyk/KvZfWmyxK5yBuIPC9hQBzd1b7NYBQ4D9j3rpbdFjhwo+YdayfEp8iW1lC/MSBkdq1ozujTGPmHNAD2lCyAgbwe57VmBWuL5gnIHU+laTpvAG0Kg7+tV7BfLvZGYADHAoAtwqW5XGB1JqGaJS5P3mHPtU7kSW5KHjPNRqCgAAIX0HU0AV0fzT85JK9Biql/pqXSHeo39mHGK0WQMQT8p9KYX3MVxgD86AOMm0qaFn2nIHcVQkRmjKSxgJ2boa7NFZpW2L8vfNOubSCdAfJQkdfegDze4MkZDpk7ejitjStdKFVlOB3zW7caPCrME4DD7vYVxd/ZGKeQRYIU9BQB1mqWkGq24ntDi8TlWHesa3uGnDW1wv74cOpqro+pT2BGQTGT1/u1salDFf24v7E/6SnLgdWoArQebYsoBPyndHN0KGvpDwRrNp8XPh7c+F/EEqpqNsn7mdsbmIHGK+cdNvY7tjBcpgsMBT2NaXhjUbrwzr0V5G5BhcHOcAjNAHN+K9AvPDet3OnX8bJJExAJGNwzwax6+r/ip4Zh+Kfge38T6HEh1C2jzKqdWGOc18pSI0cjI4KupwQexoAbRRRQAUUUUAFFFFABRRRQAUUUUAFFFdT8PfBWp+NtdhsNMhYx7h50uPljXuTQBL8NvA2p+OtejsNOjIhBzPOR8sa9+fWvsGIeF/gt4LEKMq5HOP9bcv7+1SCPw18GPAn+i7BKqc5/1lw9fLHjDxHqXj/XX1G+fYqn93EfuRL649aALHjnxVrHjvxELm/dRbof9HtQf3UK9mPvXOXkotpjBpsjXdy/Eky8sPYe1PEj3aSWOl4W2H/HxdN3+hqtJcwadEbXTBktw1x3/AANAD4oLaxlX7Y4uLo8rEDlV/wB6lnne5nJlm2r0GDx9BWSkBR2l3ls8nP3mq3bpvUMo3Mf4T/DQBYCrByiZPqav6bdNyoC7T3p9rat5O2UhwfSqckLWku/I256dhQB0kayNFxtX27U2O5VJBE4IJ6E96hsJlmVfLbr1zUl7D5h+Xhl6E9PwoA14gNo+6H/SkK7nycAeorI02/2y+TcffHQetaM13FGrSt/D27UASTSEusbYPpTmBJxnOPWqGnzfanedxwfuitCQHyR0BP50AcvroVZhcYBKmrGnXn2lVUD56bq0X2uZYVwG9BU+laUlqwd3JP8AKgDbtgPL5zkdu9IzMhkYklSpxntUrDYVeMhvU1R1OZEhkk3fLjkUAYugEx6pcu6BgSea6eJAw3nhT19a5/QVDRu4Ocnp3rooB8gyePQ0AR6jEJICACYyOnasi382wB3fNGegHattMLvWRjjsO1ULpoxGzLjaOpNAEkEnn4dcN796v/ICBEOvXFZmhnejtEAAT371qBhEwHAJ6mgDH8SEJGpwHI/SpNJbzLdPlJB6460mtFWtJEI+Xru7movD10sltswVdeB7UAbM4zIg2njoOw+tUEx9rkUYYnr/APWq4ZwIyI23f3mNZV1ILW9jmdlwemOlAGhbghsFfkXopqR2fzC68j1Hah3SWHzEbr1A6momZjsKZRO6mgCbYJlCjhutVbhCu4E/MO/ep2ZYzkOAO471m397Args/Hp3NAFfzHU+Xycn8fxq7HlEGUBJ9elU4POuH3mPZGOQT1Nait91iuSP4aAKdwCmSwJUjrXIQQCbVJT5fyZ5Ndtcsv2aUnIPYHpWdo1kY45LiQZDHhaAMK/0k24Ekahon/hNZETy6fcGWMNx1RegrubhCsZO4c9j2rG1PTTJEJIVYxn7wXqaAMuexGoR/b9ObbN1dPWrMbi/s/LJXzkGGX0rKsL3+zdQCgnZnBB7Vs39h9mA1fTmDwt/rEFAHpH7P3jc+Hdf/sW/nK2V4dnJ4yeKzP2jfhzL4a11tXsIi2m3h35UcKTXnbzRSbLu3YpJGd4I6qRX1Z8PNRtfiv8ACe50rUZUe7to9gLctwODQB8WUVpeItMk0fWruwlBBhkK89xWbQAUUUtACUUUUAFFFFABRRV3SNNutX1GCx0+FprmZgiIoySaANHwZ4X1DxZrtvpumQs8kjfMwHCr3Jr7Q0Ow0L4M+BTLIY1IXMkh+9M+Ogo+FvgLTPhV4KlvtUeP7c0fm3Nwe3GQo/lXzz8SfGt5471qaTzT/Y0DFYYugPvQBl+OfGF/458QPeXeUjziGH+GNPU1hbTqMn2GzcR2Kc3NyBjPqM1VLvqNw1naERQL/rpvT2qLVtW226aVpKBbdeGYdXPrQBHr17z9g0r5bKPjcnVz6moYofN8oxZWNfvZ/iNT6daraRlXIMjDk+la9lAWwjAeqjHWgBtvp5lDSMu1gPlWp7K0AiLbckHkitGIBInDHDgcml05gYiQvU8D1oASFTH0XBYdDVO+VY423gMp7VtlCeOD6n0rL1OLzkKJ94dCKAMbTZ/LnKgHYentXTW674RgZHvXLBHjfBOCOvFdHYN/o6YJ57UAN1SzV1BX5Zh0x1rnGa4vLtbWVyqqenrXZSuF4YZOPvVydw2NUaSM555xQB19lGsdskagLgcmnyRrtO0sB796oaXex+WSW6etayzK8O9iuOwoAzLK18udpHIbPYjkVo+SGXnp1zT4ThGJIAPSqt6zDbHHli3cUANa73nyo1y44yOlV5tPMwIdvlPUVet4UgUqBhz39ac7q6rEnEh6mgDmmiOmZkg3PEvXHatSy1E3MQlWNtvatSOxiGQw3A9RjrU4tlWPCIqqOgA6UAYtxeXEaHbCTnrntWHq9zLcywxf6qLPI9a6q6mjAKZDN7Cub1CGaa4SOJCZM8NjpQB0OmKkcCoSAQOgqXeoRnZgYh94mqum6dME/ey5YDk4q7LYxtGF5+metAGFq7SahGBZq3kjvVLS2aGbyPut3aummgSNBGmAP4iOKybmBvPQ28ZIB6+tAF8riHk/l3rMvYpL11SEZ29+wrYa1Z4l8xyrkc8dKlSBYoQkfK9zjk0AZNtaXqY82Vdo6ACpzb3WTmUbT3x0rSjLc7l+TsKHIWLBHDUAc7cadeStn7QGX2qxa6LFG6ySsZZPc9K2tmEwrAHHHHSmRqApZ16d/WgBQYkXDLg9hUPlumXJGD19qc64BLcg9PaoPtQum8mJvkT7z0ARyRC55BxEp596lccKEBXtin9iV+72FOSKR4tpYHPU46UAZk6kbwe/XNSQk/YzGv3uxq7PaxIAM5bHFVGtwoLHIPcCgDkNf00SMSF2TDnPY0nhXUZBcfYroZi6belamrszMP4lHT1FUZbY3EsU8eBIvXAxQBJrGmG3vvOiUfZm646V2vwT8TDwn8QLSNpANOvSEZR71g3EZurNrZc7Svr3rlvMlsjHhSbi1kDIfTFAHrn7WHg1NJ8Qwa3ZL/ot6uTgcA18/wBfZfiJ7f4mfAqOQYfUbSIE+oIFfHE0bQyvG4IZCQRQBHRRRQAUUUUAFFFFADlUswABJPAA719h/sx/CwaDpw8Sa9AF1CZd0COP9Wnr+NeT/s2/DN/Fmvpq+pRkaTZtuGRxK47fSvfPj/8AEZPBXhv+zNNKHUrlfKiVT90dKAPMP2i/iJN4g1weGNDlxZQn/SXVuGPpXiOpTK8q6dp5II4dh29asXQbR7Rri5YTanfEsVznbmsaaY6datHwbybl37qPSgB2oXq2VubCwfKn/Wv3Y0mn2wt0WWQEyt932qpptv5r+fMP3ann3Na8bSMzBVG09D6CgB0AWWQjnaD8x9a24SIym8Hb0UjtWTbDbIoAKqOvvW5DEZFOyQf1oAq6nI6xsIwQD39araRfOg8u6BHPB9K23jWSJVy25exHWnCziliYFQrY5xQBMs5eNdjD6+tSJCqEsoxuHJ61hJvspMoWeMHoe1a1jeR3QbAw3egCtNpe8nPBY8EVdtLYwpgDJUVfSNDEFJxnpSXGIQSXBAHegDH1S5aG3IAy78BaTTNOCwZlTDtyaZ5ZvbjzySEU8A1sZMcQYHdnj6UAYWsWsaxqYhk56ZxT7O0uJ5IVVyQB93PSo9XnIuEUY2nn3ra0lW2hioDdiaAJVspy+Wfai+9WvLCIADuz3xViOM8hjlT1pMpDGxckD+EEUAQyeXBA0sj7cDpiqGjg3EzzsMrng1W1K7+3TLZ2o3nPzEdq1rWHybYQpkEdQaALUsuFUKvHr6027k2RCNOJXHQUQEudgyxUZwags4mnvJJpDtKcAdqAG2tqkJ5USOepY4qeGOLe20AMfalu8Rxl2AJNSW4HkhyCG7DtQAr4gCqv3T1qORlhk8wgEEcAmmX8q2sBuJs+yjvVGySW9/f3assJ+4lADy3nylVBCdzVqMCMZCjHQZp0wKKFhUbR6dqfhQgLcse5oATzDt2kgZqMAgkyLwOg9akYq3EQDgdT3pXdWAL/ACgfnQBXmkWFGf7oxVDSLsTzSlmx6Z71caJbhy7gmIdB60rWkLRq23ZJ/CFoAUoAcNyxpXkjjIOBx71GyTo/lkhsjrTILZlYtId5B79qAG3XmXEZCfKjdRWfFiBxGQBH6+ta0jh8YyCPasbXM5RIR/pB6Af1oA1k8v8AgYc/wk02SeKI+X5nz+g5rKstMuPNU3UpJxyM8CtK1tIFmLAElehNAEiwMzeaxwfTNJPtjt3fjHvVhgQeQAG4xmqmoAOUttoKk5PPNAHPx2Vxcu0yLhSeAao3mYZjCAVfuPWu6RI4FUOBtQcAVyut2E08zXsPCD+GgB+m3AVUYr83Q+1ZOu27petIvMUg5qeyLRMWnON3QHtVvVIxcaWWQnenOT3oA9E/Zz8S/ZNXfRLpDLBdfKqHoM1558evCj+FfH13CFCw3P76PHTB7VB4F16Tw/4ksdUOXSJxvX2r3P8AaW0iHxf4G0/xZpMQIiUGQqMnHvQB8l0UUUAFFFFABXR+APC934v8T2mk2SMfNYeY4/gXua50AkgAEn0Ffav7L3w+Phvw2NbvY0/tC/GVyOUj7CgD0KKHSvh34GxGsdvZ2UPzHpvYDk/U18c6lqk/i/xLf+JNTYtZRM3kg9BjpXqf7TfjY63q0HhLSXPlI2bjHc+leNeLJktbS10DTGAzjzQv9aAMeKUX1/dapckCKPIjB6H0rnpHe6uWZuXY81qa/LHDHFYW5O2IfMfU1W0yHH70g5PAoA07WNtiRceWB1HrWhZQBJGjc/MemarW6AMdwIVecD1qSab94kqZ3Zxj0FAGzHbpsPIyO560LZGJfMjdg57VHFeRoQrEcjqfWkku3GEXqT1PSgCe1e5eYhiv1rVQmOPZsG49T61BZQqQG6MO3rWgEAAcq2e4oA57VGMNwo4VW7VLaWrxEugPrVm9tkvLxduCi1ejYQxlGGD0BoAal6FizMuG6ZqqW+3vsU/uR1NN1NWNv5YH3ujVd0axEMKhsknrQA5EQRiNUG1ejd6iu5haW7M3H91fWr+ozQWVu7rycfKPesXTbWa/DXN9nOflSgBum6W9xKLu6I+blU9BWjaXFv8Aa5IA5YLyR6VdiQCJt2VKjisq0tQ0ss6EBzwfegDTa9UWrvCC5XpjtXPXVzcXlwFkn2r3ANSXt29vmGyHLffY9BUGlvAXYyfO38RFAGnoEcEDSEHDdmHetwSYT94FJ7GuWnhxOpspDjrtqwt/Pho7qCRHXgHHFAG1LOttBJJITubhQOtSWsbC0QbgryHODWHaweYDNLOT6bugq19ouShUDe/8NAF52NzeCEqAkY6irUQZYzuIK+lYelXy+e8VzuE9bU06RW4jHMj9qAKOolZ72JXYiNe3atEEbh83PbHSsfVTGtxBAuc9Wb0q9ZgszBjuCjgigCedtgPl7QB94VSWV7s7I+FzyT0p0qPczBI8bFPz+tXDGiYMWFQDGD60AQyW/lxkQsUcDOR3qhYNeM0gv0QqPusvetGXdtwc4PWpXRhbqwI20AQRArGcnHoBSBh5ZL9e2Kqavci3WMJnzTTLfUo2YRTRvHIR1PQ0AWlJL9yPapUYhHHB9u9RqY4hguBmoLi6RDy67uwHegByMsO6Q5LHoKhtoCkjzzIDI3T2qe3QSLvcEexqzkBCWzQBVlbdGAVI91qWEBUDdfY0RAyHcnK9/SlPLkjAUUAIWIYsUHHTNVrNFlunmkI3DpU17KzokfHzcfLS28Ytl2blYnnPpQA6YCU4IwKr3P8Ax6ugUhQOtWmw5XGR79qhn3sGjI/EUAcxJAxiLFdxzxuqSxnAZre4TcCPwrRkj+T5efr0FYlxM8F6GYA4PGO9AFKS0JnnSFTsGTivpz9nbVbXxb8P9T8M3kediMm1/Q8V83X8rR3kVxAdpkGGU9K7v9m3WJtH+Jv2OZ9sV1+RzQB5L470Gbw14r1HTJkKeTKwXPdc8Vz9fQ37YOgCy8XWupxrhLpMMfevnqgBKKKUAk4HJoA9I+A/gpvGXjq0hlU/YrYieZscYB6V9teN/ENl4R8G3t98sa28RSFRwMgcV53+y/4P/wCEc8EpeXMOLzUiJNxHIX0rkv2ufEcSpp/hqylxJIwaZR6UAeI6PeSahd6p4k1F8l2ZhnrWBZ3Kve3Or3B4BOwHvW14rkTSvDlppluATKBuI61ympsIIIbVegG5vegCndTG6u3kIxvatqwtysXv2rHsIi9wpHAzXYW1vGYlb7zDq1AEMULmLCA+5NOa1lERPGT04rY8uMIoPI6jFMuQfKZkIyBjFAFa1tY2hSM/NJ3PpWi9krypGxBA9KxdOneG9SNsmJjyx7VvJMHuXMTAbB19aALsECquFbhatTTKtiflOO/qaowXRMZAQncfvVLdAyoFPJH4UARaZImHCfr1piEzXWwH5s8g1WFu0d0jbz5WeRVnWFaOP7Va/JIo4/2qAHhDNfKjHMadq244jsJKnHYiua0HVGkBWeIrI3XNdONkkQYP92gDntVDXOoQwrjYh5FbilIsNlVQDH0rAv7lbHVBLGhlDnn2qhq+sbZSyAzOeiL2oA1tU1CM27w2ZwxOWkY8VgSa4piWy08NNctwzKOKn07w3q/iACW9P2SzJ9MEiu+0Lw/YaTbhLSBSw6ysMk0AcXpHhPULgH7XKYlbnmujsvCdlbpmZmZv9k9a6gFVA3DANRyXNtbSYlcMx6CgCPTNMtIIyI7cFR/E3JFWHit5OkCPj1FUpdVhRXYAjHYUy11qS4TdHB8g70AWvskBzuhTaOcBaRLOCRt4QIeg4qFLudywXA3dzTmupoIibgrhejCgDL1HwypuvPsW2zDllbnNYOqFoJd84a3ccAtyK6z+2V8seYwJPYcVM95p93EEmEb+xAoA87O4MJGk89m/iBxWpDqEFvb5JIOMBc8k10Fx4Y064zJG3khuwbNUpfA9pMMJcNuHc9qAK+kgyxvMH2s/8J9K0SQYtrDCj9TVJ/DV/aqY7e5EgxxgVk2WpPb3clhqO6OUdCRwaANtgxUgNgnpnmlZsFI2bCDn61JAFMYZDmlnXELuSCMdfSgDOZftF6WkAKp0qcbJG+6mB6jmq9pENjtkknvmrSHCANgjvQBFcBWG1cZrPeyEVysv3l71obGZ2AGYx0NRlD5LMX6GgCfzVfChTilkIkAUMAB1p1u22JdqjJ/ipnJcqRtP86AHpuRDtxt9u9HmlU3KoOBz7U+RAiKScf7NVrzP2Vl+5v4oAyBdiS9eR2wuccVoW9xCGIOWU1Us9EihBLMTu55rThjjjXbHGGoARJ9wPkqQgPGaparqJgYB4mAx2rXTbvAbGB2A6VDcQpJNvYBx7igDA05jqBeT5kjB71HrEG1MqAzAZDAV0SwiFWPAB/hAxWZqhUgbBkEcmgDmtTcy6KJWHzxtyy1Y0W7bTvFXh/UoidpdQSDTRiTRdShxuxkgelZm8v4VtLqN/wB7bTA59MUAfU/7UWlHVfhtbalHAZXjRW3/AN0EZr4sr7osNSXxt8C3XYWmS12kHuQK+HLtDFdTRkYKuVx9DQBDXUfDTQZPEnjXS9OjBIeZS/GflB5rl6+jf2O/DYu/Ed5rUqfLarsQn1NAH1pY28Gl2aQx4WG1hx6AACvhnx/q8ni34uahejBhtXIX0wK+yPibqyaR4C1e7uHCt5TBcH1r4T8OvI1pqV+3WZm57mgDK1+7GoeIXkZRsj4wDkcVhXEjSTMzHJzWpZx+ZLPtAOckkVkP/rGHvQBoaSMMzY4rdgufLiCuWAz2GTWdpyKsQycCt6yiRl3KMt60ATQ3W9chw6gdO4qZGjePJY59RTY9Pi3HyhiRupFSLprq2IJGz3z0oAFETEsRnA9OtTaXYGQPNj6Amqf2e4spzJL83pjpW7pcqzRF8gN3oAt28aCMDbnHUnim5E8/lqRheSTwBUF07EbYnJHpWZeTSxRjchUH7xX0oA0p5xcziCBNyR/eYVdjsVfbJP8A6sfdWm6R9la1X7OzbiOeOM1oCRdjRvtyPegCle2cO0SbQG7YqGOJlhLXMnlw+tPvL+GEqpbzGHRRzThpN3q6CWbMcXZR6UAc1qTzanKLPSomKZwZMda6vw94Yt7JYpL795OOcY6Vu6TZQ2NsIoI0V+5PerErJFGzM+MUATSBZCBgLGo+lUb7U4bddiEMy9KyLy/lkY4fEXqDVAssjEoN7/7VAFufVHmYsWKj+6KqRGWVz5h3A/dyelKsR3AhQHPftV20t90ny4aUdjQBWtY5vtOLxNsfY+tbYRRAQoEcQ5qQeTJGfNAGwfNn+lcNrWpXOo6kbazkeK1Q4wvU0Ab+o6zFbsoJVgvYGsG51uS8uCkETlPfNaOl6FGXEl3y/bNbdvp1tEW2Lkd8DmgDlYw84wy+Ww9+tUr5bizBaXJB9D0rtJ7S2Knah3euOaxdSsdsZ2SFyP4TQBzltrd7CR9knOB1DGuo0TxwrHyNSTBPAYVx2p2azRPJap5cydUPGfpWFY3ZaQwyZWTv9aAPebS4hlXzLacnPfFRX2nW+pqftECuR/H0YV514Y1qayulinkJXOB6V6bHL50SyR4LkZzQBzk1vJpZJ3M8X8PFY1zqkl9mzij8pieeetdw8fn7lk545BrzTxb5mh3RmAJDH5WHagC5FqAtLlILkYRfU1pyXSTL+4+YMevpXDXF5HrFukiviZT8xPWtvQ9TiVhaSH5SOGPrQB0zMBEiucnHaoLoobcrj5j2PFDyCNORtK9GPQ1QmuRdTqpzx3PSgDQtlfyl2jKr2JqzEckvs5PGKggLbNpxx3qwCONjEepoAdPIqkKck4zz2qjBIty7uTwhqW9lRLeXlpJCODiqPh6IrBL5pJkJztoA1TtmVTHgjvk1LOqwxruAx7GqyLGSGUHI647VLdKZISpGT1GOaAHhoyQQMjHSmhlKl3Hyg8e1VNOuYpo2RCWkj+8PSptpbiNThvWgB17ceYFEJ5A64rD1y62WQZVAYHBFbj4RSmPu9SK43XpftF4EB/cjuKAKemO8z3ij+KMnFQaE0b+HtUtpATKpJUAdKktyYpZyjALtI61N4A2SvqMMm394DgmgD3z9lfXk1LwzfaFMC0gUjOPavm74jac2leNdVtHG0pMxx+Neu/swT3Vp8Q7mytHWMHO8MfvD2rA/aj0f+zviRcXAXaLlQx9zQB45X3H+yrpI074dpcSJtkuTu5HaviK0TzLqFP7zqv5mv0S8CQSaH4Q8P2Udu0gkjXc6jhfrQBxP7V+qRWHw5NrjEk7gA18roxs/C1ujLtZxnj+Ie9e2/tm6iWudJ04ZAHzn0NeHeJLlU0m0RkIOwAYoAwtNm8uK7lUBeMVlRjzJgPU96nBPktGu4Z5+tWdOs3LB3jPHTNAGm1udigAkAdu1RIbq3YESEIenvW7YqrLgde57VZu9NSdFc42jsKAKGlaoqzGOZtpPrXVROXhUqOvf1rmb7Rd0SlVIPY96fYXdzZbYpmJjHT1oA6a4CSWzQkYyOSetZmlYV3gjbkdzT2uhMmAeD370/TRHHPgAc9fWgCxawMlyS74HvVm8t47jCDcue3rS3CwoRKN5I7GkguhPMCMf4UALHprWsJ8lygPasC91GY3SWVv88jHBauuujutzgMQOuOteaWl8LLxrHLN/qy4GD2FAHqWieH4rKNJ7kCaVhk56CuhiwAVXgHsOlJEFuAskbL5bLkEdKjlIX5t4UD9aAI52iQM7OAqetc1qV3JeFvLbEfY1tXltFef6wv8A7q96pTafCkR8skAdQe1AHOhWVPLZ8n17VLDmNwg3EnqatpbL5/AyP0qyIUOQhAbuT/SgBI8Y3KCQvUHpV6yClTIgOT1PpUKW22HGSPb1q9JLDb6exA2vjpQBm6ldRP8AIJAAv3vU1VtjZxOJraMO7dcjpXCave3KX8m1tu48ZrU0K/cFPMIL55C0Ad/CgZt+cgjv0FSwjlljDBvWmxktbxumAhHSpYCI33EkE+tAEUv7thuH1NUdSRYsSuPlPStB/LMrZbg9z0rJ1q6SG3Kswduw9KAOb1wxhlchlJ7rXF61a+VepcRZwx5967GZRfQs/wAxA7jpWDfDYqh2RlzwvegBk+0wqyMAvXjqDXqfgy5S50NG3FpU4zXk+z95uVSRj7tb3hrxFLoEoBj823c/MvcUAeqShMjAb5hyRXOeNNMivtBm8zIZRlTVyPxVotzEzF3Q4ztz0Ncl8QPERudCWKw3CInBfvQB55p6eXK8O4BmOMmpLu2vtPKkgsh5V6t+HkhlvfLu1yY+cjvXV6hareRobdt0A4NAGBHrV59ljjlKyrjnPWty2uIrm0UwH94nVG61iavo0iTIbPcCBnae9ULe9MEuyRWjnBxzQB3djc+cOSdw4Iq8XCxEK2HP8JrjH1BYWjk3FXPoeGrt9IgW5sVuXG6Qjj2oAfawMY8NjcepPas+6V7O8DIcA9Se9bEMbIrrhsnuelU7mETwmNlLMtADrWYbjt4DdcVO21ZVLMUPbHQ1m2yOjcD92OD61deRVZVyCT03UARpFDa3rmNdjyfeI71YDHPDEDt6VDdqoIkkzvHal3IyqPmwaAK+qzSQwMsQLSP1Ydqwri0SKwOclzzmujumXAGNqj171halOi5QkAMOKAOXDr5pRxgngio/DUv2LxAYsfu5DjmomRjeNuOMHgnvTb5JLOSO4UZyep60Adf4Q1eXw18ULS/gJkBkAMadSK9N/a3tV1C00fWlidGkXBBHI4714tf3622raRqdum2RHUt7819L/HiJPEfwesNVVeFjRmK9uKAPkrwtbi58RadE3Rp0z+dfpXoCmPSLGNU+RYlHP0r84/h3GZvGeloOpmX+dfpDpXmLZWyMBgIPw4oA+Qf2uJmk+ImnRA5wgIB6dRXl3iqLKIbg7CE4FejftSSEfFOzLcqAP5iuF8ZqLqFVVDu25UUAcbZFcgAZyeM1sxNkbT8uP1rnkbymUN1U8itmOQMy+WuQe1AHQWhiREYHJrS+0RLEwfmb+HHSufEMh2lDtNWrMSpu3r8x6E80AaP2oMqght/cZrMu5kkujCgO6rh093USs2G74pIkSJjKihtvXjmgBksMxhTZxt9KRZbmOQEKTnjd6VdjvkfiEBWbg55rS0y2DRMQuX6lj/hQBNZWTrbrLOxkdqqmOTT9Q810LwN2HatqCUhfn6DoMdaj1YJdaeYgNr9h3oAmjkBhLop56c1xPirw8905vbbmQfeUdq19L1F7NxbXznA+6cV0UTQ3EJKkBvbnIoA5Xwh4purVVs71t6DgPjAFdgdehLhHCjPQnvWTfaNaXIaRkC4H3hxWIvh5pfm853UH5eelAHXS65bwKQ8gZj0x2rG1HVg+0sxCeo4zWRqFpeWXAxKoHpRpV3FqNnJZy4ScdFI5oA6bTrmG4UZPOOCKlZvLJUYJ9O9cjZXMsF+tqSCydq6eWVpocAj39qAJ570xFNvzE8EelN1qGSO0E8RMkLDn2rKJLSLHu5Bzuql4p167e0WwjXbGvBYUAc/fqk8+WzkdDUsFuI1BEoEnoKktyWgjZirbepp95tnAeNfn6cUAb2meIBaIsN3l462G8Raf5OeSD0Gea4JbSVkBwffjNWYrSdE3RqWz2xQBv3WqyE7ouB2zWFfzyXZzI+AOtXI9LlmCEqxk7r6VDe2E6FgVwCMdKALXhiPdPteJ5YfVTgVp+ItEtJbZpEgK8dR1FV/DbxRWv2GV/s8hOQ/XNbupWl6tsr2UyzFB931oA8vijXzTbvOFIPDYrQt7W1uGMfn7Z17H+KpZov8AiYedcJ5cucuu2qUuoRPq3mqoxEOCO1AGnFpluMK86HB+ZQOaxfGNw6TQxQbRbp0QDqfetqO6h1VClqdt03GQOtTaX4Zaa/A1V9o/umgDn/Cum3F5dOzArLJ0bHArp4NLvLaVoo3CqvLZ6NXRWWnR6TN5e4SI/wBzjGKmaErcMTwFGfXNAHLvf2s8nkXJ8mdeFJ9ayPEenQ3LKkn7u6x8kg6PXTJYWl5dyT3Ee584A6VHfad5sbRwR+YoHJzytAHmyxvuNrdE+YpwB6e9dj4bv7mwZIZHMkZ6c1iXts1vNkrvUHG4dRTbC6+cjf8AN2oA9PiuhONq/LnqDTZSqKVc8dmFczp2pNlQzASD9a27e6E28Ag+oNAD7QeXvDfMrd6rToWm2p8yjuO1WUYBfmOB2qBY83JZW69aAJPtUaQvG5BJH3jziqtoZowWPzJniotQtJYFLwgsGPPetDTJI5LVRvCuOqnmgCpqE87KSVCIBxkda5W6SUyieY/NnCjtXbXi+ZbyLMQTjjArjtSnjWwcZ+aM0AZGp7oLhC+C79hWo9ot1o52qfOHQE1jylZhFKyHB4zmuj0qL90QXyOv0oA47UpZIraOCTqpzzX138PJU8T/AAEkt5hu8lQvPOK+XPFtsnlK6DDD9a9//ZY1WS48HarpocBoyNpIzj8O9AHzx8OJfJ8aaU+cfvl/nX6PaeVFlAS5JKA/pX5neGpvs+v2EucbZl5/Gv0f8OXKz6Jp0qtlmiXOO/FAHyz+1hDEfE9hdou1lIBHrXBXyPJZqxX70fHHIr139r3StttbXyJgBhnFeX2B+16HZTqWGFCkgUAeVXI2yurD5g3U1vaLCHCvKQG7c9ag8XWJtdSZ1B2Pzmo9If8AdZyNw6UAdOyqI1OMkdhViAFpPlXJI61Ut5F8ob2KuenvWrApRN4+VsdfWgCwIg1tkNjaeRVSdDGhlTAXHNPFz5SO20Nn71Z17csY/wB2p8k9c0APsIRI7SxptBrYtmuIG3MNx7YrG0m6aDK9Y27V0Vo8chCowGe1AE0d2dmBlG/iOM1Y2K+1ouvrUKQnzzg4A6jsatRvnJVNo6ZFAFG5sku2If7474xiqS6dqFq2+ylO0HkHvW9yvDDOe9IhyxLHp0HrQBBbxTXIUXQ+b2PFWOUfYq4A705d3LLkf7I6CmvOqHYCzN7CgCO/jLBA2CD2riLy3Fn4nSWLAxyRmum1S8khiYkLu7DNcPezPfXoWEs0x6kdqALlurXfiCe6iBVRnNdXY74oGZvn3HjNU9FsktbTcw3P/GTWrLNAluMYHHBNAFSMiS4JRQhUZPNZV4n2iR2wAOmaSK6ImlZ8YHTnrUlvh0bbks36UAZb2xikXaSsfU45zXS6JpiXKiZzsiHT3qra2zSbgxxGvLMa07HULJMIJB5Sd2OKANLVFtdOtFlWMNn2qKxv7O+RY7YLG7feY1mavrMepN5SKFjUYBHesaCI2c4kY5DHhQaAPSIbcACOJEAHVifvUosYJM7418w8YqPTZkubSNsD5R+VXAYlkBAJY9MUAc9q2hpGGEBw3UYrG0TWJYr82N1w6nCkmu7uceWWVQWHUVw3iezVLyC/gUKwb5sd6ANfxBZQ3dqZ4yFmQc4HWvK5IxBqhnQd/mU969atZUufLlC/umXDiuF8daYLOczRKDC5+Vh2oAZoTQ2+o/2hAWUD70YXNegN9n1KFJgxMjeowRXBeEN0FzHIwBz/AHq711TzRLBt2N97B5FAFO8d8rDcsSI/uMKuQ5uLYyZaOUDHTORTb21YsM8oRkEU2xeRIZt8uWX7uaAKtmih5i+eM4BGOadZxPbxTSAAyPxknoKW0eRwzXBDkngntUVwk1w5jZSkY6H1oA5jVo/sVx59um+3JzKGHFc/r2nLEqanppzG/LoO1dp4qcJpUdv0LHHNJb6NbppUYDEzEcjqDQBw2n3huCF6Fe+eldDb3MkUaybvauf13S5dLma4t1/ct9+P0pmk6kXQwuNyevcUAd/ZXiylec8c1egCvIxztFcZZXwLqinYAevrXQ2t024lieBxnvQBorI4Dxj5Iz7ZzWZLbtHIZInMTg9uc1dgvlkIAU9eahuFL3xGcDHAHegCzaTLcwsrNmXGMHvXBa+jJevbN8jMeB6120sBSJXgG2QHketcT4wmefXrZkA3pjIoAh2yxW3kBeBWz4fLRwMJTuB6E9qqTCTUJx5KhNo+bHer1rhI2VlAZRxigCh4gIRWB+6R09a9S/ZBuHXXNShQZJUEe1eQ61N+7xM2Qe1ek/sm3htvHU0YB+dO3UUAeHWz+XcRP/dYH9a/Q/4Q3y6h4C0yZQuBGBk9a/Oyvt79lPVF1HwCbaVsyQtgAntQAn7T2iy6h4QknEn3BkDtXz34EmW48KPAp/eRtzX1h8b9OfU/BEyDMe0de1fHvw6za+ILzTpG2qc4B6GgCTxjYiWyUgEuB0NcJY7vNwoHB5r2bxFY+ZZyJGVLLnI74rx+aP7HrDRgkKTzmgDqdNti5DTqW4+X2rUjglkO3cQo7ntVfTpA1urgHgdqka58tZGZjz2oAsRxrGzAqCnr61BM6Srs2KFz+FRWklxfRfJhIwfxrSt7NEQhuT2z3oAwprYo+EJXPQDvWrpSL5OZCEl7Z61bEavghV3L6io54kEu5jh+3pQBoxQzCPczgp6d6kWRtmEDLj16VRsr7YQJ1IarryxvJw/B/h70AMnuJiVMRBA+8G/pVlWjkKuGw3pUcSrKG3fKV6e9MkjDLlvlUenWgCxeTvbqFjxlqZAjRLuPLN3rMYsLhdzlsdK1wRKoPKnGPagDlfGrta2ZlI+Y8cdKwfA5UTy3Erbm/ujrXQeOkMOlFZmB3dM1yugzjT1WRVyzdqAO5+1q2flIHcHpWPqF4LifZFjHTFVJr0nduVxv5xXUeAfD4v5zeXSYCchO5oAy7DR7m+AhijJHUvjgVqrYJbPs3YSMfO/r9K6LWdYgsI5bWzjCs3DMnb61w1/qglIhWQOoPO2gBmo6k8wkhtB+4HHua5vWkYWQaMtuU8ntV8yqly5U7FPr0qnrzuunfKRtJ6jvQAmj34mijXzMSL1HrW+xEjbnz8o4IrmdA8gWx2xlp2OM13Gn+Gr+5gV1HkqRn5+9AG54OnWWJtzcjtXUKqkNsO0+orlNM0O+00+ZG6ls8jtXS2M7STeW6qCBzQBHO7JHtUZU9WFZGvQ+ZpshQDco4raBGJASCM9BUVzEssLptIBU8dzQBzXhy9jj0gmdwoB+bNZ1yw8Q6vHDGCthFzz/ABGs9gqQX1s5IbccLXWaNFBB4etgigS5GW70AF9p1v8A2a5jiKSIMKQOlVtNtWNgGEx3A84PWtqaMyJs37IyvzbuprNsJhDNJbIqqnYsOtAFgXzqoWZNo6DHehVHKhQTJ3NSFUmtpDkNMnaktEVLQsyuZD0B7UANkEFtEYyfmPc9BVJr1TAytIxZeQRTrm0kklU3DDavNV7p4IreaZgqDG1d3c0Ac/PenVtZhWSJjDGfmyOK6lIlWYAbvIYYXb2rK0a0aGwcygCSYkgHritizlUYgDDC9Se1AGfrmmR31q1qDicc7vWvK72B9J1IjBCg4INexPAZpTMH27Txk9a4/wAcWEUgDAh5G/u9jQBhuwAS4QgxuMjHb610WjXqXMOw5aUVx2iyCK4axunCIx4Y9Aavx3L2WpeUoIRTwy/xCgDs2gZSNjsM9T6U/cCoDt869GXvSWcv2uJCrAIetWPs0aElic/wgUAMkvokKuDkqPmU9TXG35S91Ka5AKgdB3rp77TDOw2OIz3Jrn9Tj/s22lkcjaeB/tUARw3QsISxYiWXoKW0me3tp5Lkncwyue1ch50tzcoWck7uM9q27m63Wxgnz6bvWgBsziWNZMeZk85r0v8AZd3f8LHcrxLtO0noPrXnWnwobiFWYqijP6V6v+ynEs3j7UZjgoi/cHU89qAPAK+lv2QPEEdtqtxp80gUSDgE96+aa674XeIX8N+MLG9DbUDgN9KAP0Y1C1i1GzuLO4AdJFIwa+GPiHpVx4M+JDNLEUh8z5WxwRX3Bot/Dqum2epWrBkmQHj3r5//AGrvDzXK292g+UjOQOh+tAHCXUiXsQmXjzF6DvXkfjG1aK+LquApyR3r0D4fX0V5o9xbSOFuIBxuPNYXixI7jSp5G+WRCeMdaAMXQ7rzIC0TbDjB3cgU95WuZDGG3AH7wrN0GM/ZGdeTnp6VvadZxzSZd/LU9TQBoaayxxrsPzL19KvPLnnPynqarGG1A8mzy8vqK0IfD+qRos3kMymgBkkhW3ABB9MDmoyWfAyAPUiknyjtFOhiYfwnvUpKm1DKw3r2oAfbWvmhkPI9e9QywlWy+fk6EVPBNvj4yCasFCWQuBu+tAFNZJV+ZQWY1a8qWSAbjhutTSw7pASwVfapCFTazH2zmgDG8iZrgO+SB6VtIPLiUDJLdqBIiZUAHPvQrNsLAAMvfNAGH8QNPN9p0beYFaPnFcPpERijZpOQD1Ndp4k1OI2zIX+bvxXG28i+buKkIT1oA1IJFS5V1XI/2uRWvLrFzb2zLDKYt3p3rEcLvUIfkPOalZ2lmVE5I7YzQBpmdm0xmbcXbqSeTWMI3JVY0PmMeoHWup0jw1farMilTDa9WY10kmmwaVcLFaRLKFHLmgDyy7gkt3InQqD/AHqpavKX0xFxkKe1emeKrKK+0WWR0HmLyMV5XdkNalScOvFAHT/CiwiudRaaQb/L5wegr2CSVpATuCBeAB0rzD4PRHNyzHCmvQY9zOwJ3gHjtQBbglA3A5yR1qlLGxlEkZKqD971qeNt+QOT3FWVTcq7l2oP1oAqYdZfMYqGPQdqWVMlWJK5+97/AEp8u0zMcbV/OoyGeIIxwM5U0AecalM1l4tKBV2P90MK7O1xLbFZnQS9RtGABXC/Ee3eLV7e4ztdOv0rptDnt73TVaPPm46570AbIyIShcNGOpI5qrdRR+WjOpCZ4YdTVm3lMUao4Cuemec0+4XaQsw3hv0oAhhTY21PlVx361LMfssaxLMu488jNJAgMuWUsidDnpVa5uC04kEPz5wPegCV1mlgc+WWAHB9awJ4HuUCXoIKn5AK3pJJGuYvMk4/ijAxio9RkDTgRoGXsKAK9tE8YCzMAMYBNR2saLJIqKSepNSBDnzHYuq9U9PxpISGLTFdg6Bs0AOmYvFmNgrJxVR4EeBvNUNLJxn0q7bqgV9/zM3b1qpEd1xtHyIvUHmgDy7xNbG1vGjKEYOd1NtbgXUKKc+bF3J6ius8bWnmRSzCEooHDetefQlwQY8hh3zQB3/h+WdY2eQgwnjA7V0sMiOEByx7c15vpFzMsTPbOfN/jU85FdLoviC2njKS/upo+x70AdHI4PmKHGR2PauD8Z3m9Y7dTwvJPvXT6jdg2hmhOZpOABXF+IgIY0RsNK3LHOcUAUdBsnv79I0HKjPFaHiFFR47dFIl3YIrZ8D2osLWbUZyFDIQpNZdqBfaxNPM37tSW3GgC1at9jgeT5S0cfcZxXsv7M+mpZ+E/EOv3ZMULkL5gOCMHsa+fb24ma6liiJEcp249ea+mtXtx4E/Z7tbJm8u5vBvb155oA+UadG5R1ZeoOabRQB9xfsueK11rwg+mzybp7c5UE/w12Xxn0war4GuiihmhG4k9h3r5Z/ZX1+TTfHsVoz/ALmcbStfYnjZo08NahHIhZJImyBQB+ehiutN1yT7FIwUnls9a6S7mF/4cmnjwJkGHT1qbxNbLb69aKYwqSS7eO/1qDxVpc3h3VPJQA29ygIUfSgDF8HWyy7kaPcXPfjFdTqmmeSkQhX5R97Bqj4ctTGiSscTZ4Fd0tjbzriWVYywyTmgDl9Bkt9O1NXePOf71e2eH7y01Oz2JIh4wQMcV5zcaBp09sA1+AynAINULbT30G686y1N2jbkrnigDtvEnhe2uvNR5AXxlSBzXnd5oOoaTA86qbi3Q9O4/Culi1E38gkh1MJOOqs1Nktb93bytSgdG+8Gcc0AcDHq4ScFxgHseMVoT3qPGGzu+vGK1NS0O2klVrhbXenPyt1rPm8N3V+zeVJFHB6BqAK76slvCXJwmOqnJNP0aS+1+OR9MtRJGnUO20mpIfDL6cyPMgmiBzjqK6Lwy0b62htf3B6FF+7QBm2+i6rMm82UpmHAUA4H40288F+MLlf3dqsJ6gl8cV7zBJcRWIVcRuehUDmoryO+mtw00u5uy96APl3VdE1SxLJqEL7xwSg3ZqnNYzW0EbNBKoc8HYa+gNStltN/mlWkbn5h0rA09BqM0ouCWiTttGKAPKZdPure2WRrdmVv4kGa7DwhoSw2y3FzGHDcgNxW/fWoS3kTTpyoPWPHFZWnXepWsu24topol+6pPGaANW61sabdJEqDLcDtim2qFZ5WuDkSjIY9qz4bQ3uotdX4Dzf8s0/hStCRPMwzPjZ1oAztWBbTZ/J+6vUeteM6yp+1EhcZPGO1e4SIJ98SfdcY5ryXxXYtY3UsY6ZzkUAdN8KJglzJC77XPevQJVAuSqsQoOSTxXkPga8EF/EZeGJ4Ir2ObbcxB4/mkx1PQ0ASnEZEkbDHTNTbWMY3PuJqC1iUQFrjg9lpo3cknK9hQAs6NE28LzjpUds4KvI56dvSluPMyrl+PT0pIQszFo8FR1z3oA4H4kwLKsdw+7b0ziuZ0bV5NFuEIzJE38Fel+NLT7RphJjwF/hWvKprTeeXw2cAelAHoum+IdPvkw7Mj+mOldBbvHNBkMJcdGNcd4c0QQwI7Kru/UnpXRqqRHZbqYwvVR0NAFqd/wBwQh2epqrDHgli2X7M3FN35ySDk+vahGGMSjzT2z2oAsBSgCuS5fq2OlLfWQRUbeXUd6hmO0qVkf8A3cdKWOeUhlYb1PTNADEljWMoE3A9RVZVD3SxhvKXstIWSOcEMyv3BHFKMPcPK/3QOG7UAOu7W4Qkhxn1FRW8KmQZ+U9/enW87bXZh36jmllGArphyf73GKAKmuus+lzJOuAvQ4ryW7hMN4ojHBOVr1XWpMaVcRFkLkHkmuQ0XSre8j864dt8Z4AHFAGBGlzYXyqSymQZPHarF3p8kyi5t/vE8jpXXXlvFJdRmVMnG0HHSoU0mW1kKRyCWNjnGelAFDTrm5t7Bklh/e4wGJ6VlaVo1xqWosZSWRW+Zj3rsZNMe/2pK5t4l6FerU+/ntNDsfIifN0wwq9x9aAMTxVqCw26aTZICcc47VkLCEsBAxKSdWYdq1NPskieS8vXElzJ90E9Kk8O6DfeMfEsGhaKjM8zjz5scIvcn2oA0fg74Ln8eeObS0iRl0+1IkuJQMgAf416P+1D4hie7t9Fs22xWKhExyGI4NeuxWGhfCDwFNb6U6LcImZ7hsb5Gxzj1r5F8Vak2u6xJdalcbYZ3JXByw+ooA4qiiigDuvgtK0HxB0yRDgh6+zPijr4g8N7Ypdkjrg818ffAi2+0+PrXphAWyegr2P4yeKIo/Nt+pjHXtQB494y1RZ9fs0tzueNtx9zTNSvbzWNchkk3HygBz0FYtuc+bqd3/r2OIkHet7S4fstp5krFrmXkr3AoA1GQBkIZQR1K1W1G7lX5ix2Dp6U8qXXeCAq9vWqzJ5o24LZ/h9KAK63M0mGdsL2A70RX8zOyyZI6KKknjKAeWv3fWoxuQhtoLN3A4oAdJZ7kBtiFlb7xz0pgivIG++So6kHrUyXJjVk2c/zqQ3MjxqoTaKAK8LzSNvkLYFSreyiXbHJIqjv61FK5ZipYKfbpTrS2O0nJb19KAN6z1W4RAry7kPG1jxU9hMsWoCaLKtnJHasOIYRmZlCDqT/AErR0m4U3CjIMY6E0Aew6RqzvYrIzNx2atW01HzUfzHJbHBHauK8O34mDRyjkfd966by44rbzEyDjkd6AOV8Q+bdX3lq7tIzYqzJplxZ2ypbgZI+bFXNNkEt5LIY1yOhIrpNNlRo3LoC3oaAPM7iYW0wWaB8k/wjirSWQmG7LDI69q67UJLSfcFijEqnuKxtWVoI1YIUQ9T2oAwWjW33bs7emR3rP+7KwMgKHkAmpNRvo3bETFiPTpWaNxmD7cqaANWxV5iXcBFXoO5rnfHOlebF58KA5HPtXSt5kcSHIB7DvVHU5TJbSIQSpHJHagDyCJfsU/mRv905Oa9h8H6il/pAZX3OByteUazbBVk5G0HjFT+EdXk0y5RwWER4YH0oA9lkZhhnIKjoBTlLE7iACfyFV7C9h1K0ElvJGygZIHUUv2rYcPgg8fSgB8ziXgdB1btS2rLG4O0Mn+zTeFAjQfu25pkhaOXjCqOwoAsaknn2UrMXC44AryK4t9mokSrlN3brXrsLMUYSk7GHArzjW7fOsmMttXORjrQB01sVWziMZZVA6NU0V11VyC3YCsKxu9sggmLYHQmtExK0burbWHO7tQBeikxuMhGT0U1HH8kxVs5bpjoKrWlwtzb4cDcvAercEmY2QgM3r3oAmDBJAuct6nvTpIcsJBKFQdVzVNcuuR/CeSaswuW4+TYeue9AELpHKzMpLL3ZqoX6vbQEwkywfxL1rQvAjKBkog7L3qu5YxlRgoey0AV4Z1nt12nYvovap5CkcOS2FUc7uprIvpk09TMDtQdVPesia9vNROVGyFugNAEGuX6zu6xjjpjtTvDbBImDMTg5wO9FxYhYdh5l74p2gxCJ2POR1BoA3I3Ej+ZIBgcAdxU0Cphi3y56EdTVdGD5BAAP8VVNV1JNJiHmkPKf9Wg60AWdc1RNMRN3z3LcRp6Vj2OlyXUzX9+2Z25CtSaZZm8uxf6ixM55AboBVzWtWitrWRgp4G1fUmgCpZ6Zc+IvEtroWioXvbhthY9Ix6ivsHwJ4O0P4YeHnt7REfUPL33t7J1PqM+led/st+C003Tp/FeopvvrsbYCR9wGrX7RXiv+zNH/ALFtZW+13hzK4P8ACe1AHknxk8ef8JRq8iQOU0m3YgAHl29q8liuopL8y3KkoeOKXVrnzJFiQ/u4+Pqe5qgoycZAoASiitjwvo82tatDbxIWTcC59qAO5+F80XhywudWulKzSDbD71keLNVm1AtLduRvbdgntXc+NPC91pmmWszWrLp2AqEcivOtZsmnmht1bG7kD2oAj0iQ313HtGIYumRXSSAuSc4foKg02xWyg2qADjk4qzGC/wAqcMOd1AE0S4iAzvPoKlRCoIUfvD+lQxFTJvOVK9fercarMpKgl/X0oAjmUIqxsuc96ieeJP3bAH3A6VYkXjauc9GY1TjgEc2wNuU9yKAJv3aqrRbWB7Ec0nkyNJ8y7c9KsNagphJQp9cVXmlkSMRzf6sdweTQA2RSVIwgK+3WltZmWFgFAP0qtcIZnQxggfWrAkMcexk2kd/WgCO4TzFUuRj0FRKklvKDDyD1PpVj9zt3yN85/gpUZNrZ+52WgDZ07VLu0RbgxkwL1cV1EHja0eEA5cMMH2rgI9QuLaMiJS6HjyyKu6fo91fWslxbwiFepJNAHoFhr2lx/vQf1qpceN7S3lmMQMhbpg4xXmF3b3Kkia4wAcYFRJbxS7ViuTK/c4xigDqr/wAVXDyrIjhQWzWz/wAJU15p7QX0RI2/KQetcHLZW5dVdMkf7fWoVJtpGGSQOg3dKANm2DXEjOcxqG+VT3rdXFsmGIZyOBXK2mtBXxLCdg7etakeuqsLgW+7d0JP3aALkd5JIcsQUU4I7irWDIksaYJdTisO1UuRJG2/cctW7azRpj5fmA4BNAHnmpWjSw3MGzdMjHIAri2LwTYyQR2r1nVEeG9Ny4Ajk4cYrjvFeifZx9pt1DQv8wIPQ0AGjXtxHs8iYqp+8F4r1XTgPsUW7lnH3zyK8L0u6eG4Rd2ATXqvhLWvtEf2eVeB905oA6iTKqVzh17etM3BovmOWP6U6YPtV85NJEpZjgAjru6YoAVMqinkle1cbq4eXXxIijngj0rsJZyrbhzjg+9cfrw/0wyxkqepoA14LODyGIUeYeueapXiN5kcLN+5PXHFJo87zQ7iOB3z1qzdw+ad03zDtjigB8aLCmIwBGOlEcil8tkSdsVURZEUrv8AkPaniU7lTIyvOaALQbzZMqen3lqNpdjkH7p6H0qOW7iEnmEgnGCoqgdQiNyYQeDyD1xQBrTyMY12jLjoKzL26ljfFvjefvei0tzPKSMN07iqIheWb53JT1HegBothfsY93mY5Zj0qbT4vLMxcAxxDr2FXIAUYBMZ6bQMVQ1O4a0hkzgoeuD0oAqXksbWrSKfnY4HrUmlRt8qsOT14rLsVlumDsPlz8o9a0L3U4tLUKPnu8fLGvO2gC3rN0mjW5knAM78RRjvWLptnd31yL6+j3d8H+EU3TdOu9Zv/td7KS4OdxHCj0rT1u/t9Pt/LiBJHHlg8uaAIdS1SK0fGAsR4yat/DLwXf8AxJ8YQW8KsmlQuGnmI+UKO31NYmgeGtQ8V6xbWxLB5mxtA+4K+2vh/wCGdO8E+G4NK05FExUGaYDBc0AdDHDYaRpUVnaxiOysYwFI6HAr4o+L/iJtV8WajcFgwUlIx/dFfR/xs8YR+F/C0sKSD7RcjYiA8jPevjLW5iPlYlpZT5jsT69qAMhiWYk9TzQBk8nFJSqSDkUAKil2CqMsTgCvpL4HeCfsNiL29UbpRlwewryP4YeH11PVVu7nAtoDkg9zX0hZatb2kcSodiYxx0oA3fGtxax+FpYPLSWzC42N1B9a+YSscmoSsp/dqcqf7tep/ELxIr2U9vEwLMDg5ryq3TyNKZ5zhnboOpoA045EkAdjlun1qwluiKTHyD1U1FZokcCNIgJYfLir8QAj/er8xoApLbPP8xBVV6DHWrMIblsbVHFWHvoYl29SB1NZdxdmUFl4GeRQBpi5ijXaUEme/pTbjUrGRNgtVG3q+etZDS7iPmwn90VBKdwbC5HbNAFy61FMBQmB2Aqr50Gcv1+uarLBKqlnJOegp0VpzvOfxoAvQKkkZaKUhvcVDL5pwqPtX+9UMqlXDIxBPekdnLbSwVR12nk0ATC2MbATSb5D0xzV1IGuECwRYK9WNVbL52yvykVswsIIzLdSLHEBk7jigCtBFJGdsrB5OwAqfytcuCIYh5Vn/E2cVzt/4thacw6bCg5wZj1rYh8Quth5ct7GxxyrMAaALMulBRiRAw+v3qgFg6giACFe+Oal0G+gvreV2uw8q9Iwc1eiXzVEvKEevegCguh2zgSzszMP1pf7FtnBbaSvoe1aUcymQ7B8/v0pN4STksxbr7UAUPs9vEArxAgdMc0qWNuzZMeENXZIxExcYJ7AdaZDvmfMpC+1AGXNa3GnlrmzUPCv3oc9ant7+3vollXIkB+4eCh+ner96ywwgrkv6VzOphJZRLGCkg/5aR8sD9KANq5Lyti4+eIjBJ9K53UY1sVkgjH2rT5uuT/qzWhaag0VuV1FTg8LIP4vrVPU1jVQ0cmIH+8vpQBxGr2TWUoOMRnlHHer3h/VDa3KOWxk4Naqww3cclnMC0bD93KR0Ncnd2s2n3ZSVSCp4PY0Ae76bKbizjKMChHXNSgtHIQBuHucVxHgDWFlQwTvwOBnqK7iT5QpIDehNADJcK4OcL6Vm6vaRzW0oC8sOBWnOwwGxlvQVXkZWK7gVQ8ECgDhvD981vcS2cnAB9a6oXCSR+WDxXIeIYlsPE0TInyOeM9K6WF90eFRd2OlACDCOVXkehplzgj5flHekldsKSApHU1HO6sP3bZPcmgDOt8NLKCGZPU1TsJEguZEZsox471s2+1VbkknruFY+jqh1idWGUOcZ6UAb8cYWEeT36mo2jETeZ5gHqamhBhDDKtk8c9KguBFHJ5kn+rPXHegA+1wqjSFhx1Nc1OW1Od5CSIFPU1dnVJfMcDZarySayjLLqm6GyUw2K8NLjBagCSfUSqi000Bph96bsop+j2ZedpPMYk8O7L94+1LbCy0+Fo59ohHP+0/1q5pUt7rt2sOkWbLbrxuK4RfxoA1Y/NZlsdPjyx5LL/D9aoT6bBa3xnmbzrkfKvfmuvnij8M2JtYCrXc4/eS9xVn4N+EZ/GHij7RIm7TrVtzs3RjQB6/8D/BUeiaB/a2oxrJfXQ3ICPuiu18R61ZaJpU97fSiPyVLDPc+lbbCGCBBEDHbwLgjGBgV8mfHjxk/iXxFJp2mzEWlsTvweDigDjvHPiufxdrtzqd4x+zREiGMng153dTtcTNI/Unp6VZ1O685xGmBGnHHeqFABT4iocF13L6UynJncNuc+1AH0f8L/D8Nr4fklmRSecKe9Ta+7W+nt5v7pM/KOlO0zUHbQxHGVjC85Fctrf27VpcyF2jToQfl/GgDndQSW7ukfezDso70up2sixxRFCC351qzXFvo8CtIUmuW6bei1i3WrmW6BuWweq0AadtE0aR+ayhV7d6lu7hMZL/ACnsK5u+1K5KOSV8sdCOtZVvqLuSrvwehoA6Ga5UMyMQV7H0qvGzMD82B/OobZI24kJLt6dBWgLeKOHAnjz2zQAyCIZJ+b6HrVw+ZNb/ACQ4Rf4iKqJeqkiozKJfeq881zeXJSO6QKP4UOB+NADprx4z5YBZjwD6UhFxtHmyHb1wtL9jvI0YuY8+pqhJdw2wPnXA3/3c0AXYzJKSo37uwqxFaiKMy3c8UZHbPNc+uq3cjlLKMyOf7o6VWMV/MzLJBKWPXzOaAN6XxDDGGWxh3uv8TDiuY1HVrzUXZrh2aNf4B0rctfDV7cRqcqB3VOD+NWNS8LTQQB7PEkgHKL1/GgDhwxQ5XKmmuzOxZiST3NaN9Zyqf3i7JB1Ws943jxvUjPTNAFrSdRm0y6W4twC49a9b0bxNFr2jhfLjiuYh8yr1NeL1LBPLbtugkaNvVTigD221YvGXwKlbLLxkGvOPDXjGexcQXoElu3BbuPevS4yj2cdzDKk0MgyGXtQBDGQjkFTuPdqfHFnIIx33GozKctkEgdzSIzSMGO4R0ATptYMWBbHGe1YIhWO+kaPhG6gVtuTyeqjqFrLuZrdbkAE4bjAoAfpKWt7JNFeMoROinoasPpdldxNFbwS5HAZh8tUoLNVmfzcYPK4612PhbS7mKNrudgbQep4oA4yGwSxcxbRIo67u1Z+t2drqURjCkgdH7qa3vEFxFFqMphwQ/AAqnBEgt2VhtLcmgDzq383RdUCueM8N616/p14LvS4WOXyOR3rzvxHaCSMtEAwT+L0rpfBFyJdPCoWZk64oA6SQ/PldwwO9RR4zvB3MT36U6aZFQv8AMT6U1XH2YyLhT1we9AHF+LiH163R2JORgDpWzGyJtwdrAdq5PUpW1DxOqgE7T2610zxmJAMEsB1NAD2zM5aQED07mq5Kgsm0+3tU2WZA5z7VVnJ3gbgGPWgBwBaB2Zvuj86y9EmQzTs3r17CtC7dYrR2J2LjnPesDStN1TVJX/sq2edM5JQcD60AdDLfR2+N2wk9PeszUdUto323MpKnnZGeRWTrLXOnz+TLNA1wOCmMlaz7PTLu6c7V+d+rMP5UATanqxvWWJS0Vmp+73ardu15ehYrKMxW4GAMYrY0DwPc3l2gWJiB1d/u1654b8CW9knmP++l/ujpQB594T8AJcTxz64ZnRzwvrXq91Hp3h/TDDbwpDCF+SOMck/7VbjWKWemGSdkQKP4uq1474q1l5NX2W8wuFJwoXkk0AZmqTXGpagtnbIZr26fYqLztGa+qfhx4Yi8IeFrazTK3Eih5sdQSK4H4I+Al0pn8R64ge/kGbdCPu166JHaYyvxKeWz0xQByHxX8UDw14Mu7iRwGlUpHk9c18WaxeKIXZSwuLpi7kfXpXrH7QeujUvF4s7W4ZrWH78bnKA+wrxC/l866dgQVzxjpQBWooooAKcjFDkHB9RTantIlnnWNmCZ/iPQUAeu6LqyQSN5j53A7RniuT8V3mpq0rxzPHCx6IazdGuluLYxmTbcJyoJ+9WpDfyMnlyFS/TawoA5S2nvJJwBI7H/AGualu57hXIckkdeK6uwsxPcMZIhGg6sB1rWgg0hSVu7YyA8K/SgDjNHmVpFaTceejdDXQ/YrHUJ18uWO0kUZIYcGtG+8PKtuzW1qRGwzvHPFcb5PlzOqksiHk5oA1Ly40+2keGCQ3Ei9WXgVmTXL7VeOFwAfvE5FOhdJ5CXUKF9B1q5LFEbXeg2hexNAFEXTTSfu2BkxySK1NOtFkBIYiU/xjoKzLAJNOXUjI74xV+KW4ctaWfyq33iR/WgBdWtJ0kWKbUlZT/drNSO1t5SyxvdSDueQKnuEtLSXZeXBZxztHP61Tm1tIyRYwCPtuPOaANS11q/gjYWkUEYP8ZTmm3N5qFxCHuoyc90OK52XUrqUYZxj2GKhZ7h8ZMh/OgDqdOGqK+beR9h5BLdK2ra31yJ/PEoGeCTyDXFWkWqNhoBKBV+DxBrFkfKlLtH3Ur/AFoA7fT/AAxPfTPLOm925L9qWTw5DIGSeMZTtim+DPiBbRTiC+TyFPAJ5BruL24tL1PMVkJb7pU0AedXHg2zuGADbGPQCsm98CyxbjFOGA6V3ckTJKRu57GoFdpA6tlXHQ+tAHlV9oGo2fMls5TswGQaveHdevtEYxMrvbt96Ju3uK9R065XaYnQSOOoYU+/0TTtUt2LxKjHgEcYNAGFYaja38XmWtwA3dCa1rV2wHcEf7PY15t4i0G60C73ws2zOVYV0fhXW7i90yRZ3DPGefpQB1G8vIwAxntVOKON7rO0Bl6kjNAuFZ4vKOQw+atHQLVWnujJ8o7Z5oAx7+6EN0JG5iTqAcZrL8ReLNU1G3S0snaO0H8CcGofHFrNDd23ysUdxkg1atcLexRRoAu0ZG3+tACabcJHaI11l1QZYnqKt2+u2E8oSPMe7gFu9ZesXEn2wQKAFz1AqrcxIxPKgoM8DFAGnrMYMhhOF3DPHeqHgi8aHVprNWGwnGBWZd3E1zCoJMm3gdiKXwYXbxEQw5xznjFAHp8sAHy7TnrjNZepXi2tnO7rhwMAGnzyIpkXeze47VgeKZX+xIucg/w9zQBlaFEzvLct/rGJ57it0SSnpIMepHWsPS38hQi9T2PatNWZssy5I/CgC1uWOMrKczN0ApCqQQtIzABepbmq8JZ5dzjjsK3NK8Ia74zJs9BitppUPzRtdxRuBjrsZgxHuAaAMm2sbiaIaleWMs1qD8iKeGq7a6nf6zfLp2mBdKhI+cBcMR9a9r8E/B/xXZ6U1tq0+nJx8gMpfafwXH61na78JdU8OxLqNxq1vdXEkhUQwwFQFwT94nn8qAOF0/w1pMDMkNnJcXS/feT5ixrqbLwzmJbg28UK+rAcVHZa1LpYePTLUG8Iw8jjIH51UsJtZ8RXLrdB43jOdynAP4UAdrY6RJ9lAREitByzjq1WJdWsLOFlRslB2GDVa0jmjt0fULvy4Ixjb61wnxD8WW1mFhtEXfKdqY5JoAo+P/Gc15aNZWisqOccclq6r4MfC/cYde1fClfmSJxnPvWT4E+Hd/JrFjqd/GZxMQ+wjhRX0M9qbbbHbELGq/Mo6UAQswabEWEUcY7fhXKfFDxdB4P8L3MzSqbqVSqLnnJrU8VeI7Lw3pEt7qTLEqglEJ5Y18gfELxlceNNWkupmZbaI/JHnjFAHNarfzXBuLu6Ytc3TFuewzWDU11N50xboOwqGgAooooAKXpSU5VLHA5NAArFWDKcEdDWxZaqjyL9tHIH+sHX8qxaKAPRvC+p2d28qTSt5vRBt61patC9rPA0h3oxzwOlZfgDSVW3F1Ku4Oc59BWpr9wpu2KSYCLxQB2ukXqxeG72YBZEEZALDpXiMDpLJdsw2+Y5xz716LbXHk+B7uRpCWfOVFeYrIvDtggk4B7UAW2uDCAo+UJ/FjrUslwHtzNKT83AT1qIp5kOGBZDzgc01IZb+5igjXaE4AHagB+nRPOfKhJTPLewo1fW3WL7FZHZEvDuByxo1q7WyjNnan94f9bIOp9q52gBSSTkkk+9WrGwnvZAkKdf4jwKv6HocmoZllby7dep7n6V18drFCkcUKhYk6L6/WgDO07w3a2rFrwG4JHAxgA1uWkMcX3Ik29AMdKEkdW2j7p6+lSn93Ivy8e1AAIlLMHPyHoQOlORY2+RkAX1K9aJ3O7cpPvmlt5C4LEg47GgCrqWgabd4xCI37utT6dCtggTzHG3hWNTBhsYgA56kdqdJIHiRGyfSgC99uVo/LZTk/xY61DJuO0bwAOmO9ZeoNc27gxPufH3D0NMsdWtJwYplaC5HVB0NAG2o8t/Nb5Tjt3p0d00YYnlT09qr2kx2Mrj932JpxKCAjHJ6ZoAj16eK9011mQFwODXmOmX7abfOpP7stg16LPG5hYYByOa83162EF2xUHBPegDutA1G0vrwRLL5RHb1rqLljYQboZc57CvELSSSOdWico2eorvdMv5HhVZJGfA5zQB0GqyCezRnPmN71Mk1rOlrbR/LIcbsCs+4JezWWMd+1ULy4l06/tLiJGwcZ9DQA7VYol8Ti3iXCqvPvTbq1DWszMoZgflHTFPNtLfa018zmPK9DU8lqzRyAzYQ+poA5zVB9lFs6ndL3yMAVH4Ym+0eJHaQAcdRWjrdoj2KuJN5T+Gue0KYJrabMjJwQaAPR3G1mSJ9rE/erlPEDSf2jDD5hYd3rqm5Pzj5fQVzOsBJ9YhAG1B1oAbKiQsF/1hx0qaKVpSqH8h0pLsZLrEO3anae/losZQ5J60AWEfy5n+bZtGcDnNN8K3SPrq3sjMrROCm08g+tZupysly0cf+sfjIqSKYaRFE4VHkJyRmgD6j8N/FW5slhhv5TeAgYEn3h/wLr+ea6vWPHL39vbS6LcfZtobzo5VRg/TA5z7+lfNPhTVIddu1ELlZVGGB6Crniy7uNHjeBW+R/4kOcUAeyt4rhuZjHqejaNcburvbjcf+BCprTxB4bVilzoYsnHCyW8zAH8DwK8F0vXJYUghuJ/MLn5dx5rtNWvvsunqLhg6uvG77woA6zxFf+CLiORbq/1mzfq8m1JUH5c1y/hL4feEfE3iSHVtL8YQ6pbW5/49prGSDafcscH8BXlfi/VVGmmCFQJJWxuzXu/wT0SDR/BsMqxxGeYZZs0AeqWOkXcMxeGe1ePG1FicHA/Gqviu8fwx4evdY1CCRobZDI4QbuPU46CokbBQbhsXkgHrXzT8cvGt3rfiGbSbG9nh06Ndk8SyFUYe4HB6d6AOM+I3ju98b6mbh3MdoDhIs8KPWuFu51CmCA/J3b+9Tb2SMSslsT5Y4z61UoAKKKKACiiigAqW2k8mZXxnHaoqWgBKfEu6VF9SBTKkt+J4/wDeFAHsHh0/Z9OSOVPKiVOSKwNRMc1xIY2Hlk8E9a2kkP8AZCvLnaF4HrWTbpFKjTONuOid6AHRyI2lSWgcgsPwrjjpjR3S283rkH1rstOtvOjmkdSu3oDReafcPZC/iiWWJDggfeFAGSp+xEpFFuOMEkcCqk92NMspHQ4uZTwe4FWNQ1O1so98b+bct1Tsv1rlb67kvZvMmxn0AwBQBA7M7lnJLHkk96u6JYnUNQjh/gzlj6CqFd34ftYrXTFkUjzJOWPcCgDWRI4h5cQXyoxge9KwCpkZOf0qIupUHjHbHepPMIQbxj0NADkk8sjO0+3anhmByWUE9B2ppKMAoC5/vdqjcEt1Ax60AWXckhJQuT3FQQp9nmJG593Y9KYsZc5lYlu22piGUZLdO1ABOxjcLGQFbqlSmQGNSOMf3e1UZXXf5i53+h609XaQERsvv7fWgC6qeZOitls/xN2qpr1hE9xDJAuy4Q8t61dQ7LQNks49Kk3ebEABl8fxUAU4ZX84EksMfMvarjPC8HyudwPQ9qy1L+cwzhgecVZwrYfYcDqRQBZkC71O84xzXO3+kLrdzJHbyBGXpu6Gt202XLnLDA9K0bqK1tIRMAsZA6mgDx68tZdPvmglx5kZwcV2XhsR3KBV4fHOe9cz4kuku9QkkjIbnlhW94aZo0hmi2jHB3d6AOxlSKCwMSZ80ckCqV2sl9LZxyD5cjAWrSBmd2kUlnHGKkiCi3Nwcj7PycUAQzzJDqy2cygyBflVev40t1aR3Cs8zoij+FTWBp009zqlxqU3Cn5VdutamoSLLZLHvVXJyW9aAKOp29vDYvJAzMw/hPU1w1tKY9VimYY3OMiu3i8kxTBy0hxgYrhb6CS1uAXV15yA3WgD1hj5jwpGGKsoNc5rUYOpL5Z+71zWpo10W0mCfD7tuMd6o6wpOJXG1c5I7mgBFR1RmXGT0qSJVESkNg5+aoFZZxGysVQVaxGCQvIA5NAHMaxdKutJ5eQBUIikkvfNnfCOcAnpUrWR1HUJWQjCnmlurS4vAkCAqqHAPrQBtaCsln4ktItPYhnxuI6GvUdbtEinSSZPOyPnQ9KzvDGlaR4d0W3vLuT7Rq8uNiZ+7XYQTW2qzRmIr9rQbnVulAHI3GjWd1tukg8oxjKqwwRXKXerzzXskVwwk28KT2rvPiC0iWH2qH5AnysqcV5ZqM0KRi6jOGYdPf3oAjjsrrxF4otNMso/Nk3gvtHQZr6v0XSJLHT7O2tcBoFHmKehNeafs96Itjp93q7xo95N0cjlR7V69FcKY444yUJOXZupoAkubgNZXcyxhJFjI2j+lfE3jGUDWdScSkvJIQQTz9K+t/GfirTdF029X7XELxoyFVjzXxXq9wbrULmdiN0khY0AUqKKKACiiigAooooAKfEQHBPSmUo5PWgBK2vDenx3NwZ7pttvFyT6msWuv8ACjxT2TwABHU5JP8AFQBuS6nLdRLEseYF+7jjNRSubiI+SNjJ1FPI+ZSpDAcYFNkiVY5C7e4xxigC3b4OntOXKleq561g+IbiX+yt8UsiKx6K2AaWSdmtxFGxDMcfWsvxTMyiC1LZMYycUAc+SSSSSSaSilALEAdTQBq+HtPN9d5biOP5jnvXYuFlUBMIi8cCqOiQmx00RlNry8s1XwwKAn7qd6AJQu5Ng4Ud6bCrFGDndjpTVl3fvE+50xU0cu04zuJ6HHSgBjysoC4G0eg6Ubike5nDehpGdxuG4c9SaZ8rIAg59fWgCRJGZdycKPvA9TUqyJKm6NsMOxqrFldy7syH+GnBwSEHEooAkBM4IZNjD9ajVlVtqnDD9akQgSkPw2Ogqq6hZGcN9DQBrWZMcg3jKt2zTnZ1usgFV7VlwszMGYnI7Z61ozzNcRr5XOOp9KAK8277SzqOe4qtf37QadLtU7u2K1FR1i4w4xyKyzGjyOX4j75oAwvD2qXRuSQNxzyK6bxHqCw6OVlPzOOhqG3tIY5VkRVVSeMd6xPHsxM0MYPy45oA5ZpFYnK/lW/oGpeXauJ8bVPy8VzsmN2F5FdPoNmn2MPOhLE8CgD0XwzeQ6v5SHAnC4A9a6qbRorXwnq1zIoLhTwK8tsTLaXsc0TbQOw4r0nTNdh1Dw5e6bI5M0qkUAcDoN/atoJ3ATOHPyDjFLJcRxO0k9qY4yONxBrnwj288mmwMFRXJZqtvaNIpIBCgYyzZzQA6SdZEJidYkJ9KwvFJ3CLy/3iAcye9X4reRU2eYIiTxnms7xLAbeNFMu8nk8YoA6HwvdI2jxr8zFePpWlfRtcWzRuRyMgd6w/BciyadJG6bsNkYre83LqwGAOCDQBySahJau0LRlSh4zTLjVzKSobkjnbxU3i+18uXeo4bnd6Vy4bBBTgjvQB1nhaF50upI2EaIMsW71dttWgijEkYDTI3THDVh6JaST28uycorDnFdB4Y8Ltqz7BOqIh5PegDufDk+ieK2AaRoNWiX7pPA/Cuh8Gaalhf3JuJjJKSRkVzOh6HbeHdYWaCMyk8NN0x+FdJbarBNr6pZnJPUY6mgCh8SHRrVo4JChHLA9DXkNw7ERArujLgcfWvU/iJdTnzhMqrgcDFeXaW63WoWsBcIhkG5se9AH1P4JgFn4SsdqYygOF4/Op9VknWwvbq1jYTKhxk8HjtVfTbmGGys7SIl1CDnpnitN7p2tGiVAF6UAfI/iG31q/u7y5v5WVt5wjtzj2rknBU7W6jrXpvxls3j8RAgFAR94HA/KvMnGGIznB60ANooooAKKKKACiiigAooooAKs2N09pMHQnHQj1FVqKAO/07ULO4t1S0lxN1KPwM/WicySOVkVlfsByD+NcCCQcg4NXRqt8FCi5kwOnNAHUStDpUP2m6ZXnP3Iwc4rj7u4e6uHmkOWY5pksjyuXkYsx6k0ygAq7pEHn30a7dwByRVKup8OWyR2bTkje/TPagDfDxyqduQqcdOlELJIrKqfL3J70loOSpJHqakkBiGyPDBu/pQBHEpRthUBT93mp4lkJYMvzL0qFMg4Zs7elWkMqoZQVx6Z5oAq3KqyruX5j6dqRl8vEakNxnGaRnJLtng9QKhAUJuXJY9DQArK8IMij6j0pBJhBMo+b+dIsxJ2MM46hulNt5R55VlAB6f3aANCMhitwigSEc1VuE3yuvIB5yO9WgY/LIc+WRzx3qhJcfvN0JOBxx3oAWJ2UY3BQtSxXxgfK8qevvVGdvmzKoXPb1q/ZWJm/0hjtgQZw1AGh/aEaWu9wAx+6PSjTLf7fdL574RuoHeualvFubmTA2IhwAO9adhdvEyPExx6HtQB099pkFs2Y+Y1HArgvFttJcTiRPujtXYx3vnRusrnce9ZGotE6bcHfnuKAOU0nTkaXzbtSqDooGcmurgVkjJHpxx0FRwQlIVbGee/Srdy5SIGPhyOaAKaXGZlCrvUHp71r6VNLbXszADLJwuelc+AwkABKHOSRVuyuTFdSbznK4DUAZ1pb3V5d3twBjax4PAqzBIzsI5Y/MP8AdzUdhcTKlzHOyhGJIx3pkjRrKhgkn3Dr8tAEkzOucQAIh4BNZHiV5rpY5G2hVH3Qa0pLgfP5hB/2T3rO1Oe3kstjRiOTsV6UAS+Cbny55YicKwzXWllVfnG9+x9K898PTGHUUIwQeCDXdO+V4xGSODQBneLAJdN8wtkjtXCEgngYrv8AVFE+mSZAJUck964FuGP1oA1LDUpLSIxxLuJ6HpWnpWvzWMourckToctGTgNVHT7SO6t0ZeJV/Kun8KWOlyXrDU1Tf2BPymgDvdE1dfEGlC68z7Mx4ZMdTTtX0q80exXUYCN3UHPJqobOG1kia3hbywchQPlFaesSXdxAj3TAW4HygUAcn4s1N9Q0qKWZsTtwRXI+GYYk8VW0cgMnzA7O1bXiOBgvmTfu0H3B61F8OYkuddaW4yNnRsUAfRGmSC6EXyiIIoAx2q4knlmSIOOuT6msvTrmJrULGGBHdhgGrMSN9o8z90SR13cigDzP426P9s09Lq2iIKfeNfP7KVJB619i6/Yf2npctpKFYv8AdC818v8AjrRG0XVWicrk9lPSgDmaKKKACiiigAooooAKKKKACiiigAooooAKKcil2CqMk9BXT6dpdtbxqbhDNckZ2DoBQBy1bdhq0MFrHHLGxKHt3Fatxp1jcxkmF4ZP4QOKy7jw3exRl0Ak77R1xQB1UF/Y3UaSWrlUx84bqDWfeXrQ3AKL+4/vVyUccySmIsY27g8VpRGaKIiVw6+hoAvy68Vuc28Jkx7U9fFN2gO+xjwfasneqRGVSFz2FTWUgbln3A9c9qALia7HM+2WMwMT1HA/GtESmRFePkf7HQ1zl5BDucq2T6moLCW8ijaSAsY16+1AHQaldhVUEMq981MkoaOLcVCHpisAzNf3kO05AxuBroo1SMESoqp2z0oAmdyF2FfMXHDDpU9hpt3dAeXH5aE9T0NUp7k4WNFxjkEdDUMmt6iYzHuIjHA28UAdBf6LDZxB551klAzjPSsOa/kkikiJ2LjAA6GqXm3Eq5kkYt1+Y80kTFopTKAPc0AW7C3iWxZmX5ic5brVmERyFAhIYetZthDc+SV8uWSNuj+lWY4pLcEFWz64oAu2+8SSh5Aw7EHpSxR+bIEk3HngnvUNvJsjKhQSaatzIsgHJJ/SgDTuWbyvKVflHeoYgfs537m+vWkSV4kIcEhvWhZ9sgXqp/SgCgVcT5UMQDzuq47xCWMjGDwQKqzsFu2VWZgep9KlBjDAsMAfrQBQLpFqUinDA8jPSo5GmeQMBIqg9B1ot1jbUJZGzkdAagkGJTIZ2C54ANAGm1rEo3zfxDOWqjrywrpKeX5RbPXvU7W8ckOZmnLHogPWqc1kwiK/Z5REOSz0AYFs/lTxv/dYGu+WZZ7WOYnqOBXn8gAkYKcgHius0iQTacqx5DL/ABHoKANSYKbeRGIbcOBXAToUmdWBBz0Nd7F1Ak27QOtcZrK7dQlwSRng0AEM0ghSO3JVj1NWU+04WNwSxPGzqDUWmolxG0ch2kchhW5ol3FpVwHkCzD+83NAHZaDq1zbWMdreSEyEfKX9K6GTUII4ES7JKddvrXD3d1pGoRyM80kVyeVG7p9KzW1ILaeRO8kijgPnmgDY8a3MFzAXhkEjp92MHhfrV34fJFYWaXx2y7zh0PQVwK7BLLtdypHc13PwoVZLK6EqPMgPAFAHrlnNEZopJmcWzjKgdBWpG1ujs0Sk49e9cnaXtwvlW01qzR5+XA+79a6Hy5CQyyodo529qANa2lXcCqFSfWvCPjhBBHqJZQvmHkmvbl2LHGzOc14J8ZLgS62XzkKMAUAeY0UpOSTSUAFFFFABRRRQAUUUoGTycUAJRRRQAUUUUAX9Fj8y/TvjnFb0TmW7Z3Y5BxxxXNWE3kXUchOADzXWRRLcY8lgxPOelAG9ut2tlEoGAOD3zWe1zIrEjOR90g1W1HUsRiJYjlBgnFZ0GqxEFZVIYdDQBcurWO/k3EBZu4xjNZl5ZS2j/vI3WM9zyK6/Q4LHWgEZykoH38Yq9Y3MVtdy6VqEC3EB4DnrQB53lI42BUMh/WktDBDIGOVjP8ACTmus8V+EIbFBeaWxkgY5aHutcXeWjRMroT5fr6GgDdttOutWlk+xxDaB97HGK3tE06PTdOmt32bpeHLDNVfDmsLDbpGH2SHgnH3q1ZoEZjM7mODOc9eaAPP721fTNX2EkIzZBxjIrUu5mcxqhLJ61r/ABDSCTTLK5jlDuCAuFxxWba3S3FpFHDbsZgvzOFyKAEnChFbf84HBHSo/NxHtZdoPc1JbR3DOyvayls8DYea3tK8F6xqrZigaOPqXYYxQBz0R6hRknpXR+GvCNzezJJdHbCTkqe9bdn4TXRYzLdgSziul0Sdp02BMRjr7UATWmjWqssMca7FGMVov4cspLd0MSlm746VYhjVIvlHHY9zXJeLPG7aLMkCDB70Acv4y8OPocnmof3THpXKmT51dXrtLbxaniOdrGRPMZxwprhb+2ez1K4tmO1VOQMdKAL6XEsh3Lyo65psZ8uRpS+729Kp2bygBkA54HPWp5JGMoRBk/xcUAQ3MjOfMVTjPbinwtJJOgHKN1HpRfJ5seSdgA4ApbWUxRIV4cHk+tAFeYfZrp1HJPQd6beec8Ks0kUWOxXmm6tdbNTjuIxuJGCMcU10S4kLu3J53f0xQAlpdSBiIlaROhcn+VSCO62SSMX8v0Zs1E0yZURN5W3+DH3qLm4PklFBDt6mgDDlOZGOMc1t6Dc/umhbtyMd6xJY2jba/X61Y0+VY5lyCHzw3pQB1oJMYPIYHpWD4li2zxvs27h1rUE8nmIpOd3fFVtcjke1LBcKvUnvQBgQyFAwUHJ9KswW/mRhjIevPPSqcZKyKR61sNaiKWKdHG1vvUAA0+RwDC25T1OMmtFIgluIWdcehHNdZ4Si00Rvs+/IMFm7Guf8Sae9hcybZNysch8cUAUk09vIkuJcBU6Ad69B+F1zEto7SKIQeNvc15st44ULIcoeNueta3gPVjYa40E+WWT7o9KAPY/Mv47gy6UUe3/5aBxk49q0IrqCUA26yK/8YJ4zWJZN9ruNpkMJ79g1aBSeEsttKnl9170AbUNycrgb8D7uK8H+LojfWmkJxIf4B2r2hLx0EX7vZIOreteKfF5A2tiULjPU0Aef0UUUAFFFFABRRRQAUUUoGelACUUUUAFFFFABWnp2rPaJ5ckYmi7KTjFZlFAGtfa5dXPyqRHF0CAVnCZxnnqcmoqKAO28Ka5LLPFatEgjX+IdRW1rsckNyLmAE+hrz7Rrk218j5x2r1bS7iK+twJhu44oAwrfxHKTt1DIyMA44qquk/bI7iSLo3IX1q/rGjuQ5CrtPQntVbR9ROnMI51JRerUAcxJ51tKFlHltGfl9qvHU7twpkl3Anp611F+NG1WAvFJHvP3gxwa4/WtNNpIj2jM8Q6D+7QBe1u7/ty5sNNs1PGAwA6GvcvCumabo2lw2wsomcIN7Hksa8T8IPcaVeLPJYtLLOcJOy8LmvYba0nihjkuJy0sg3Y7UAb5vrKOLKWUIIPChRTbjUZZkxE6xgj+EVjfaEAcoNzjhvaopLqONEEUbEk8nvQAl+jOcj5xn5hUlmotj8uAj9KezER+YFIGOc1VQiUsd+D2zQBreaUdUU4frXkfxX8u51JFUAuOpFd3q+rR2OmySE/vFrzawifXdW+0MTszQBu/D/QEjvYLwL5bY575rH+JUDWnihnTGyQc16Xp8a2ltHGow47iuB+MIAu7aVBn1NAHI20gBMe3j6065u3jwE6e1UtwU7hnOPwNG7zF372VB1FAFmSV2UHd16jtUCzzSExRtlf7vb86pyyHDBnIQ9AOpqazcIoJBWgCzdmRY4y4GFPKinyiORFbCxjHBzSTIjqSrk56+tUkCD/WHcR0Q0ATxYe4BXDFe5p9xJbM5835j6DpVSYMCFDqobqFNSWEcfIbd8p6HoaAKNyELkxLtX0qKM7XUg4wat6qytOpVQvHQVSoA6q1kDiNYwPMP8eaffNJJG8UhyQOorH0mbClOMnue1a5OVABGfUd6AOUYEMQatRXAEAVieKZfLtuX4xz+FQoPmHGR3FAGvb6rcRbSHZF7YrTk8Ria1a3vYhMp+656isny0cAow2njb6VPa2iySeTCpllPbHAoAgLwtFvA3Mp4zxitTR5Y21O0kwFfPPvVb+w7wxzSYQRJ95QajhK20MUxyoVuKAPbftEBEe75RtHy9K07YQBA8Tnc38XpXJaVcfb9Pgnb7yDjPeun0uKO8gNxCRGyfeQnANAF4zqjYlcMR0PrXm/xZsvOgW5KYbsa7Qzx3d0VXKlD97tXOfFqUf2NCqsCTx9aAPEqSnyqFbAOaZQAUUUUAFFFFABTkcowZTgim0UAFFFFABRRRQAUUUUAFFFFAD4jiVT712nhm8mS4KBjgiiigDvUkDWXzor/Ws7+zreWbY6Aq/WiigBV8MadHLlI8FeavWtjbwsZDEsg6bW6UUUAWZbgfZntxEgi6gAdKu6ddSz2axu33OAe4oooAt26hS2Op6mpPM/c5wMg0UUAWSxeBS3Q9qzNTURbSgxRRQB5xr95Le6q1u7bYx2Heuk8F2cMauVUDbRRQB1LNtiZsDd2NeefE5c2kchJyTRRQBwYkLBEPTFW41U2rKQMCiigCjsUYOATS3ZMUakc59aKKAJbY7rYnofX0qnZ/NcNu+b60UUAK02EY7FznGat2y+fEjElfYUUUAUZpMTOCoOOmarnrRRQBJbyGN+Mc1tQTsyKCBz1oooAz9WGJhiqcTESDBoooAuxxBbtQCcNXcaVbR2oRoh87jlu9FFAEjw+WlyoZsMMn3ridRlLSiLACZ6UUUAdt8P7mR3eydi0eOCeortYi0ciqjEKDgj1oooA1jEkMLOqj5hnFcL8Tvm0eKQ9QeBRRQB5GTk5pKKKACiiigAooooAKUUUUAf/9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A sagittal T1-weighted MRI of the brain shows the low-lying and elongated cerebellar tonsils (arrow), which are displaced below the level of the foramen magnum.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Eric D Schwartz, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_47_4852=[""].join("\n");
var outline_f4_47_4852=null;
var title_f4_47_4853="Lymphatic drainage of the stomach";
var content_f4_47_4853=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F83510&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F83510&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 539px\">",
"   <div class=\"ttl\">",
"    Lymphatic drainage of the stomach",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 519px; height: 418px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_47_4853=[""].join("\n");
var outline_f4_47_4853=null;
var title_f4_47_4854="Megaloblastic smear";
var content_f4_47_4854=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F58820&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F58820&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1040px;\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Megaloblastic blood picture",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 389px; height: 252px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Peripheral blood smear showing a hypersegmented neutrophil (seven lobes) and macroovalocytes, a pattern that can be seen with cobalamin or folate deficiency.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Stanley L Schrier, MD.",
"    </div>",
"   </div>",
"  </div>",
"  <div class=\"figure\" style=\"width: 450px\">",
"   <div class=\"ttl\">",
"    Normal peripheral blood smear",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 393px; height: 257px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    High power view of a normal peripheral blood smear. Several platelets (black arrows) and a normal lymphocyte (blue arrow) can also be seen. The red cells are of relatively uniform size and shape. The diameter of the normal red cell should approximate that of the nucleus of the small lymphocyte; central pallor (red arrow) should equal one-third of its diameter.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Carola von Kapff, SH (ASCP).",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_47_4854=[""].join("\n");
var outline_f4_47_4854=null;
var title_f4_47_4855="What's new in nephrology and hypertension";
var content_f4_47_4855=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   What's new in nephrology and hypertension",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/47/4855/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/47/4855/contributors\">",
"     Alice M Sheridan, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/47/4855/contributors\">",
"     John P Forman, MD, MSc",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?4/47/4855/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 25, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    The following represent additions to UpToDate from the past six months that were considered by the editors and authors to be of particular interest. The most recent What's New entries are at the top of each subsection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     ACUTE AND CHRONIC KIDNEY DISEASE",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h2\">",
"     Antiplatelet therapy in patients with CKD",
"    </span>",
"   </p>",
"   <p>",
"    The effectiveness and safety of antiplatelet therapy to prevent cardiovascular disease (CVD) in&nbsp;patients with chronic kidney disease (CKD) is not clear.&nbsp;In a meta-analysis of over 27,000 patients with CKD who participated in 50 randomized trials, antiplatelet therapy&nbsp;(mostly aspirin) reduced the incidence of fatal or non-fatal myocardial infarction as compared with either placebo or no therapy (6.7 versus 7.0 percent, or 3 myocardial infarctions prevented for every 1000 patients treated) but had no effect on stroke or overall mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?4/47/4855/abstract/1\">",
"     1",
"    </a>",
"    ]. Antiplatelet therapy also increased the rate of major bleeding (4.4 versus 2.9 percent, or 15 additional major bleeding events for every 1000 patients treated). Based upon these data, we suggest that decisions about antiplatelet therapy in patients with CKD be individualized&nbsp;based upon the patient's overall risks for CVD and for bleeding. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/31/34298?source=see_link&amp;anchor=H14#H14\">",
"     \"Chronic kidney disease and coronary heart disease\", section on 'Antiplatelet therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Acute kidney injury after synthetic cannabinoid use",
"    </span>",
"   </p>",
"   <p>",
"    Synthetic cannabinoids, including tetrahydrocannabinol [THC], cannabidiol [CBD], and cannabinol [CBN], are analogs of naturally-occurring chemicals found in marijuana. In two small case series, synthetic cannabinoid or &ldquo;Spice&rdquo; use has been associated with reversible acute kidney injury necessitating renal replacement therapy&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?4/47/4855/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. Pathologically, the injury is characterized by acute tubular necrosis and interstitial nephritis. In some instances, these previously-healthy&nbsp;young adults&nbsp;reported smoking a blueberry- or bubblegum-flavored synthetic cannabinoid. A unique synthetic cannabinoid, 1-((5-fluoropentyl)-1H-indol-3yl) (2,23,3,-tetramethylcyclopropyl) methanone (also called XLR-11) was found in clinical specimens and product samples [",
"    <a class=\"abstract\" href=\"UTD.htm?4/47/4855/abstract/3\">",
"     3",
"    </a>",
"    ]. However, the specific chemical agent responsible for causing renal toxicity is not known. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/47/1784?source=see_link&amp;anchor=H1913412#H1913412\">",
"     \"Designer drugs of abuse\", section on 'Clinical manifestations'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     KDIGO guidelines for anemia in chronic kidney disease (CKD)",
"    </span>",
"   </p>",
"   <p>",
"    More aggressive iron repletion is being advocated for CKD patients in an effort to decrease utilization of erythropoietin stimulating agents (ESAs) to avoid potential adverse outcomes associated with ESAs. The 2012 Kidney Disease: Improving Global Outcomes (KDIGO) guidelines revised suggested parameters for initiating and maintaining iron therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?4/47/4855/abstract/4\">",
"     4",
"    </a>",
"    ]. We agree with the revised guidelines and suggest that oral or intravenous iron therapy be administered to patients who have transferrin saturation &le;30 percent and ferritin &le;500",
"    <span class=\"nowrap\">",
"     ng/mL,",
"    </span>",
"    providing an underlying infection has been excluded and an increase in hemoglobin is desired. This is a change from prior recommendations in which a more stringent threshold (transferrin saturation &lt;20 percent) was advised for initiation of iron therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/55/37752?source=see_link&amp;anchor=H4#H4\">",
"     \"Iron balance in non-dialysis, peritoneal dialysis, and home hemodialysis patients\", section on 'Indications for iron therapy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/39/38521?source=see_link&amp;anchor=H4#H4\">",
"     \"Use of iron preparations in hemodialysis patients\", section on 'Overview of therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     DIALYSIS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Vascular access survival and daily dialysis",
"    </span>",
"   </p>",
"   <p>",
"    More frequent vascular access cannulation required for daily hemodialysis may result in decreased access survival. This issue was addressed in the Frequent Hemodialysis Network (FHN) daily&nbsp;trial [",
"    <a class=\"abstract\" href=\"UTD.htm?4/47/4855/abstract/5\">",
"     5",
"    </a>",
"    ]. Among all participants (including 198 with a fistula or graft and 47 with a tunneled catheter), the risk for a first access event (including repair, loss of access, or access-related hospitalization) was higher in the daily group compared with the conventional group. The increased risk was even greater when patients with a tunneled catheter were excluded from the analysis. The risk of permanent access loss and of infection did not differ between the groups. These outcomes should be considered when patients and clinicians&nbsp;are weighing dialysis options. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/45/18137?source=see_link&amp;anchor=H26#H26\">",
"     \"Short daily hemodialysis\", section on 'Vascular access'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Peginesatide, cardiovascular events, and drug withdrawal",
"    </span>",
"   </p>",
"   <p>",
"    Peginesatide is a synthetic peptide that stimulates&nbsp;hematopoiesis but does not cross react with erythropoietin antibodies. Pooled data from two randomized open-label studies in hemodialysis patients&nbsp;(EMERALD 1 and EMERALD 2) showed that peginesatide was&nbsp;as effective as&nbsp;erythropoietin in maintaining the hemoglobin concentration among hemodialysis patients and&nbsp;there was no difference in a cardiovascular safety endpoint [",
"    <a class=\"abstract\" href=\"UTD.htm?4/47/4855/abstract/6\">",
"     6",
"    </a>",
"    ].&nbsp;However, two randomized studies (PEARL-1 and PEARL-2) that compared peginesatide to darbepoetin among non-dialysis chronic kidney disease (CKD) patients showed that peginesatide increased cardiovascular events [",
"    <a class=\"abstract\" href=\"UTD.htm?4/47/4855/abstract/7\">",
"     7",
"    </a>",
"    ].",
"    <br/>",
"    <br/>",
"    Subsequent to approval of peginesatide by the U.S. Food and Drug Administration and publication of these studies, peginesatide was withdrawn from the market and distributed lots recalled&nbsp;due to serious hypersensitivity reactions reported in patients following the first dose of intravenous administration with death occurring in 0.02 percent of patients&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?4/47/4855/abstract/8\">",
"     8",
"    </a>",
"    ].(See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/31/5626?source=see_link&amp;anchor=H1130568215#H1130568215\">",
"     \"Erythropoietin for the anemia of chronic kidney disease in hemodialysis patients\", section on 'Peginesatide'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Cinacalcet and the risk of death and/or cardiovascular events",
"    </span>",
"   </p>",
"   <p>",
"    Secondary hyperparathyroidism may contribute to vascular calcification and cardiovascular mortality among CKD patients. The EVOLVE randomized trial compared effects of cinacalcet, a calcimimetic agent, versus placebo on mortality and cardiovascular events among hemodialysis patients with moderate to severe hyperparathyroidism [",
"    <a class=\"abstract\" href=\"UTD.htm?4/47/4855/abstract/9\">",
"     9",
"    </a>",
"    ]. At a median followup of less than two years, cinacalcet did not decrease the risk of death or major cardiovascular events. Cinacalcet did reduce the rate of parathyroidectomy by approximately half. We generally administer cinacalcet to hemodialysis patients who have PTH levels greater than 300",
"    <span class=\"nowrap\">",
"     pg/mL",
"    </span>",
"    despite optimal phosphate binder therapy, and serum calcium and phosphate concentrations that are close to the upper limit of target values. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/36/38474?source=see_link&amp;anchor=H26#H26\">",
"     \"Management of secondary hyperparathyroidism and mineral metabolism abnormalities in dialysis patients\", section on 'Efficacy studies'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Buttonhole cannulation of fistulas and infection",
"    </span>",
"   </p>",
"   <p>",
"    Buttonhole cannulation of arteriovenous fistulas is commonly used for nocturnal or daily hemodialysis. Buttonhole cannulation may be associated with a higher rate of infection compared with conventional &ldquo;rope ladder&rdquo; cannulation. The risk of infection was examined in a randomized trial of 140 conventional hemodialysis patients assigned to either the buttonhole technique or to conventional needling [",
"    <a class=\"abstract\" href=\"UTD.htm?4/47/4855/abstract/10\">",
"     10",
"    </a>",
"    ]. At eight weeks, the rate of localized infection was higher among patients assigned to the buttonhole technique compared with conventional needling. The degree to which these data from conventional hemodialysis patients may be extrapolated to nocturnal, daily hemodialysis, or self-cannulating patients is not clear [",
"    <a class=\"abstract\" href=\"UTD.htm?4/47/4855/abstract/11\">",
"     11",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/16/264?source=see_link&amp;anchor=H13#H13\">",
"     \"Technical aspects of nocturnal hemodialysis\", section on 'Arteriovenous fistulas'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     GLOMERULAR DISEASE AND VASCULITIS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Treatment of patients with idiopathic membranous nephropathy and declining renal function",
"    </span>",
"   </p>",
"   <p>",
"    Some patients have deteriorating kidney function due to idiopathic membranous nephropathy. The United Kingdom (UK) Membranous Trial, an open-label randomized trial of 108 patients with idiopathic membranous nephropathy whose renal function had declined by 20 percent or more during the two years prior to enrollment, randomly assigned patients to one of three therapies: supportive treatment plus glucocorticoids and cytotoxic therapy for six months; supportive treatment plus cyclosporine for 12 months; and supportive treatment alone&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?4/47/4855/abstract/12\">",
"     12",
"    </a>",
"    ]. The primary endpoint (an additional decline in eGFR of at least 20 percent) occurred significantly less frequently with glucocorticoids and chlorambucil as compared with supportive treatment alone (58 versus 84 percent). However, cyclosporine therapy did not reduce the incidence of renal function loss as compared with supportive treatment alone. In addition, fewer patients who received glucocorticoids and chlorambucil developed end-stage renal disease. Combination therapy with glucocorticoids and a cytotoxic drug (ie, cyclophosphamide or chlorambucil, preferably cyclophosphamide) appears to provide the best protection against progressive renal disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/41/37530?source=see_link&amp;anchor=H23#H23\">",
"     \"Treatment of idiopathic membranous nephropathy\", section on 'High risk for progression'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Chapel Hill Consensus Conference on nomenclature of vasculitides",
"    </span>",
"   </p>",
"   <p>",
"    Revisions in the commonly used terms for the various vasculitides have been proposed by the 2012 International Chapel Hill Consensus Conference (CHCC) on nomenclature of vasculitides [",
"    <a class=\"abstract\" href=\"UTD.htm?4/47/4855/abstract/13\">",
"     13",
"    </a>",
"    ]. The&nbsp;2012 CHCC suggests&nbsp;\"eosinophilic granulomatosis with polyangiitis (Churg-Strauss),\" abbreviated EGPA, in place of Churg-Strauss syndrome, and formal adoption of \"antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV)\" for the group&nbsp;of disorders&nbsp;that includes&nbsp;microscopic polyangiitis, granulomatosis with polyangiitis (Wegener&rsquo;s), and EGPA. Some of the other changes suggested by the 2012 CHCC included \"immunoglobulin A (IgA) vasculitis (Henoch-Sch&ouml;nlein)\" in lieu of Henoch-Sch&ouml;nlein purpura, further definition of hypocomplementemic urticarial vasculitis (HUV) as \"HUV (anti-C1q vasculitis),\" and \"cryoglobulinemic vasculitis\" in place of essential cryoglobulinemic vasculitis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/23/37241?source=see_link&amp;anchor=H2#H2\">",
"     \"Classification of and approach to the vasculitides in adults\", section on 'Classification'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Monoclonal gammopathy of renal significance",
"    </span>",
"   </p>",
"   <p>",
"    The term &ldquo;monoclonal gammopathy of renal significance&rdquo; (MGRS) has been proposed by the International Kidney and Monoclonal Gammopathy Research Group to describe cases that would otherwise meet the criteria for monoclonal gammopathy of undetermined significance (MGUS), but demonstrate monoclonal immunoglobulin deposits in the kidney by immunofluorescence [",
"    <a class=\"abstract\" href=\"UTD.htm?4/47/4855/abstract/14\">",
"     14",
"    </a>",
"    ]. The presence of MGUS is",
"    <strong>",
"     not",
"    </strong>",
"    in itself an indication for renal biopsy and the introduction of this terminology does not change the indications for renal biopsy. However, this distinction between MGUS and MGRS is important because the monoclonal protein appears to be the direct cause of kidney disease in such cases, and treatment that targets the responsible clone is associated with restoration and preservation of kidney function. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/17/13594?source=see_link&amp;anchor=H56342434#H56342434\">",
"     \"Evaluation and treatment of membranoproliferative glomerulonephritis\", section on 'Treatment of the underlying cause'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/59/15290?source=see_link&amp;anchor=H2549497#H2549497\">",
"     \"Diagnosis of monoclonal gammopathy of undetermined significance\", section on 'Monoclonal gammopathy of renal significance'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Mycophenolate mofetil versus cyclophosphamide for lupus nephritis",
"    </span>",
"   </p>",
"   <p>",
"    Mycophenolate mofetil (MMF) is an alternative to cyclophosphamide as induction therapy for proliferative lupus nephritis. In a meta-analysis that included 45 trials involving 2846 patients, there were no significant differences between cyclophosphamide-based and MMF-based induction therapy with respect to mortality, incidence of end-stage renal disease, and relapse during induction [",
"    <a class=\"abstract\" href=\"UTD.htm?4/47/4855/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]. However, MMF produced a numerically higher rate of complete remissions (19.5 versus 13.8 percent), although this was not statistically significant. Major infections were also similar with both drugs, but MMF therapy resulted in less ovarian failure and alopecia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/37/37466?source=see_link&amp;anchor=H18#H18\">",
"     \"Therapy of diffuse or focal proliferative lupus nephritis\", section on 'Mycophenolate mofetil'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Soluble urokinase receptor in primary FSGS",
"    </span>",
"   </p>",
"   <p>",
"    Increased circulating levels of soluble urokinase receptor (suPAR) may be a common causative factor of primary focal segmental glomerulosclerosis (FSGS). Serum suPAR was measured, using a commercially available assay, in a cohort comprised of 70 adult and 94 pediatric patients with biopsy-proven primary FSGS and an estimated glomerular filtration rate greater than 40",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per 1.73 m",
"    <sup>",
"     2",
"    </sup>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?4/47/4855/abstract/17\">",
"     17",
"    </a>",
"    ]. Serum suPAR levels greater than 3000",
"    <span class=\"nowrap\">",
"     pg/mL",
"    </span>",
"    were found in 84 percent of adults and 55 percent of children. In contrast, elevated suPAR was detected in only 6 percent of healthy controls. Patients treated with immunosuppression had lower suPAR levels, and a reduction in suPAR with immunosuppressive therapy was associated with a reduction in proteinuria and a higher likelihood of achieving complete remission. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/6/41066?source=see_link&amp;anchor=H166292499#H166292499\">",
"     \"Epidemiology, classification, and pathogenesis of focal segmental glomerulosclerosis\", section on 'Soluble urokinase receptor'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     HYPERTENSION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Diagnosis of hypertension in childhood requires repeated blood pressure measurements",
"    </span>",
"   </p>",
"   <p>",
"    The need for confirmation of the diagnosis of hypertension based on three&nbsp;blood pressure (BP)&nbsp;measurements at separate clinical vists&nbsp;was illustrated in a large cohort study of children cared for in community-based practices [",
"    <a class=\"abstract\" href=\"UTD.htm?4/47/4855/abstract/18\">",
"     18",
"    </a>",
"    ]. In the United States, normative BP percentiles are based upon data on gender, age, height, and blood pressure measurements from the National Health and Nutrition Examination Survey (NHANES) and other population-based studies (",
"    <a class=\"graphic graphic_table graphicRef63856 \" href=\"UTD.htm?7/45/7894\">",
"     table 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef52646 \" href=\"UTD.htm?7/46/7910\">",
"     table 2",
"    </a>",
"    ). Initial BP measurement was normal (below the 90th percentile), prehypertensive&nbsp;(systolic or diastolic BP between the 90th or 95th percentile)&nbsp;and hypertensive (systolic or diastolic BP &ge;95th percentile) in 82, 13, and 5 percent of children. At follow-up, subsequent hypertensive measurements were observed in only 4 percent of the 10,848 children who had initial hypertensive values. In this cohort, the overall prevalence of hypertension&nbsp;was&nbsp;0.3 percent. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/45/17113?source=see_link&amp;anchor=H7#H7\">",
"     \"Definition and diagnosis of hypertension in children and adolescents\", section on 'Diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Incidentally discovered renal artery stenosis",
"    </span>",
"   </p>",
"   <p>",
"    Radiographic evaluation of peripheral artery disease or coronary artery disease often reveals that renal arterial lesions are also present (ie, incidentally discovered renal artery stenosis). Such patients do not require therapy directed at the renal vasculature since there is evidence that renal artery revascularization does",
"    <strong>",
"     not",
"    </strong>",
"    improve blood pressure, renal function, or other outcomes in this setting [",
"    <a class=\"abstract\" href=\"UTD.htm?4/47/4855/abstract/19\">",
"     19",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/17/31001?source=see_link&amp;anchor=H16699645#H16699645\">",
"     \"Establishing the diagnosis of renovascular hypertension\", section on 'Incidental lesions'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     OTHER NEPHROLOGY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Intravenous albumin for the prevention of hepatorenal syndrome",
"    </span>",
"   </p>",
"   <p>",
"    Several trials have suggested that, in patients with spontaneous bacterial peritonitis (SBP), the administration of intravenous albumin (1.5",
"    <span class=\"nowrap\">",
"     g/kg)",
"    </span>",
"    at the time that the infection is diagnosed&nbsp;and another dose of albumin (1",
"    <span class=\"nowrap\">",
"     g/kg)",
"    </span>",
"    on day&nbsp;three of antibiotic treatment may improve outcomes.&nbsp;In a&nbsp;meta-analysis of four controlled trials (with a total of 288 patients), albumin infusion (in addition to antibiotics) significantly decreased the incidence of renal impairment (8 versus 31 percent) and mortality (16 versus 35 percent) compared with antibiotics alone [",
"    <a class=\"abstract\" href=\"UTD.htm?4/47/4855/abstract/20\">",
"     20",
"    </a>",
"    ].&nbsp;(See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/50/29482?source=see_link&amp;anchor=H21#H21\">",
"     \"Hepatorenal syndrome\", section on 'Prevention'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Hepatoxicity associated with tolvaptan",
"    </span>",
"   </p>",
"   <p>",
"    Concerns about the safety of tolvaptan were raised by a multicenter trial (TEMPO 3:4) that examined its effect on the progression of kidney disease in polycystic kidney disease [",
"    <a class=\"abstract\" href=\"UTD.htm?4/47/4855/abstract/21,22\">",
"     21,22",
"    </a>",
"    ]. A greater than 2.5-fold increase in liver enzymes was more common among patients who received tolvaptan compared with placebo. Based upon these data, a safety warning was issued in the United States by the Food and Drug Administration (FDA) regarding the use of tolvaptan [",
"    <a class=\"abstract\" href=\"UTD.htm?4/47/4855/abstract/23\">",
"     23",
"    </a>",
"    ]. The FDA recommends that liver function tests be promptly performed among patients who report symptoms that suggest liver injury, including fatigue, anorexia, right upper quadrant discomfort, dark urine, or jaundice. In addition, we suggest that liver function tests be measured three to four months after initiating therapy and then again at six-month intervals. If liver injury is suspected, tolvaptan should be discontinued and not re-initiated unless the cause for liver injury is established to be unrelated. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/57/17306?source=see_link&amp;anchor=H14#H14\">",
"     \"Treatment of hyponatremia: Syndrome of inappropriate antidiuretic hormone secretion (SIADH) and reset osmostat\", section on 'Limitations to use of tolvaptan'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Aliskiren in diabetic nephropathy",
"    </span>",
"   </p>",
"   <p>",
"    The use of aliskiren, a direct renin inhibitor, in combination with either an angiotensin-converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB) does",
"    <strong>",
"     not",
"    </strong>",
"    appear to preserve renal function, and it increases the risk of adverse events. This was shown in the multinational Aliskiren Trial in Type 2 Diabetes Using Cardiorenal Endpoints (ALTITUDE trial), which randomly assigned 8561 diabetic patients with either preexisting renal or cardiovascular disease to 300",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    aliskiren or placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?4/47/4855/abstract/24\">",
"     24",
"    </a>",
"    ]. At baseline, the majority of patients had nephropathy, and all patients were receiving an ACE inhibitor or ARB. After a median follow-up of 32.9 months, more patients in the aliskiren group reached the composite primary endpoint (which included both renal and cardiovascular outcomes; 18.3 versus 17.1 percent). Adverse events requiring cessation of randomized therapy (usually hyperkalemia) were significantly more frequent with aliskiren (13.2 versus 10.2 percent). Due to the lack of apparent benefit and higher risk of side effects, the trial was stopped early for futility. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/48/40714?source=see_link&amp;anchor=H16004841#H16004841\">",
"     \"Treatment of diabetic nephropathy\", section on 'Aliskiren plus angiotensin inhibition'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Tolvaptan may slow progression of autosomal dominant polycystic kidney disease",
"    </span>",
"   </p>",
"   <p>",
"    Vasopressin V2 receptor antagonists decrease renal enlargement and dysfunction in animal models of polycystic kidney disease. A large clinical trial now suggests a beneficial effect of tolvaptan on the progression of kidney disease in autosomal dominant polycystic kidney disease (ADPKD) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/47/4855/abstract/22\">",
"     22",
"    </a>",
"    ]. Among 1157 patients who were randomly assigned to tolvaptan or placebo, there was a smaller annual increase in total kidney volume and a slower annual decline in kidney function among patients who received tolvaptan compared with placebo. We suggest that tolvaptan not be used for the treatment of ADPKD pending further assessment of risks and benefits for individual patients and review by regulatory agencies for use for this indication. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/27/27066?source=see_link\">",
"     \"Course and treatment of autosomal dominant polycystic kidney disease\"",
"    </a>",
"    .)",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/47/4855/abstract/1\">",
"      Palmer SC, Di Micco L, Razavian M, et al. Antiplatelet agents for chronic kidney disease. Cochrane Database Syst Rev 2013; 2:CD008834.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/47/4855/abstract/2\">",
"      Bhanushali GK, Jain G, Fatima H, et al. AKI Associated with Synthetic Cannabinoids: A Case Series. Clin J Am Soc Nephrol 2012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/47/4855/abstract/3\">",
"      Centers for Disease Control and Prevention (CDC). Acute kidney injury associated with synthetic cannabinoid use--multiple states, 2012. MMWR Morb Mortal Wkly Rep 2013; 62:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/47/4855/abstract/4\">",
"      KDIGO clinical practice guidelines for anemia in chronic kidney disease. Kidney Int Suppl 2012; 2:288.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/47/4855/abstract/5\">",
"      FHN Trial Group, Chertow GM, Levin NW, et al. In-center hemodialysis six times per week versus three times per week. N Engl J Med 2010; 363:2287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/47/4855/abstract/6\">",
"      Fishbane S, Schiller B, Locatelli F, et al. Peginesatide in patients with anemia undergoing hemodialysis. N Engl J Med 2013; 368:307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/47/4855/abstract/7\">",
"      Macdougall IC, Provenzano R, Sharma A, et al. Peginesatide for anemia in patients with chronic kidney disease not receiving dialysis. N Engl J Med 2013; 368:320.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm340895.htm.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/47/4855/abstract/9\">",
"      EVOLVE Trial Investigators, Chertow GM, Block GA, et al. Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis. N Engl J Med 2012; 367:2482.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/47/4855/abstract/10\">",
"      MacRae JM, Ahmed SB, Atkar R, Hemmelgarn BR. A randomized trial comparing buttonhole with rope ladder needling in conventional hemodialysis patients. Clin J Am Soc Nephrol 2012; 7:1632.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/47/4855/abstract/11\">",
"      Zimmerman D, Lok CE. Accessing the access. Clin J Am Soc Nephrol 2012; 7:1548.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/47/4855/abstract/12\">",
"      Howman A, Chapman TL, Langdon MM, et al. Immunosuppression for progressive membranous nephropathy: a UK randomised controlled trial. Lancet 2013; 381:744.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/47/4855/abstract/13\">",
"      Jennette JC, Falk RJ, Bacon PA, et al. 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum 2013; 65:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/47/4855/abstract/14\">",
"      Leung N, Bridoux F, Hutchison CA, et al. Monoclonal gammopathy of renal significance: when MGUS is no longer undetermined or insignificant. Blood 2012; 120:4292.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/47/4855/abstract/15\">",
"      Henderson LK, Masson P, Craig JC, et al. Induction and maintenance treatment of proliferative lupus nephritis: a meta-analysis of randomized controlled trials. Am J Kidney Dis 2013; 61:74.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/47/4855/abstract/16\">",
"      Henderson L, Masson P, Craig JC, et al. Treatment for lupus nephritis. Cochrane Database Syst Rev 2012; 12:CD002922.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/47/4855/abstract/17\">",
"      Wei C, Trachtman H, Li J, et al. Circulating suPAR in two cohorts of primary FSGS. J Am Soc Nephrol 2012; 23:2051.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/47/4855/abstract/18\">",
"      Lo JC, Sinaiko A, Chandra M, et al. Prehypertension and hypertension in community-based pediatric practice. Pediatrics 2013; 131:e415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/47/4855/abstract/19\">",
"      Marcantoni C, Zanoli L, Rastelli S, et al. Effect of renal artery stenting on left ventricular mass: a randomized clinical trial. Am J Kidney Dis 2012; 60:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/47/4855/abstract/20\">",
"      Salerno F, Navickis RJ, Wilkes MM. Albumin infusion improves outcomes of patients with spontaneous bacterial peritonitis: a meta-analysis of randomized trials. Clin Gastroenterol Hepatol 2013; 11:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/47/4855/abstract/21\">",
"      Higashihara E, Torres VE, Chapman AB, et al. Tolvaptan in autosomal dominant polycystic kidney disease: three years' experience. Clin J Am Soc Nephrol 2011; 6:2499.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/47/4855/abstract/22\">",
"      Torres VE, Chapman AB, Devuyst O, et al. Tolvaptan in patients with autosomal dominant polycystic kidney disease. N Engl J Med 2012; 367:2407.",
"     </a>",
"    </li>",
"    <li>",
"     Samsca (tolvaptan): Drug Warning - Potential Risk of Liver Injury file://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm336669.htm?source=govdelivery (Accessed on January 28, 2013).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/47/4855/abstract/24\">",
"      Parving HH, Brenner BM, McMurray JJ, et al. Cardiorenal end points in a trial of aliskiren for type 2 diabetes. N Engl J Med 2012; 367:2204.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8352 Version 2390.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-200.131.240.2-B63444C5D6-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_47_4855=[""].join("\n");
var outline_f4_47_4855=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      ACUTE AND CHRONIC KIDNEY DISEASE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      Antiplatelet therapy in patients with CKD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Acute kidney injury after synthetic cannabinoid use",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      KDIGO guidelines for anemia in chronic kidney disease (CKD)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      DIALYSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Vascular access survival and daily dialysis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Peginesatide, cardiovascular events, and drug withdrawal",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Cinacalcet and the risk of death and/or cardiovascular events",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Buttonhole cannulation of fistulas and infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      GLOMERULAR DISEASE AND VASCULITIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Treatment of patients with idiopathic membranous nephropathy and declining renal function",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Chapel Hill Consensus Conference on nomenclature of vasculitides",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Monoclonal gammopathy of renal significance",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Mycophenolate mofetil versus cyclophosphamide for lupus nephritis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Soluble urokinase receptor in primary FSGS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      HYPERTENSION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Diagnosis of hypertension in childhood requires repeated blood pressure measurements",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Incidentally discovered renal artery stenosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      OTHER NEPHROLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Intravenous albumin for the prevention of hepatorenal syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Hepatoxicity associated with tolvaptan",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Aliskiren in diabetic nephropathy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Tolvaptan may slow progression of autosomal dominant polycystic kidney disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEPH/8352\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/8352|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?7/45/7894\" title=\"table 1\">",
"      Normal BP boys",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?7/46/7910\" title=\"table 2\">",
"      Normal BP girls",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/31/34298?source=related_link\">",
"      Chronic kidney disease and coronary heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/23/37241?source=related_link\">",
"      Classification of and approach to the vasculitides in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/27/27066?source=related_link\">",
"      Course and treatment of autosomal dominant polycystic kidney disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/45/17113?source=related_link\">",
"      Definition and diagnosis of hypertension in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/47/1784?source=related_link\">",
"      Designer drugs of abuse",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/59/15290?source=related_link\">",
"      Diagnosis of monoclonal gammopathy of undetermined significance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/6/41066?source=related_link\">",
"      Epidemiology, classification, and pathogenesis of focal segmental glomerulosclerosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/31/5626?source=related_link\">",
"      Erythropoietin for the anemia of chronic kidney disease in hemodialysis patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/17/31001?source=related_link\">",
"      Establishing the diagnosis of renovascular hypertension",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/17/13594?source=related_link\">",
"      Evaluation and treatment of membranoproliferative glomerulonephritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/50/29482?source=related_link\">",
"      Hepatorenal syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/55/37752?source=related_link\">",
"      Iron balance in non-dialysis, peritoneal dialysis, and home hemodialysis patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/36/38474?source=related_link\">",
"      Management of secondary hyperparathyroidism and mineral metabolism abnormalities in dialysis patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/45/18137?source=related_link\">",
"      Short daily hemodialysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/16/264?source=related_link\">",
"      Technical aspects of nocturnal hemodialysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/37/37466?source=related_link\">",
"      Therapy of diffuse or focal proliferative lupus nephritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/48/40714?source=related_link\">",
"      Treatment of diabetic nephropathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/57/17306?source=related_link\">",
"      Treatment of hyponatremia: Syndrome of inappropriate antidiuretic hormone secretion (SIADH) and reset osmostat",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/41/37530?source=related_link\">",
"      Treatment of idiopathic membranous nephropathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/39/38521?source=related_link\">",
"      Use of iron preparations in hemodialysis patients",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f4_47_4856="Diagnostic evaluation of relapsing polychondritis";
var content_f4_47_4856=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Diagnostic evaluation of relapsing polychondritis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/47/4856/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/47/4856/contributors\">",
"     Clement J Michet, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/47/4856/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/47/4856/contributors\">",
"     Peter H Schur, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/47/4856/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/47/4856/contributors\">",
"     Paul L Romain, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?4/47/4856/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 27, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Relapsing polychondritis (RPC) is a systemic",
"    <span class=\"nowrap\">",
"     inflammatory/degenerative",
"    </span>",
"    disease process that may potentially compromise the structural and functional integrity of cartilage, organs of special sense, and the cardiovascular, renal, and nervous systems (",
"    <a class=\"graphic graphic_table graphicRef76071 \" href=\"UTD.htm?19/45/20188\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/63/26616?source=see_link\">",
"     \"Clinical manifestations of relapsing polychondritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The current understanding of the etiology and pathogenesis of RPC is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/59/42935?source=see_link\">",
"     \"Etiology and pathogenesis of relapsing polychondritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no test that is specific for RPC. The diagnosis is established by the combination of clinical findings, supportive laboratory data, imaging procedures, and biopsy of an involved cartilaginous site.",
"   </p>",
"   <p>",
"    A spectrum of histologic findings may be present in involved organs. The specific findings depend, in part, on the timing of the biopsy. The pathologic features of auricular chondritis and lesions of the aorta, tracheobronchial tree, synovium, kidneys, and eye are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/32/29187?source=see_link\">",
"     \"Pathology of relapsing polychondritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Diagnostic criteria",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two sets of empirically derived diagnostic criteria have been used to define RPC. The original (McAdam's criteria) required the presence of three or more of the following clinical features [",
"    <a class=\"abstract\" href=\"UTD.htm?4/47/4856/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Bilateral auricular chondritis",
"     </li>",
"     <li>",
"      Nonerosive, seronegative inflammatory polyarthritis",
"     </li>",
"     <li>",
"      Nasal chondritis",
"     </li>",
"     <li>",
"      Ocular inflammation (conjunctivitis, keratitis,",
"      <span class=\"nowrap\">",
"       scleritis/episcleritis,",
"      </span>",
"      uveitis)",
"     </li>",
"     <li>",
"      Respiratory tract chondritis (laryngeal",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      tracheal cartilages)",
"     </li>",
"     <li>",
"      Cochlear",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      vestibular dysfunction (neurosensory hearing loss, tinnitus,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      vertigo)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A histologically compatible biopsy (ear, nose, respiratory tract) was considered necessary unless the diagnosis was clinically obvious (",
"    <a class=\"graphic graphic_picture graphicRef55022 \" href=\"UTD.htm?43/29/44498\">",
"     picture 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/32/29187?source=see_link\">",
"     \"Pathology of relapsing polychondritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Modifications were subsequently proposed because of the variability of clinical manifestations occurring at a given point in time [",
"    <a class=\"abstract\" href=\"UTD.htm?4/47/4856/abstract/2\">",
"     2",
"    </a>",
"    ]. To establish the diagnosis, all patients were required to have one of the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      At least three of McAdam's diagnostic criteria",
"     </li>",
"     <li>",
"      One or more of the above clinical findings with positive histologic confirmation",
"     </li>",
"     <li>",
"      Chondritis at two or more separate anatomic locations with response to steroids",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/59/32688?source=see_link\">",
"       dapsone",
"      </a>",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     LABORATORY STUDIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nonspecific although useful information may be found in a number of laboratory studies (",
"    <a class=\"graphic graphic_table graphicRef67505 \" href=\"UTD.htm?26/60/27595\">",
"     table 2",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Elevations in the erythrocyte sedimentation rate or C-reactive protein level and a modest leukocytosis or thrombocytosis are helpful in gauging clinical and subclinical disease activity. However, these parameters cannot be used as indices of disease progression, which often reflects insidiously advancing fibrosis.",
"     </li>",
"     <li>",
"      Anemia is usually present at some point during the course of illness. It is typically normocytic and normochromic, findings consistent with anemia of chronic disease. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/13/9434?source=see_link\">",
"       \"Anemia of chronic disease (anemia of chronic inflammation)\"",
"      </a>",
"      .) Coombs reactive hemolysis is unusual.",
"     </li>",
"     <li>",
"      Eosinophilia occurs in about 10 percent of patients. Its significance is unclear since it does not appear to correlate with disease activity.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Nonspecific autoantibodies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Serologic studies have revealed antinuclear antibodies (ANA) in percentages varying from 22 to 66 percent of RPC patients [",
"    <a class=\"abstract\" href=\"UTD.htm?4/47/4856/abstract/3\">",
"     3",
"    </a>",
"    ]. A homogeneous or speckled pattern is usually evident by immunofluorescence, but the specificity of the responsible antigens is unknown. Antibodies to native DNA, Sm, U1 RNP, and",
"    <span class=\"nowrap\">",
"     Ro/La",
"    </span>",
"    are not characteristic of RPC.",
"   </p>",
"   <p>",
"    Other serologic abnormalities including rheumatoid factor (in 16 percent of cases), a false positive serologic test for syphilis, and antiphospholipid antibodies (positive in one of eight reported cases, manifested clinically by acute thrombosis) can also occur [",
"    <a class=\"abstract\" href=\"UTD.htm?4/47/4856/abstract/4\">",
"     4",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/31/23034?source=see_link\">",
"     \"Clinical manifestations of the antiphospholipid syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Anti-type II collagen antibodies",
"    </span>",
"    &nbsp;&mdash;&nbsp;It has long been recognized that patients with RPC may have humoral",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    cell-mediated immune responses to extracellular matrix components of cartilage. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/59/42935?source=see_link\">",
"     \"Etiology and pathogenesis of relapsing polychondritis\"",
"    </a>",
"    .) Although their pathophysiologic significance is not completely understood, antibodies to native and denatured type II collagen and proteoglycans have largely been regarded as epiphenomena, emanating from tissue destruction, that lack disease specificity [",
"    <a class=\"abstract\" href=\"UTD.htm?4/47/4856/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. Anti-type II collagen antibodies have been identified in other diseases including rheumatoid arthritis (RA), the seronegative spondyloarthropathies, hip and knee osteoarthritis, and connective tissue disorders such as systemic sclerosis, lupus, and Sj&ouml;gren's syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?4/47/4856/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Anti-type II collagen antibodies are found in less than one-half of patients with RPC, occurring more frequently in the early active phase of disease [",
"    <a class=\"abstract\" href=\"UTD.htm?4/47/4856/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. Their usefulness in monitoring disease activity and the response to therapy requires further analysis.",
"   </p>",
"   <p>",
"    More recent studies have noted differences in the epitope specificity of the anti-type II collagen antibody appearing in RPC compared with that in RA [",
"    <a class=\"abstract\" href=\"UTD.htm?4/47/4856/abstract/8\">",
"     8",
"    </a>",
"    ]. The spectrum of anti-collagen response has also been extended. Antibodies to native and denatured type IX and denatured type XI collagen have been identified using immunoblotting and enzyme-linked immunosorbent (ELISA) assays [",
"    <a class=\"abstract\" href=\"UTD.htm?4/47/4856/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. Such antibodies have been reported in the sera (single time point of analysis irrespective of pattern of clinical disease) of 21 percent of 97 RPC patients, but titers could not be correlated with disease severity or autoantibody response to other cartilage matrix components [",
"    <a class=\"abstract\" href=\"UTD.htm?4/47/4856/abstract/11\">",
"     11",
"    </a>",
"    ]. These antibodies also lack specificity.",
"   </p>",
"   <p>",
"    Antibodies to the minor collagens may be paralleled by a cell-mediated immune response as gauged by lymphocyte proliferation [",
"    <a class=\"abstract\" href=\"UTD.htm?4/47/4856/abstract/10\">",
"     10",
"    </a>",
"    ]. A similar cellular response to cartilage proteoglycans, which paralleled disease activity, has also been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?4/47/4856/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Antineutrophil cytoplasmic antibodies",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are several features of RPC which suggest the potential for an increased frequency of antineutrophil cytoplasmic antibodies (ANCA). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/28/9674?source=see_link\">",
"     \"Clinical spectrum of antineutrophil cytoplasmic antibodies\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Fourteen percent of patients with RPC have clinically evident vasculitis [",
"      <a class=\"abstract\" href=\"UTD.htm?4/47/4856/abstract/13\">",
"       13",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/63/26616?source=see_link\">",
"       \"Clinical manifestations of relapsing polychondritis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Vasculitis is probably operative in the pathogenesis of specific organ system involvement in a far greater percentage of patients.",
"     </li>",
"     <li>",
"      ANCA is prevalent in granulomatosis with polyangiitis (Wegener&rsquo;s), abbreviated as GPA, which shares a number of features with RPC such as laryngotracheal bronchial disease, necrotizing glomerulonephritis, episcleritis, saddle nose deformity, and auricular chondritis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There is discordance in the literature on the role of ANCA in the vasculitis of RPC. One report, for example, found low titer ANCA (as assessed by immunofluorescence) in 8 of 23 patients with RPC [",
"    <a class=\"abstract\" href=\"UTD.htm?4/47/4856/abstract/14\">",
"     14",
"    </a>",
"    ]. Three had a C-ANCA pattern (diffuse granular cytoplasmic staining), and five had P-ANCA reactivity (perinuclear staining) (",
"    <a class=\"graphic graphic_picture graphicRef66748 graphicRef78968 \" href=\"UTD.htm?26/1/26640\">",
"     picture 2A-B",
"    </a>",
"    ). The specificity of these antibodies was examined by ELISA. None of the C-ANCA responders were positive for serine proteinase 3, the dominant antigen responsible for this pattern in GPA. Four of the five positive P-ANCA patients were reactive with myeloperoxidase, the antigen associated with P-ANCA in GPA and microscopic polyarteritis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/28/9674?source=see_link\">",
"     \"Clinical spectrum of antineutrophil cytoplasmic antibodies\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A subsequent study demonstrated ANCA reactivity in three of six patients in whom RPC appeared in conjunction with a systemic necrotizing form of vasculitis (GPA or microscopic polyarteritis) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/47/4856/abstract/15\">",
"     15",
"    </a>",
"    ]. Thus, although ANCA may be detected in RPC, its relevance and relationship to associated vasculitis require further analysis. In other diseases associated with ANCA (eg, GPA and microscopic polyangiitis), the ability of changes in ANCA titers to predict disease flares is poor. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/28/9674?source=see_link\">",
"     \"Clinical spectrum of antineutrophil cytoplasmic antibodies\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Other studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Total hemolytic complement and C3 and C4 levels are usually normal in RPC [",
"    <a class=\"abstract\" href=\"UTD.htm?4/47/4856/abstract/16\">",
"     16",
"    </a>",
"    ]. Occasional elevations in complement levels probably reflect an acute phase response. The prevalence and significance of circulating immune complexes have not been systematically evaluated. Using varying methodologies, immune complexes have been identified in 15 of 35 reported cases (43 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/47/4856/abstract/5\">",
"     5",
"    </a>",
"    ]. Cryoglobulins appear to occur less frequently, being detected in 7 of 32 cases (22 percent) compiled from the literature.",
"   </p>",
"   <p>",
"    Transient increases may occur in IgG, IgA, or IgE levels. Serum protein electrophoresis may show nonspecific abnormalities, such as a decrease in albumin and elevations in the alpha-1 and gamma globulin regions.",
"   </p>",
"   <p>",
"    An adequate laboratory gauge defining active cartilage catabolism and, thus, a means of monitoring disease activity is lacking in RP. Still in a preliminary stage are studies investigating the feasibility of measurement of serum content of noncollagenous cartilage-specific adhesive glycoproteins [",
"    <a class=\"abstract\" href=\"UTD.htm?4/47/4856/abstract/17,18\">",
"     17,18",
"    </a>",
"    ]. Also preliminary is the assessment of serum matrillin-1 fragments to reflect active inflammation [",
"    <a class=\"abstract\" href=\"UTD.htm?4/47/4856/abstract/18\">",
"     18",
"    </a>",
"    ]. Urine levels of a type II collagen specific neoepitope generated by specific interstitial collagenase CII cleavage are being investigated, but the clinical usefulness is uncertain [",
"    <a class=\"abstract\" href=\"UTD.htm?4/47/4856/abstract/19\">",
"     19",
"    </a>",
"    ]. Serum cartilage oligomeric matrix protein (COMP) is also being investigated as a potential biomarker of disease activity [",
"    <a class=\"abstract\" href=\"UTD.htm?4/47/4856/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although analysis of cerebrospinal fluid may be normal in the presence of clinical evidence of central nervous system involvement, there is usually a pleocytosis with a predominance of lymphocytes, a protein content that is either normal or slightly elevated, and a normal glucose concentration [",
"    <a class=\"abstract\" href=\"UTD.htm?4/47/4856/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     EVALUATION FOR PULMONARY INVOLVEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Functional and anatomical evaluation for upper and lower airway disease is essential in the evaluation and management of RPC. Imaging studies can provide important information noninvasively in the evaluation of the larynx and trachea.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Pulmonary function testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pulmonary function testing may show varying degrees of inspiratory",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    expiratory obstruction; the magnitude varies with the location and character of the pathologic process [",
"    <a class=\"abstract\" href=\"UTD.htm?4/47/4856/abstract/22\">",
"     22",
"    </a>",
"    ]. A complete spirometric evaluation should include both maximal inspiratory and expiratory flow-volume loops (",
"    <a class=\"graphic graphic_figure graphicRef55235 \" href=\"UTD.htm?9/2/9261\">",
"     figure 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/17/25878?source=see_link\">",
"     \"Flow-volume loops\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Expiratory obstruction correlates well with bronchoscopically defined abnormalities such as collapse",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    narrowing. In contrast, inspiratory obstruction correlates poorly with bronchoscopic findings in the extrathoracic airway. As an example, a normal appearing larynx associated with decreased maximum inspiratory flow may represent abnormal cricoarytenoid joint motion.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Bronchoscopy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bronchoscopy may be a high-risk procedure in individuals whose airways are already substantially compromised. Thus, it should be undertaken only by experts experienced in dealing with potentially collapsible airways.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Chest radiography",
"    </span>",
"    &nbsp;&mdash;&nbsp;A plain chest film can demonstrate one of more of the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Tracheal narrowing",
"     </li>",
"     <li>",
"      Opacities secondary to pneumonia or atelectasis induced by obstruction",
"     </li>",
"     <li>",
"      Increased pulmonary vascularization or pulmonary edema",
"     </li>",
"     <li>",
"      A lateral view of the neck may reveal calcification of the tracheal or laryngeal cartilage.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although baseline chest radiographs are useful in some patients, the greater detail offered by computed tomography (CT) makes this the study of choice in RPC.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Computed tomography",
"    </span>",
"    &nbsp;&mdash;&nbsp;A CT scan of the large airways should be performed at baseline in all patients with RPC. CT scanning is more useful than conventional tomograms and laryngotracheograms in evaluating laryngotracheal bronchial wall thickening, luminal narrowing, and cartilaginous calcification [",
"    <a class=\"abstract\" href=\"UTD.htm?4/47/4856/abstract/23,24\">",
"     23,24",
"    </a>",
"    ]. As a result, it can usually provide an explanation for hoarseness, dysphagia, or respiratory distress in patients with RPC.",
"   </p>",
"   <p>",
"    Attention to the technique of performing the CT scan may be important. If the CT scan is only performed during inspiration (which is the usual method), changes in the caliber of the tracheobronchial tree may be missed. This was illustrated in a report of 18 patients with RPC who were referred for airway imaging [",
"    <a class=\"abstract\" href=\"UTD.htm?4/47/4856/abstract/25\">",
"     25",
"    </a>",
"    ]. The majority of patients exhibited expiratory CT abnormalities, but only one-half had abnormalities on routine inspiratory CT scans. Thus, selected slices covering at least the major airways should be obtained in expiration (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef80171 \" href=\"UTD.htm?28/20/28992\">",
"     image 1",
"    </a>",
"    ). A three dimensional reconstruction of the tracheobronchial images may be useful.",
"   </p>",
"   <p>",
"    The CT scan is partially limited by its inability to distinguish fibrosis from inflammation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Magnetic resonance imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;MRI, with its multiplanar imaging capability and superior soft tissue contrast, is particularly useful for evaluating the trachea and larynx in patients with RPC. It distinguishes fibrosis from inflammation (in contrast to CT) and inflammation from edema, even in the presence of subclinical disease [",
"    <a class=\"abstract\" href=\"UTD.htm?4/47/4856/abstract/26,27\">",
"     26,27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are two potential limitations to MRI. The length of time required for imaging may create a problem in the patient with respiratory compromise, and there may be low anatomical resolution due to image degradation caused by respiratory motion.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Other imaging techniques",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several other imaging techniques have been used in small series or case reports, including gallium radionuclide imaging, 99m Tc methylene diphosphonate bone scintigraphy, endobronchial ultrasonography, and positron emission tomography [",
"    <a class=\"abstract\" href=\"UTD.htm?4/47/4856/abstract/28-33\">",
"     28-33",
"    </a>",
"    ]. The value of these techniques in routine clinical practice is not established.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     EVALUATION FOR CARDIAC INVOLVEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Active inflammation of the heart valves and large arteries may be totally asymptomatic and difficult to detect clinically. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/63/26616?source=see_link\">",
"     \"Clinical manifestations of relapsing polychondritis\"",
"    </a>",
"    .) The following findings may be seen:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A chest radiograph or CT may disclose cardiomegaly or may identify aortic arch widening or prominence of the ascending or descending aorta.",
"     </li>",
"     <li>",
"      Arrhythmic events secondary to myocarditis or myocardial ischemia can be detected on the electrocardiogram. Holter monitoring may be required to document and define the nature of such events.",
"     </li>",
"     <li>",
"      Doppler echocardiography is the method of choice for the evaluation of cardiac valve status, for measurement of the degree of valvular regurgitation, and for imaging of left ventricular size and function. We suggest obtaining a baseline transthoracic echocardiogram in all patients.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Enlargement of the ascending aorta can be further assessed by transesophageal echocardiography or by MRI. The latter can also be used to locate aneurysmal dilatation along the course of the aorta. Invasive procedures such as aortography and coronary angiography may be indicated for the evaluation of vasculitis or aneurysms. However, their use may be potentially dangerous because of increased fragility of the vessel wall. Vascular injury can induce a false aneurysm, dissection, or thrombosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;RPC is distinguished from other diseases by the coexistence of usually widespread, potentially destructive inflammatory lesions involving cartilaginous structures throughout the body, organs of special sense, and the cardiovascular system. However, the variable, unpredictable expression of clinical features over time may make the diagnosis difficult to establish.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Auricular inflammation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Auricular inflammation simulating that occurring in RPC (",
"    <a class=\"graphic graphic_picture graphicRef81482 graphicRef82354 \" href=\"UTD.htm?26/33/27159\">",
"     picture 3A-B",
"    </a>",
"    ) may be secondary to an acute pyogenic or chronic granulomatous infectious process such as tuberculosis, fungal disease, syphilis, or leprosy. The absence of regional lymphadenopathy should trigger the suspicion of a noninfectious process. It is important to appreciate that the expression of auricular cellulitis and chondritis following even minor burns may be delayed, in some cases by weeks, occurring at sites that have long since healed.",
"   </p>",
"   <p>",
"    On occasion, chondrodermatitis helicis nodularis, an inflammatory and degenerative skin lesion of unknown etiology, may cause confusion because of its histologic resemblance to RPC [",
"    <a class=\"abstract\" href=\"UTD.htm?4/47/4856/abstract/34-36\">",
"     34-36",
"    </a>",
"    ]. Its more localized, circumscribed distribution and the absence of other features of disease assist in the differentiation.",
"   </p>",
"   <p>",
"    Cystic chondromalacia usually presents as a painless, non-tender cystic swelling involving the upper ear region. Serous fluid can often be aspirated. Auricular inflammation caused by trauma, such as ear piercing, irritant chemicals and frostbite, must be excluded.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Saddle nose deformity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chondritis with destruction of nasal cartilage and the potential development of a saddle nose deformity, although characteristic of RPC (",
"    <a class=\"graphic graphic_picture graphicRef80564 \" href=\"UTD.htm?8/27/8638\">",
"     picture 4",
"    </a>",
"    ), may also be induced by an infectious granulomatous lesion, granulomatosis with polyangiitis (Wegener&rsquo;s), lymphomatoid granulomatosis, carcinoma, or lymphoma. A useful differentiating feature is the absence of mucosal inflammation in RPC.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Narrowing of the airway",
"    </span>",
"    &nbsp;&mdash;&nbsp;Airway narrowing can result either from an intrinsic lesion or from extension or compression afforded by an extrinsic process. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/42/25256?source=see_link&amp;anchor=H9#H9\">",
"     \"Radiology of the trachea\", section on 'Tracheal narrowing'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Epiglottitis must always be considered when suspecting an upper airway obstruction. The chief complaint is invariably the sudden onset of a severe sore throat in a previously healthy individual. Death may quickly ensue if the diagnosis is not promptly established and appropriate therapy instituted. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?4/45/4826?source=see_link\">",
"       \"Epiglottitis (supraglottitis): Clinical features and diagnosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Airway lesions may result from trauma induced by endotracheal intubation, neoplastic disease, granulomatosis with polyangiitis (Wegener&rsquo;s), the saber-sheath trachea associated with chronic obstructive pulmonary disease, or the rare tracheobronchopathia osteochondroplastica characterized by osseocartilaginous mucosal nodules which project into the lumen of the larynx, trachea, and bronchi. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/42/25256?source=see_link&amp;anchor=H10#H10\">",
"       \"Radiology of the trachea\", section on 'Long segment narrowing'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The larynx and tracheobronchial tree may be involved by the localized tumor-forming variant of amyloidosis. Individual and coalescent nodules may develop in the supraglottic or subglottic regions of the larynx in this disorder. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?1/31/1530?source=see_link&amp;anchor=H17#H17\">",
"       \"An overview of amyloidosis\", section on 'Pulmonary disease'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Rhinoscleroma, a chronic granulomatous disease caused by Klebsiella rhinoscleromatis, is endemic to Asia, Africa, and South America. It may progress to a cicatricial stage with dense fibrotic narrowing of the larynx or trachea [",
"      <a class=\"abstract\" href=\"UTD.htm?4/47/4856/abstract/37\">",
"       37",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The larynx may rarely be involved in pemphigus vulgaris, the supraglottic region having an erythematous appearing ulcerated mucosa with a fibrinous exudate. Laryngeal lesions have been reported in 10 percent of patients having cicatricial pemphigoid. Bullae or ulcers mainly occur on supraglottic structures and may be associated with odynophagia. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/11/22714?source=see_link\">",
"       \"Clinical features and diagnosis of bullous pemphigoid and mucous membrane pemphigoid\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/44/19146?source=see_link\">",
"       \"Pathogenesis, clinical manifestations, and diagnosis of pemphigus\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Infectious and noninfectious mediastinal lesions (such as tuberculosis, histoplasmosis, and sarcoidosis) may be associated with chronic inflammation, thickening, and stenosis of the tracheal wall. Mediastinal lymphadenopathy has not been described in RPC. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/10/15526?source=see_link\">",
"       \"Fibrosing mediastinitis\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Ocular inflammation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ocular inflammation, audiovestibular dysfunction, and polyarthritis may be seen in systemic necrotizing forms of vasculitis such as polyarteritis nodosa, granulomatosis with polyangiitis (Wegener&rsquo;s), Cogan's syndrome, and Beh&ccedil;et&rsquo;s disease. However, these are not generalized chondropathies like RPC.",
"   </p>",
"   <p>",
"    Granulomatosis with polyangiitis (Wegener&rsquo;s) may be particularly difficult to distinguish from RPC because of the potential of additional shared expressions of auricular chondritis, saddle nose deformity, laryngotracheal bronchial disease, glomerulonephritis, nervous system involvement, and the presence of ANCA. The correct diagnosis must be established by histologic means and by the recognition of more specific clinical features such as cavitary lung lesions in granulomatosis with polyangiitis (Wegener&rsquo;s) and such as diffuse dynamic tracheobronchial collapse and aortic aneurysms in RPC. An overlap is the most plausible explanation when discriminating data do not allow differentiation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/62/17386?source=see_link\">",
"     \"Clinical manifestations and diagnosis of granulomatosis with polyangiitis (Wegener's) and microscopic polyangiitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Ocular inflammation in conjunction with polyarthritis must be further distinguished from rheumatoid arthritis, the seronegative spondyloarthropathies (ankylosing spondylitis, reactive arthritis, psoriatic arthritis), and sarcoidosis. The individual characteristics of these diseases usually permit the diagnosis to be established.",
"   </p>",
"   <p>",
"    The presence of aortitis and aortic aneurysms warrants consideration of developmental connective tissue diseases such as Marfan's and Ehlers-Danlos syndromes, as well as idiopathic medial cystic necrosis, syphilis, and arteriosclerosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Costochondritis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tietze's syndrome should be considered in the differential diagnosis of costochondritis, as well as infection (pyogenic organisms, tuberculosis, fungal, viral), costochondral injury (eg, trauma or a sternotomy incision), drainage from intrathoracic or peritoneal foci, chest wall irradiation, and deep chest wall burns (particularly of electrical origin). Costochondritis secondary to hematogenous seeding of Candida albicans in intravenous drug abusers has become increasingly recognized. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/9/2201?source=see_link\">",
"     \"Major causes of musculoskeletal chest pain\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Relapsing polychondritis (RPC) is a systemic",
"      <span class=\"nowrap\">",
"       inflammatory/degenerative",
"      </span>",
"      disease process that may potentially compromise the structural and functional integrity of cartilage, organs of special sense, and the cardiovascular, renal, and nervous systems (",
"      <a class=\"graphic graphic_table graphicRef76071 \" href=\"UTD.htm?19/45/20188\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/63/26616?source=see_link\">",
"       \"Clinical manifestations of relapsing polychondritis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In the absence of a reliable diagnostic test for RPC, the diagnosis is based on empirically derived diagnostic criteria. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Diagnostic criteria'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Elevation of acute phase reactants (eg, ESR, CRP, leukocyte counts), anemia, and eosinophilia are frequent, though nonspecific, laboratory findings, as are measurable titers of some autoantibodies. Antineutrophil cytoplasmic antibodies (ANCA) may be present in the serum of some patients, and the prevalence may be greater in those with vasculitis. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Laboratory studies'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Functional and anatomical evaluation for upper and lower airway disease is essential in evaluation and management of the disease. We suggest a complete spirometric evaluation with inspiratory and expiratory flow-volume loops and a chest CT scan with both inspiratory and expiratory views of the major airways. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Evaluation for pulmonary involvement'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest an electrocardiogram and transthoracic echocardiogram as baseline examinations for all patients regardless of symptoms or physical examination findings. If enlargement of the ascending aorta is suggested, further evaluation with transesophageal ultrasonography or MRI may be useful to assess for aneurysmal dilation. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Evaluation for cardiac involvement'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/47/4856/abstract/1\">",
"      McAdam LP, O'Hanlan MA, Bluestone R, Pearson CM. Relapsing polychondritis: prospective study of 23 patients and a review of the literature. Medicine (Baltimore) 1976; 55:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/47/4856/abstract/2\">",
"      Damiani JM, Levine HL. Relapsing polychondritis--report of ten cases. Laryngoscope 1979; 89:929.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/47/4856/abstract/3\">",
"      Piette JC, El-Rassi R, Amoura Z. Antinuclear antibodies in relapsing polychondritis. Ann Rheum Dis 1999; 58:656.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/47/4856/abstract/4\">",
"      Balsa-Criado A, Gonzalez-Hernandez T, Cuesta MV, et al. Lupus anticoagulant in relapsing polychondritis. J Rheumatol 1990; 17:1426.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/47/4856/abstract/5\">",
"      Foidart JM, Abe S, Martin GR, et al. Antibodies to type II collagen in relapsing polychondritis. N Engl J Med 1978; 299:1203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/47/4856/abstract/6\">",
"      Ebringer R, Rook G, Swana GT, et al. Autoantibodies to cartilage and type II collagen in relapsing polychondritis and other rheumatic diseases. Ann Rheum Dis 1981; 40:473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/47/4856/abstract/7\">",
"      Charri&egrave;re G, Hartmann DJ, Vignon E, et al. Antibodies to types I, II, IX, and XI collagen in the serum of patients with rheumatic diseases. Arthritis Rheum 1988; 31:325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/47/4856/abstract/8\">",
"      Terato K, Shimozuru Y, Katayama K, et al. Specificity of antibodies to type II collagen in rheumatoid arthritis. Arthritis Rheum 1990; 33:1493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/47/4856/abstract/9\">",
"      Yang CL, Brinckmann J, Rui HF, et al. Autoantibodies to cartilage collagens in relapsing polychondritis. Arch Dermatol Res 1993; 285:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/47/4856/abstract/10\">",
"      Alsalameh S, Mollenhauer J, Scheuplein F, et al. Preferential cellular and humoral immune reactivities to native and denatured collagen types IX and XI in a patient with fatal relapsing polychondritis. J Rheumatol 1993; 20:1419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/47/4856/abstract/11\">",
"      Hansson AS, Heineg&aring;rd D, Piette JC, et al. The occurrence of autoantibodies to matrilin 1 reflects a tissue-specific response to cartilage of the respiratory tract in patients with relapsing polychondritis. Arthritis Rheum 2001; 44:2402.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/47/4856/abstract/12\">",
"      Herman JH, Dennis MV. Immunopathologic studies in relapsing polychondritis. J Clin Invest 1973; 52:549.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/47/4856/abstract/13\">",
"      Michet CJ. Vasculitis and relapsing polychondritis. Rheum Dis Clin North Am 1990; 16:441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/47/4856/abstract/14\">",
"      Papo T, Piette JC, Le Thi Huong Du, et al. Antineutrophil cytoplasmic antibodies in polychondritis. Ann Rheum Dis 1993; 52:384.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/47/4856/abstract/15\">",
"      Handrock K, Gross WL. Relapsing polychondritis as a secondary phenomenon of primary systemic vasculitis. Ann Rheum Dis 1993; 52:895.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/47/4856/abstract/16\">",
"      O'Hanlan M, McAdam LP, Bluestone R, Pearson CM. The arthropathy of relapsing polychrondritis. Arthritis Rheum 1976; 19:191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/47/4856/abstract/17\">",
"      Saxne T, Heineg&aring;rd D. Involvement of nonarticular cartilage, as demonstrated by release of a cartilage-specific protein, in rheumatoid arthritis. Arthritis Rheum 1989; 32:1080.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/47/4856/abstract/18\">",
"      Saxne T, Heineg&aring;rd D. Serum concentrations of two cartilage matrix proteins reflecting different aspects of cartilage turnover in relapsing polychondritis. Arthritis Rheum 1995; 38:294.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/47/4856/abstract/19\">",
"      Kraus VB, Stabler T, Le ET, et al. Urinary type II collagen neoepitope as an outcome measure for relapsing polychondritis. Arthritis Rheum 2003; 48:2942.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/47/4856/abstract/20\">",
"      Kempta Lekpa F, Piette JC, Bastuji-Garin S, et al. Serum cartilage oligomeric matrix protein (COMP) level is a marker of disease activity in relapsing polychondritis. Clin Exp Rheumatol 2010; 28:553.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/47/4856/abstract/21\">",
"      Hanslik T, Wechsler B, Piette JC, et al. Central nervous system involvement in relapsing polychondritis. Clin Exp Rheumatol 1994; 12:539.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/47/4856/abstract/22\">",
"      Krell WS, Staats BA, Hyatt RE. Pulmonary function in relapsing polychondritis. Am Rev Respir Dis 1986; 133:1120.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/47/4856/abstract/23\">",
"      Behar JV, Choi YW, Hartman TA, et al. Relapsing polychondritis affecting the lower respiratory tract. AJR Am J Roentgenol 2002; 178:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/47/4856/abstract/24\">",
"      Lin ZQ, Xu JR, Chen JJ, et al. Pulmonary CT findings in relapsing polychondritis. Acta Radiol 2010; 51:522.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/47/4856/abstract/25\">",
"      Lee KS, Ernst A, Trentham DE, et al. Relapsing polychondritis: prevalence of expiratory CT airway abnormalities. Radiology 2006; 240:565.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/47/4856/abstract/26\">",
"      Fornadley JA, Seibert DJ, Ostrov BE, Warren WS. The role of MRI when relapsing polychondritis is suspected but not proven. Int J Pediatr Otorhinolaryngol 1995; 31:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/47/4856/abstract/27\">",
"      Heman-Ackah YD, Remley KB, Goding GS Jr. A new role for magnetic resonance imaging in the diagnosis of laryngeal relapsing polychondritis. Head Neck 1999; 21:484.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/47/4856/abstract/28\">",
"      Dupont A, Bossuyt A, Somers G. Relapsing polychondritis: gallium-67 uptake in recurrent lung lesions. J Nucl Med Allied Sci 1983; 27:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/47/4856/abstract/29\">",
"      Chang MC, Tsai SC, Lin WY. Value of gallium-67 scanning in monitoring therapeutic effectiveness in a patient with relapsing polychondritis. Kaohsiung J Med Sci 2008; 24:328.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/47/4856/abstract/30\">",
"      Kao CH, Wang SJ, Yeh SH. Radionuclide imaging of relapsing polychondritis. Clin Nucl Med 1992; 17:397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/47/4856/abstract/31\">",
"      Shi XH, Zhang FC, Chen LB, Ouyang M. The value of 99mTc methylene diphosphonate bone scintigraphy in diagnosing relapsing polychondritis. Chin Med J (Engl) 2006; 119:1129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/47/4856/abstract/32\">",
"      Murgu S, Kurimoto N, Colt H. Endobronchial ultrasound morphology of expiratory central airway collapse. Respirology 2008; 13:315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/47/4856/abstract/33\">",
"      Nishiyama Y, Yamamoto Y, Dobashi H, et al. [18F]fluorodeoxyglucose positron emission tomography imaging in a case of relapsing polychondritis. J Comput Assist Tomogr 2007; 31:381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/47/4856/abstract/34\">",
"      Thompson LD. Chondrodermatitis nodularis helicis. Ear Nose Throat J 2007; 86:734.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/47/4856/abstract/35\">",
"      Moncrieff M, Sassoon EM. Effective treatment of chondrodermatitis nodularis chronica helicis using a conservative approach. Br J Dermatol 2004; 150:892.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/47/4856/abstract/36\">",
"      Zuber TJ, Jackson E. Chondrodermatitis nodularis chronica helicis. Arch Fam Med 1999; 8:445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/47/4856/abstract/37\">",
"      Verma G, Kanawaty D, Hyland R. Rhinoscleroma causing upper airway obstruction. Can Respir J 2005; 12:43.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5609 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-115.66.252.144-AD9E7E195A-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_47_4856=[""].join("\n");
var outline_f4_47_4856=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H23\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Diagnostic criteria",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      LABORATORY STUDIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Nonspecific autoantibodies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Anti-type II collagen antibodies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Antineutrophil cytoplasmic antibodies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Other studies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      EVALUATION FOR PULMONARY INVOLVEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Pulmonary function testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Bronchoscopy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Chest radiography",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Computed tomography",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Magnetic resonance imaging",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Other imaging techniques",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      EVALUATION FOR CARDIAC INVOLVEMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Auricular inflammation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Saddle nose deformity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Narrowing of the airway",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Ocular inflammation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Costochondritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"RHEUM/5609\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"RHEUM/5609|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?28/20/28992\" title=\"diagnostic image 1\">",
"      Relapsing polychondritis CT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"RHEUM/5609|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?9/2/9261\" title=\"figure 1\">",
"      Flow volume loop in RPC",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"RHEUM/5609|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?43/29/44498\" title=\"picture 1\">",
"      Cartilage inflammation in RPC",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?38/51/39742\" title=\"picture 2A\">",
"      C ANCA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?17/6/17518\" title=\"picture 2B\">",
"      P ANCA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?25/39/26226\" title=\"picture 3A\">",
"      Auricular inflammation RPC",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?3/60/4034\" title=\"picture 3B\">",
"      Cauliflower ear in RPC",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?8/27/8638\" title=\"picture 4\">",
"      Saddle nose in RPC",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"RHEUM/5609|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?19/45/20188\" title=\"table 1\">",
"      Clinical features of RPC",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?26/60/27595\" title=\"table 2\">",
"      Laboratory tests in RPC",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/31/1530?source=related_link\">",
"      An overview of amyloidosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/13/9434?source=related_link\">",
"      Anemia of chronic disease (anemia of chronic inflammation)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/11/22714?source=related_link\">",
"      Clinical features and diagnosis of bullous pemphigoid and mucous membrane pemphigoid",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/62/17386?source=related_link\">",
"      Clinical manifestations and diagnosis of granulomatosis with polyangiitis (Wegener's) and microscopic polyangiitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/63/26616?source=related_link\">",
"      Clinical manifestations of relapsing polychondritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/31/23034?source=related_link\">",
"      Clinical manifestations of the antiphospholipid syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/28/9674?source=related_link\">",
"      Clinical spectrum of antineutrophil cytoplasmic antibodies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/45/4826?source=related_link\">",
"      Epiglottitis (supraglottitis): Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/59/42935?source=related_link\">",
"      Etiology and pathogenesis of relapsing polychondritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/10/15526?source=related_link\">",
"      Fibrosing mediastinitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/17/25878?source=related_link\">",
"      Flow-volume loops",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/9/2201?source=related_link\">",
"      Major causes of musculoskeletal chest pain",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/44/19146?source=related_link\">",
"      Pathogenesis, clinical manifestations, and diagnosis of pemphigus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/32/29187?source=related_link\">",
"      Pathology of relapsing polychondritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/42/25256?source=related_link\">",
"      Radiology of the trachea",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f4_47_4857="Clinical manifestations, diagnosis, and nonsurgical management of posterior vaginal defects";
var content_f4_47_4857=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Clinical manifestations, diagnosis, and nonsurgical management of posterior vaginal defects",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/47/4857/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/47/4857/contributors\">",
"     Amy J Park, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/47/4857/contributors\">",
"     Tristi W Muir, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/47/4857/contributors\">",
"     Marie Fidela R Paraiso, MD, FACOG",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/47/4857/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/47/4857/contributors\">",
"     Linda Brubaker, MD, FACS, FACOG",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/47/4857/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/47/4857/contributors\">",
"     Sandy J Falk, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?4/47/4857/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 25, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pelvic organ prolapse (POP) includes defects of the anterior, apical, and posterior vaginal wall. Defects of pelvic support often do not occur in isolation. As an example, one series of 384 women undergoing surgical repair of POP reported the following types and frequencies of defects: anterior compartment only (40 percent), posterior compartment only (7 percent), apex only (6 percent), anterior and posterior compartments (16 percent), anterior compartment and apex (9 percent), posterior compartment and apex (5 percent), and all three compartments (18 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/47/4857/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Posterior vaginal defects may be associated with:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Rectocele (anterior protrusion of the rectum)",
"     </li>",
"     <li>",
"      Sigmoidocele (protrusion of the sigmoid colon)",
"     </li>",
"     <li>",
"      Enterocele (protrusion of the small bowel).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These entities can be difficult to distinguish on physical examination. Pelvic floor fluoroscopy has confirmed that there is no correlation between the fluoroscopic position of the small bowel or rectum and any apical or posterior wall POP site [",
"    <a class=\"abstract\" href=\"UTD.htm?4/47/4857/abstract/2\">",
"     2",
"    </a>",
"    ]. Furthermore, the degree of anatomic distortion often does not correlate with functional impairment [",
"    <a class=\"abstract\" href=\"UTD.htm?4/47/4857/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     RISK FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common risk factors for any form of vaginal prolapse are vaginal childbirth, advancing age, and increasing body mass index.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Vaginal childbirth",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vaginal childbirth, particularly delivery in the occiput posterior position or instrumental delivery, is the factor most consistently associated with prolapse, while Cesarean delivery appears to be protective [",
"    <a class=\"abstract\" href=\"UTD.htm?4/47/4857/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. Injury to the levator ani or local nerves, especially the pudendal nerve, during childbirth may be responsible for the anatomic abnormality [",
"    <a class=\"abstract\" href=\"UTD.htm?4/47/4857/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. Other childbirth-related factors associated with prolapse include high infant birth weight, prolonged second stage of labor, and maternal age less than 25 years at first delivery [",
"    <a class=\"abstract\" href=\"UTD.htm?4/47/4857/abstract/4,8\">",
"     4,8",
"    </a>",
"    ]. However, posterior vaginal prolapse can also occur in a nulliparous woman [",
"    <a class=\"abstract\" href=\"UTD.htm?4/47/4857/abstract/9\">",
"     9",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/18/19753?source=see_link\">",
"     \"Pelvic floor disorders associated with pregnancy and childbirth\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Pelvic surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;The role of hysterectomy in the development of subsequent pelvic organ prolapse is controversial. The risk may depend on age, whether prolapse is present at the time of hysterectomy, and on the surgical approach. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/19/12602?source=see_link&amp;anchor=H22#H22\">",
"     \"Overview of hysterectomy\", section on 'Pelvic organ prolapse'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Retropubic urethropexy or needle suspension procedures may result in a more anterior deviation of the anterior vaginal wall, which alters the distribution of force on all of the vaginal walls. As a result, the apex and posterior vaginal wall may become prone to the development of support defects, including enterocele or rectocele.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Elevated intra-abdominal pressure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronic constipation and other conditions that cause elevated intra-abdominal pressure, such as chronic obstructive pulmonary disease, may cause stretch injury to the pudendal nerve [",
"    <a class=\"abstract\" href=\"UTD.htm?4/47/4857/abstract/10\">",
"     10",
"    </a>",
"    ]. One study that determined the prevalence of functional bowel and anorectal disorders in patients with advanced POP and urinary incontinence reported 36 percent also had constipation [",
"    <a class=\"abstract\" href=\"UTD.htm?4/47/4857/abstract/11\">",
"     11",
"    </a>",
"    ]. Prolapse does not cause constipation. Moreover, constipation was not related to the severity of prolapse, and was equally present in those patients whose only symptom was urinary incontinence, implying that either it does not significantly contribute to prolapse, or that it contributes equally to both prolapse and urinary incontinence.",
"   </p>",
"   <p>",
"    Women who are",
"    <span class=\"nowrap\">",
"     laborers/factory",
"    </span>",
"    workers have significantly more severe POP than the other job categories, probably as a result of increased intraabdominal pressure related to lifting [",
"    <a class=\"abstract\" href=\"UTD.htm?4/47/4857/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Collagen abnormality",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women with hypermobile joints have a higher prevalence of prolapse than women with normal joint mobility, suggesting abnormalities of collagen may play a role in both disorders [",
"    <a class=\"abstract\" href=\"UTD.htm?4/47/4857/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]. One possibility is that these women may metabolize collagen such that there is a decrease in type I collagen and an increase in type III collagen. Type I collagen forms large, high tensile strength fibers that constitute such tissues as ligaments, tendons, skin, and bone. Type III collagen forms smaller fibers of lower tensile strength, and predominates in more flexible, distensible tissue types, and is the major collagen subtype in the vagina. Type V collagen forms small fibers of low tensile strength. Type III and V collagen fibers copolymerize with type I collagen to form fibrils of varying diameters and tensile strength. A higher ratio of type I collagen to type III and type V collagen results in higher tensile strength [",
"    <a class=\"abstract\" href=\"UTD.htm?4/47/4857/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Advancing age",
"    </span>",
"    &nbsp;&mdash;&nbsp;Epidemiologic studies have generally shown an increased risk of POP with advancing age [",
"    <a class=\"abstract\" href=\"UTD.htm?4/47/4857/abstract/1,15,16\">",
"     1,15,16",
"    </a>",
"    ]. As an example, women enrolled in the Women's Health Initiative trial (n = 27,342 women) were asked to complete baseline questionnaires regarding demographics and personal habits and to undergo a baseline pelvic examination to assess uterine prolapse, cystocele, and rectocele [",
"    <a class=\"abstract\" href=\"UTD.htm?4/47/4857/abstract/15\">",
"     15",
"    </a>",
"    ]. There was a small, but statistically significant, progress increase in the prevalence of rectocele with age (50 to 59 compared to 60 to 69 and 70 to 79 years). In another study looking at a managed health care population, the number of women seeking care for symptomatic pelvic floor disorders (prolapse and incontinence) increased by age, with the largest number of consults generated by women in their 60s and 70s [",
"    <a class=\"abstract\" href=\"UTD.htm?4/47/4857/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Increasing body mass index",
"    </span>",
"    &nbsp;&mdash;&nbsp;Along with age, increasing body mass index (BMI) is another risk factor for POP. In the Women's Health Initiative trial, obese women were found to have higher prevalence of rectoceles compared to nonobese women (BMI &lt;25",
"    <span class=\"nowrap\">",
"     kg/m",
"     <sup>",
"      2",
"     </sup>",
"     ),",
"    </span>",
"    with an increased risk of 38 and 75 percent for those with BMIs 25 to 30",
"    <span class=\"nowrap\">",
"     kg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    and over 30",
"    <span class=\"nowrap\">",
"     kg/m",
"     <sup>",
"      2",
"     </sup>",
"     ,",
"    </span>",
"    respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?4/47/4857/abstract/15\">",
"     15",
"    </a>",
"    ]. In another study, women with a BMI &gt;25",
"    <span class=\"nowrap\">",
"     kg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    had a three-fold higher risk of having POP compared to nonobese women [",
"    <a class=\"abstract\" href=\"UTD.htm?4/47/4857/abstract/16\">",
"     16",
"    </a>",
"    ]. The reasons for this association are not clear, but may be related to chronic increased mechanical forces transmitted to the pelvic floor.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS AND DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of posterior wall defects is clinical, based on findings from history and physical examination. Normal support of the posterior vagina is poorly defined, especially in vaginally parous women.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     History",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prolapse is asymptomatic or associated with only mild symptoms in many women. Prolapse-related symptoms tend to become bothersome when the prolapse extends beyond the hymenal ring [",
"    <a class=\"abstract\" href=\"UTD.htm?4/47/4857/abstract/8\">",
"     8",
"    </a>",
"    ]. However, individual variation exists: some women with pelvic support defects are very symptomatic, whereas others who have a similar degree of prolapse remain asymptomatic.",
"   </p>",
"   <p>",
"    Nevertheless, a four-year prospective longitudinal study of women at one of the Women's Health Initiative sites demonstrated that vaginal descent progression over time was associated with pelvic floor symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?4/47/4857/abstract/18\">",
"     18",
"    </a>",
"    ]. For example, increasing apical descent was associated with symptomatic prolapse, and increasing posterior descent was associated with obstructive bowel complaints (eg, splinting or straining to defecate or incomplete bowel emptying). A threshold effect was seen when the leading edge of the vaginal prolapse approached the hymen [",
"    <a class=\"abstract\" href=\"UTD.htm?4/47/4857/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Symptoms commonly associated with posterior POP include defecatory dysfunction, pelvic pressure, and sexual dysfunction. Increasing severity of prolapse does not necessarily correlate with increased symptomatology [",
"    <a class=\"abstract\" href=\"UTD.htm?4/47/4857/abstract/19,20\">",
"     19,20",
"    </a>",
"    ]. Fecal incontinence is not a symptom of prolapse, but sometimes occurs in women with POP since both disorders share some of the same risk factors (eg, prior vaginal birth).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Defecatory dysfunction &mdash; Defecatory dysfunction refers to difficulty with defecation, but excludes fecal incontinence. It is often multifactorial. Systemic causes include diabetes mellitus, thyroid disorders, and neuromuscular diseases. Drug-related causes include beta blockers, calcium channel blockers, anticholinergics, antidepressants, nonsteroidal anti-inflammatory drugs, iron sulfate, aluminum antacids, and opiates. Mechanical obstruction from Hirschsprung's disease, malignancy, or inflammatory bowel disease, and psychiatric conditions, such as dementia, anorexia, and depression, can also affect bowel function. Insufficient fiber or fluid intake may be contributing factors [",
"      <a class=\"abstract\" href=\"UTD.htm?4/47/4857/abstract/21\">",
"       21",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?13/22/13673?source=see_link\">",
"       \"Etiology and evaluation of chronic constipation in adults\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Many women state that they are constipated; it is important to determine whether they are referring to excessive straining, hard lumpy stools, splinting, feeling of incomplete emptying, or infrequent stools. Women with a large rectocele may trap stool within this rectal pocket, which may lead to a feeling of incomplete emptying, and possibly soiling.",
"   </p>",
"   <p>",
"    The need to splint, or place manual pressure on the vagina, rectum, or perineum, to defecate is the most common symptom of posterior vaginal prolapse [",
"    <a class=\"abstract\" href=\"UTD.htm?4/47/4857/abstract/19,22\">",
"     19,22",
"    </a>",
"    ]; however, many women with rectoceles do not have this symptom, and women without rectoceles may require splinting in order to defecate [",
"    <a class=\"abstract\" href=\"UTD.htm?4/47/4857/abstract/20\">",
"     20",
"    </a>",
"    ]. Infrequent defecation is not likely related to a rectocele and may require additional evaluation.",
"   </p>",
"   <p>",
"    Idiopathic constipation consists of two main categories: (1) motility disorders with dilation (eg, megacolon), or without dilation (eg, global motility disorder); and (2) outlet obstruction. Examples of outlet obstruction include pelvic floor dyssynergia (or failure of the puborectalis to relax during defecation), and pelvic support defects, eg, rectocele, enterocele, rectal prolapse. Differentiation between these diagnoses has therapeutic ramifications. Treatment of motility disorders should primarily be dietary or pharmacologic, while biofeedback and pelvic physical therapy work well for pelvic floor dyssynergia. Pelvic support defects can be corrected via surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?4/47/4857/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Pelvic pressure &mdash; Another common symptom of prolapse is a sensation of pelvic",
"      <span class=\"nowrap\">",
"       pressure/heaviness",
"      </span>",
"      or protrusion of tissue from the vagina. Patients frequently describe this as feeling like they are sitting on an egg or complain of low backache or heaviness. This feeling is usually relieved by lying down, is less noticeable in the morning, and worsens as the day progresses.",
"     </li>",
"     <li>",
"      Sexual dysfunction &mdash; Sexual dysfunction is also a common complaint of women with pelvic floor disorders. One study reported patients with increasing severity of prolapse and detrusor instability were less likely to be sexually active compared to patients with stress incontinence or mixed incontinence, but overall sexual satisfaction was independent of diagnosis or therapy for urinary incontinence or prolapse [",
"      <a class=\"abstract\" href=\"UTD.htm?4/47/4857/abstract/23\">",
"       23",
"      </a>",
"      ]. Another study noted that women with prolapse and urinary incontinence did not differ significantly from continent women without prolapse in terms of sexual function, although increasing age correlated with worse sexual function [",
"      <a class=\"abstract\" href=\"UTD.htm?4/47/4857/abstract/24\">",
"       24",
"      </a>",
"      ]. Increasing prolapse severity predicted interference with sexual activity, but did not affect frequency of intercourse or sexual satisfaction.",
"     </li>",
"     <li>",
"      Fecal incontinence &mdash; The rate of fecal incontinence in patients who present to urogynecology clinics ranges from 16 to 54 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?4/47/4857/abstract/25,26\">",
"       25,26",
"      </a>",
"      ]. In one population-based study of women aged 50 years and older, the age-adjusted prevalence of fecal incontinence alone was 15 percent, urinary incontinence alone was 48 percent, and combined urinary and fecal incontinence was 9 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?4/47/4857/abstract/27\">",
"       27",
"      </a>",
"      ]. It is not surprising that fecal incontinence is associated with prolapse, as both disorders share similar risk factors, such as obstetric trauma and advanced age [",
"      <a class=\"abstract\" href=\"UTD.htm?4/47/4857/abstract/15\">",
"       15",
"      </a>",
"      ]. Nevertheless, a cause and effect relationship between fecal incontinence and posterior vaginal prolapse has not been proven, and studies have not shown a consistent correlation between fecal incontinence and severity of prolapse. Because many women are reluctant to initiate a conversation about anal incontinence due to embarrassment, it is important to ask about accidental loss of solid or liquid stool or gas.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Physical examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;The woman is generally examined in the dorsal lithotomy or semirecumbent position. There is good correlation between the degree of prolapse in the supine and standing positions during maximal Valsalva [",
"    <a class=\"abstract\" href=\"UTD.htm?4/47/4857/abstract/28\">",
"     28",
"    </a>",
"    ], but prolapse is still more evident in the upright position [",
"    <a class=\"abstract\" href=\"UTD.htm?4/47/4857/abstract/29\">",
"     29",
"    </a>",
"    ]. Therefore, if the degree of prolapse observed in the lithotomy position is not consistent with the patient's description of her symptoms, a standing examination should be performed. However, it is physically more difficult to make measurements of prolapse in this position.",
"   </p>",
"   <p>",
"    To determine the severity of prolapse, the posterior vaginal wall is visualized with the posterior blade of a bivalve speculum or a Sims speculum. The speculum elevates the anterior wall and reduces any uterine or apical prolapse. The patient is asked to increase abdominal pressure with a Valsalva maneuver or cough. The stage of prolapse (Stage 0-IV) (",
"    <a class=\"graphic graphic_figure graphicRef58962 graphicRef69729 \" href=\"UTD.htm?27/23/28022\">",
"     figure 1A-B",
"    </a>",
"    ) is described using the pelvic organ prolapse quantitation (POP-Q) system, a standardized, validated tool for measuring and staging POP [",
"    <a class=\"abstract\" href=\"UTD.htm?4/47/4857/abstract/30\">",
"     30",
"    </a>",
"    ]. Evaluation and staging of concurrent anterior wall and apical prolapse should also be performed, so that they may be addressed at the time of surgery. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/46/8937?source=see_link\">",
"     \"Pelvic organ prolapse in women: Diagnostic evaluation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The perineal body should be evaluated for descent. This may be difficult to measure, but documentation of its presence or absence can be helpful in planning surgery. Descent of the perineal body occurs from lack of continuity of suspensory support from the apex (level I) to the perineal body (level III) (",
"    <a class=\"graphic graphic_figure graphicRef61643 \" href=\"UTD.htm?26/4/26693\">",
"     figure 2",
"    </a>",
"    ); pudendal neuropathy may also play a role. It also may result from a mass effect of the rectum or small bowel herniating into the perineal body (perineocele). Fecal incontinence may be an associated finding [",
"    <a class=\"abstract\" href=\"UTD.htm?4/47/4857/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The posterior vaginal wall and perineal body are best evaluated by rectovaginal examination. The diagnosis of rectocele is confirmed if the areas of anterior rectal wall bulging and posterior wall prolapse are the same. An enterocele should be suspected if loops of small bowel can be palpated, and a sigmoidocele should be suspected if sigmoid colon is palpated. Performing a rectovaginal examination in the standing position may improve detection of an enterocele by allowing the bowel to enter the enterocele sac. Revaluation for enterocele should be performed in the operating room (if the patient undergoes surgical repair) because if an enterocele is missed, posterior wall prolapse may persist following surgical management. Many surgeons elevate the rectal finger up to the posterior vaginal wall to identify an area with less support, although the preoperative clinical examination is less accurate than surgical identification of site-specific defects of the posterior vaginal wall (",
"    <a class=\"graphic graphic_figure graphicRef57551 \" href=\"UTD.htm?7/22/7520\">",
"     figure 3",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?4/47/4857/abstract/32\">",
"     32",
"    </a>",
"    ]. Finally, pressure on the posterior wall of the vagina, directed downward toward the rectum, may facilitate identification of rectal prolapse or intussusception.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Anal sphincter",
"    </span>",
"    &nbsp;&mdash;&nbsp;The anal sphincter should be assessed for tone, squeeze, and symmetry since anal incontinence commonly occurs with a rectocele. If a symptomatic woman is found (or suspected) to have a disrupted anal sphincter on examination, further testing is indicated. A focused neurologic examination to evaluate for neuropathy includes evaluation of sensation, motor function, and reflexes of sacral nerves 2-4. The patient is asked to discriminate between sharp and dull stimuli on the perineum. Pelvic floor muscle strength is assessed with the patient contracting and relaxing the pelvic floor muscles around the examiner's fingers. Reflex testing includes the bulbocavernosus reflex and anal wink. The American Gastroenterological Association (AGA) guideline for anorectal testing techniques [",
"    <a class=\"abstract\" href=\"UTD.htm?4/47/4857/abstract/33\">",
"     33",
"    </a>",
"    ], as well as other AGA guidelines, can be accessed through the AGA web site at",
"    <a class=\"external\" href=\"file://www.gastro.org/practice/medical-position-statements\">",
"     www.gastro.org/practice/medical-position-statements",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Associated urinary incontinence",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most women with stage II-IV prolapse have symptoms of urinary incontinence. This is not surprising as prolapse and urinary and fecal incontinence result from a weakened pelvic floor and share similar risk factors. Clinically, screening for stress urinary incontinence can be performed as part of the patient's initial evaluation, either with office cystometry or urodynamics. With a full bladder, the patient is asked to stand with her legs slightly spread and then Valsalva or cough as hard as possible. Demonstrable urine loss with this maneuver is considered a positive cough stress test and may indicate the presence of stress urinary incontinence. A similar test may be performed in the supine position with office cystometry with retrograde filling of the bladder. Urodynamic testing may also be helpful, especially in the setting of urge symptoms suggesting detrusor overactivity or mixed incontinence, or patients who have undergone prior incontinence surgery. Some physicians routinely obtain urodynamics on all patients prior to undergoing prolapse surgery. Assessment of urinary incontinence symptoms preoperatively will aid in planning a concomitant anti-incontinence procedure at the time of prolapse repair.",
"   </p>",
"   <p>",
"    In contrast to the patients who present preoperatively with simultaneous complaints of urinary incontinence and prolapse, others may develop de novo urinary incontinence post-operatively. Posterior wall defects may compress the urethra and thereby mask stress urinary incontinence, which has been termed occult stress incontinence. There is no certain method for assessing for occult stress incontinence. Gentle reduction of the posterior vaginal wall into its correct anatomic position at the time of Valsalva or cough may demonstrate the previously occult stress urinary incontinence. During urodynamics, simulating correction of the prolapse may also cause women to demonstrate stress incontinence or to have an increase in leak volumes. If occult stress urinary incontinence is uncovered, then this should be factored into preoperative surgical recommendations and surgical planning.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     DIAGNOSTIC EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinical examination has good sensitivity for the detection of a rectocele; therefore, radiologic confirmation of the presence or absence of a rectocele is not necessary unless there are physical examination findings that do not correlate with symptoms. There is no standardized method of establishing a radiological diagnosis of a rectocele; however, a number of imaging techniques have been used, as indicated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Imaging does not play a role in the evaluation of most women with prolapse. For women with unusual or recurrent posterior wall prolapse, a variety of imaging techniques may be useful.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Defecography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Defecography provides a two-dimensional view of the efficiency of rectal emptying and quantification of rectal parameters. The size of the rectocele is determined by measuring the distance between the line of the anterior border of the anal canal and the maximal point of the bulge of the anterior rectal wall into the posterior vaginal wall. Anything less than 2 cm is considered normal, while a rectocele is considered large if the anterior rectal wall protrudes more than 3.5 cm. Defecography performed following surgical management of rectoceles has generally shown a reduction in the size of the rectocele and improvement in emptying. The American Gastroenterological Association (AGA) guideline for anorectal testing techniques (see section on Evacuation proctography (defecography)) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/47/4857/abstract/33\">",
"     33",
"    </a>",
"    ], as well as other AGA guidelines, can be accessed through the AGA web site at",
"    <a class=\"external\" href=\"file://www.gastro.org/practice/medical-position-statements\">",
"     www.gastro.org/practice/medical-position-statements",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    Rectoceles that retain contrast tend to be larger than those that do not [",
"    <a class=\"abstract\" href=\"UTD.htm?4/47/4857/abstract/34\">",
"     34",
"    </a>",
"    ]. However, fluoroscopic evidence of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/17/12564?source=see_link\">",
"     barium",
"    </a>",
"    trapping does not correlate well to patient symptoms. In the symptomatic, elderly population, one study found no association between the abnormalities demonstrated by defecography and symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?4/47/4857/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Defecography is also useful to exclude pelvic floor dyssynergia, which is not managed surgically. Defecation is effective through the coordination of relaxation of the levator ani and external anal sphincter, and contraction of the colon. If the puborectalis or external anal sphincter is paradoxically contracted during defecation (pelvic floor dyssynergia), then conservative measures, such as enemas or biofeedback, may be more therapeutic than surgery. An electrophysiologic analysis of the puborectalis also may lead to this diagnosis. Another situation in which defecography might influence treatment is the identification of a sigmoidocele; the surgical approach to prolapse management might then also include a Halban's culdoplasty, a sigmoid resection, or a sigmoidopexy.",
"   </p>",
"   <p>",
"    The limitations of defecography include that it requires special equipment, exposes the patient to radiation, does not show the rectum and adjacent soft tissue structures simultaneously, and is uncomfortable and poorly tolerated. Additionally, standardized criteria are not uniformly applied, making this a difficult test to interpret, and there has been only a limited correlation between clinical outcome and radiologic results [",
"    <a class=\"abstract\" href=\"UTD.htm?4/47/4857/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Contrast studies of bowel",
"    </span>",
"    &nbsp;&mdash;&nbsp;A contrast study of the small and large bowel may reveal an enterocele, sigmoidocele, or perineocele. Rectal intussusception and perineal descent may also be identified, although the clinical significance of rectal intussusception has not been determined. The dynamic nature of the study provides insight into the defecation process. Retention of more than 10 percent of the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/17/12564?source=see_link\">",
"     barium",
"    </a>",
"    following defecation is referred to as barium trapping. However, this examination is done in an artificial environment, which may make the patient more prone to incomplete emptying.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Magnetic resonance imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dynamic magnetic resonance imaging (MRI) provides high quality images of the pelvic soft tissues and viscera, is noninvasive, and does not require ionizing radiation or significant patient preparation. However, there is poor correlation between MRI grading of prolapse and clinical staging. MRI defecography has also been performed in the dorsal supine position with a sonographic transmission gel placed in the rectum and vagina. Images are obtained resting, while performing a Valsalva maneuver, and with evacuation in the dorsal supine position with the legs together. However, the true extent of the prolapse may not be exhibited during a Valsalva maneuver in this position, since this is not a normal position for defecation and may not simulate the woman's ability to defecate. An upright evaluation has been described, but requires an open configuration MRI unit that is available in only a few medical centers.",
"   </p>",
"   <p>",
"    The limitations of MRI imaging include a lack of standardization in the grading of prolapse, high cost, and relatively limited availability. At this time, it is mainly utilized in the research setting.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Ancillary testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;The patient's preoperative symptoms and surgical goals should guide the provider in the selection of additional testing.",
"   </p>",
"   <p>",
"    As discussed above, while defecatory dysfunction is common in women with prolapse, the extent of the prolapse does not necessarily correlate with the extent of bowel symptoms. If the woman's primary complaint is defecatory dysfunction or fecal incontinence, and not a bulge, ancillary testing should be pursued based on the woman's complaints. In this setting, surgical correction of a rectocele or perineal body defect may not correct her symptoms, although it may improve them [",
"    <a class=\"abstract\" href=\"UTD.htm?4/47/4857/abstract/37-42\">",
"     37-42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A woman who describes life-long infrequent bowel movements (less than one per week) and absence of a daily urge to defecate is unlikely to be cured of her constipation with a rectocele repair. Dietary modifications, including increased fluid intake, fiber, and laxatives, should be encouraged in any woman whose main complaint is constipation. Women with symptoms of anal incontinence should have an evaluation and attempt at medical management prior to rectocele repair. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/57/30616?source=see_link\">",
"     \"Management of chronic constipation in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/59/22458?source=see_link\">",
"     \"Fecal incontinence in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/29/34263?source=see_link\">",
"     \"Delayed surgical management of the disrupted anal sphincter\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A colon transit study may be helpful for identifying patients with slow-transit constipation. The test entails ingestion of radio-opaque markers, followed by serial abdominal radiographs until all of the markers are gone.",
"   </p>",
"   <p>",
"    An EMG study of the external anal sphincter can provide neurologic information. An endoanal ultrasound evaluates the integrity of the external and internal anal sphincters; a defect should prompt consideration of an anal sphincteroplasty.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment should be pursued only if the patient's prolapse is symptomatic. She should be counseled regarding potential outcomes with expectant management, nonsurgical options (pessary, physical therapy), and surgery. It is crucial to determine what the patient wants and expects from any intervention.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Expectant management",
"    </span>",
"    &nbsp;&mdash;&nbsp;The natural history of prolapse in a six-year longitudinal study of postmenopausal women enrolled in the Women's Health Initiative estrogen and progestin trial demonstrated that mild posterior vaginal prolapse (Baden Walker grade 1) had an annual regression rate of 22 percent per 100 woman-years, but more advanced stages of prolapse (grades 2-3) were unlikely to regress [",
"    <a class=\"abstract\" href=\"UTD.htm?4/47/4857/abstract/43\">",
"     43",
"    </a>",
"    ]. Rectocele progression significantly increased with increasing parity. Another WHI site followed women over the course of four years, and reported that annual progression rates (defined as &ge;1 cm change in leading edge of prolapse) exceeded regression rates when the POP-Q stage was &ge;stage II, and regression exceeded progression rates in stage 1 prolapse [",
"    <a class=\"abstract\" href=\"UTD.htm?4/47/4857/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Observation with yearly examinations is appropriate for women who are mildly symptomatic. Pelvic floor muscle exercises can also be recommended. Surgery for asymptomatic patients is not indicated. On the other hand, expectant management should be abandoned if the woman develops hydronephrosis from chronic ureteral kinking, vaginal erosions that do not resolve with conservative management, or obstructed urination or defecation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Pessary",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are two main categories of pessaries: supportive and space-occupying. The ring pessary, with or without support, is a commonly used supportive pessary, while Gelhorn and cube pessaries are commonly used space-occupying pessaries [",
"    <a class=\"abstract\" href=\"UTD.htm?4/47/4857/abstract/45\">",
"     45",
"    </a>",
"    ]. In one series, 73 of 100 consecutive women with pelvic organ prolapse were successfully fit for a pessary [",
"    <a class=\"abstract\" href=\"UTD.htm?4/47/4857/abstract/46,47\">",
"     46,47",
"    </a>",
"    ]. Nearly all prolapse symptoms (bulge, pressure, discharge, splinting) resolved, urinary symptoms improved by 50 percent, and de novo occult stress urinary incontinence developed in 20 percent of women. Unsuccessful pessary fitting was associated with a short vaginal length (&le;6 cm) and a wide vaginal introitus (four finger breadths). There was no difference in success rates in patients with anterior versus apical versus posterior vaginal prolapse.",
"   </p>",
"   <p>",
"    There are no data that support the use of one type of pessary over another in women with posterior defects. Those who choose a pessary over surgery are more likely to be older than 70 years of age, and have less severe prolapse [",
"    <a class=\"abstract\" href=\"UTD.htm?4/47/4857/abstract/48\">",
"     48",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/7/17530?source=see_link\">",
"     \"Vaginal pessary treatment of prolapse and incontinence\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Pelvic floor muscle training",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pelvic floor muscle training can be effective for treatment of urinary and fecal incontinence, but its role in treatment of prolapse is unclear. Physical therapy aims to increase the strength and endurance of the pelvic muscles and therefore improve support for pelvic organs. One trial attempted to investigate the role of perioperative (both pre- and post-operative) physiotherapy in women undergoing corrective surgery for pelvic organ prolapse [",
"    <a class=\"abstract\" href=\"UTD.htm?4/47/4857/abstract/49\">",
"     49",
"    </a>",
"    ]. Women were randomly assigned to perform or not perform physical therapy before undergoing surgery. Those assigned to the intervention had higher scores on quality of life questionnaires and higher maximum pelvic floor muscle squeeze on manometry. It may be that increasing the strength of the levator ani muscles improved support of the pelvic organs during the crucial window of post-operative healing. However, this study was hampered by short follow-up of three months, and long-term studies have not been performed that demonstrate persistent benefits.",
"   </p>",
"   <p>",
"    Given that there are minimal adverse effects from pelvic floor muscle training, the main drawbacks are the cost of providing instruction and the investment of time patients need to make in order to maximize efficacy. Patients will obtain the most benefit from physical therapy by an experienced physical therapist or nurse practitioner in a supervised program, usually consisting of one to two visits per week for 8 to 12 weeks, with ongoing maintenance exercises. Nevertheless, advanced prolapse is unlikely to resolve with physical therapy alone.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;The surgical approach to management of posterior vaginal wall defects is reviewed separately. Constipation should be managed in women with posterior wall prolapsed to avoid progression of the prolapse or recurrence if surgical management is pursued. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/24/44424?source=see_link\">",
"     \"Surgical management of posterior vaginal defects\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Posterior vaginal defects may lead to one or more of the following: rectocele (anterior protrusion of the rectum), sigmoidocele (protrusion of the sigmoid colon), and enterocele (protrusion of the small bowel). (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Vaginal childbirth, increasing age, and increasing body mass index are the most consistently identified risk factors for developing prolapse. Hysterectomy and chronic elevated intra-abdominal pressures have also been implicated. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Risk factors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Symptoms commonly associated with posterior vaginal defects include defecatory dysfunction, pelvic pressure, and sexual dysfunction. Increasing severity of prolapse does not necessarily correlate with increased symptomatology. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Clinical manifestations and diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of posterior wall defects is clinical, based on findings from history and physical examination. The routine use of adjunctive imaging or other adjunctive studies is not necessary for the majority of affected women. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Clinical manifestations and diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Physical examination should include a POP-Q examination. A rectovaginal examination should be performed to look for an enterocele or sigmoidocele, which should be taken into consideration for preoperative planning. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Physical examination'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Neurologic examination to assess S2-S4 nerves is also important. Anal sphincter assessment should be performed, especially in the setting of a history of a prior fourth degree laceration or symptoms of fecal incontinence. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Anal sphincter'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Women with more than mild prolapse (Stage I) should be evaluated for occult urinary incontinence. Posterior wall defects may compress the urethra and thereby mask stress urinary incontinence. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Associated urinary incontinence'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Asymptomatic prolapse does not require treatment. For women with bothersome symptoms who wish to avoid surgery and the cost and time requirements of pelvic floor muscle training, a pessary should be fitted (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H22\">",
"       'Pessary'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/47/4857/abstract/1\">",
"      Olsen AL, Smith VJ, Bergstrom JO, et al. Epidemiology of surgically managed pelvic organ prolapse and urinary incontinence. Obstet Gynecol 1997; 89:501.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/47/4857/abstract/2\">",
"      Kenton K, Shott S, Brubaker L. Vaginal topography does not correlate well with visceral position in women with pelvic organ prolapse. Int Urogynecol J Pelvic Floor Dysfunct 1997; 8:336.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/47/4857/abstract/3\">",
"      Fenner DE. Diagnosis and assessment of sigmoidoceles. Am J Obstet Gynecol 1996; 175:1438.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/47/4857/abstract/4\">",
"      Moalli PA, Jones Ivy S, Meyn LA, Zyczynski HM. Risk factors associated with pelvic floor disorders in women undergoing surgical repair. Obstet Gynecol 2003; 101:869.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/47/4857/abstract/5\">",
"      Lukacz ES, Lawrence JM, Contreras R, et al. Parity, mode of delivery, and pelvic floor disorders. Obstet Gynecol 2006; 107:1253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/47/4857/abstract/6\">",
"      DeLancey JO, Kearney R, Chou Q, et al. The appearance of levator ani muscle abnormalities in magnetic resonance images after vaginal delivery. Obstet Gynecol 2003; 101:46.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/47/4857/abstract/7\">",
"      Chen L, Ashton-Miller JA, Hsu Y, DeLancey JO. Interaction among apical support, levator ani impairment, and anterior vaginal wall prolapse. Obstet Gynecol 2006; 108:324.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/47/4857/abstract/8\">",
"      Swift SE, Tate SB, Nicholas J. Correlation of symptoms with degree of pelvic organ support in a general population of women: what is pelvic organ prolapse? Am J Obstet Gynecol 2003; 189:372.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/47/4857/abstract/9\">",
"      Dietz HP, Clarke B. Prevalence of rectocele in young nulliparous women. Aust N Z J Obstet Gynaecol 2005; 45:391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/47/4857/abstract/10\">",
"      Spence-Jones C, Kamm MA, Henry MM, Hudson CN. Bowel dysfunction: a pathogenic factor in uterovaginal prolapse and urinary stress incontinence. Br J Obstet Gynaecol 1994; 101:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/47/4857/abstract/11\">",
"      Jelovsek JE, Barber MD, Paraiso MF, Walters MD. Functional bowel and anorectal disorders in patients with pelvic organ prolapse and incontinence. Am J Obstet Gynecol 2005; 193:2105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/47/4857/abstract/12\">",
"      Woodman PJ, Swift SE, O'Boyle AL, et al. Prevalence of severe pelvic organ prolapse in relation to job description and socioeconomic status: a multicenter cross-sectional study. Int Urogynecol J Pelvic Floor Dysfunct 2006; 17:340.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/47/4857/abstract/13\">",
"      Moalli PA, Shand SH, Zyczynski HM, et al. Remodeling of vaginal connective tissue in patients with prolapse. Obstet Gynecol 2005; 106:953.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/47/4857/abstract/14\">",
"      Norton PA, Baker JE, Sharp HC, Warenski JC. Genitourinary prolapse and joint hypermobility in women. Obstet Gynecol 1995; 85:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/47/4857/abstract/15\">",
"      Hendrix SL, Clark A, Nygaard I, et al. Pelvic organ prolapse in the Women's Health Initiative: gravity and gravidity. Am J Obstet Gynecol 2002; 186:1160.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/47/4857/abstract/16\">",
"      Swift S, Woodman P, O'Boyle A, et al. Pelvic Organ Support Study (POSST): the distribution, clinical definition, and epidemiologic condition of pelvic organ support defects. Am J Obstet Gynecol 2005; 192:795.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/47/4857/abstract/17\">",
"      Luber KM, Boero S, Choe JY. The demographics of pelvic floor disorders: current observations and future projections. Am J Obstet Gynecol 2001; 184:1496.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/47/4857/abstract/18\">",
"      Bradley CS, Zimmerman MB, Wang Q, et al. Vaginal descent and pelvic floor symptoms in postmenopausal women: a longitudinal study. Obstet Gynecol 2008; 111:1148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/47/4857/abstract/19\">",
"      Ellerkmann RM, Cundiff GW, Melick CF, et al. Correlation of symptoms with location and severity of pelvic organ prolapse. Am J Obstet Gynecol 2001; 185:1332.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/47/4857/abstract/20\">",
"      Weber AM, Walters MD, Ballard LA, et al. Posterior vaginal prolapse and bowel function. Am J Obstet Gynecol 1998; 179:1446.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/47/4857/abstract/21\">",
"      Cundiff GW, Fenner D. Evaluation and treatment of women with rectocele: focus on associated defecatory and sexual dysfunction. Obstet Gynecol 2004; 104:1403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/47/4857/abstract/22\">",
"      Burrows LJ, Meyn LA, Walters MD, Weber AM. Pelvic symptoms in women with pelvic organ prolapse. Obstet Gynecol 2004; 104:982.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/47/4857/abstract/23\">",
"      Barber MD, Visco AG, Wyman JF, et al. Sexual function in women with urinary incontinence and pelvic organ prolapse. Obstet Gynecol 2002; 99:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/47/4857/abstract/24\">",
"      Weber AM, Walters MD, Schover LR, Mitchinson A. Sexual function in women with uterovaginal prolapse and urinary incontinence. Obstet Gynecol 1995; 85:483.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/47/4857/abstract/25\">",
"      Jackson SL, Weber AM, Hull TL, et al. Fecal incontinence in women with urinary incontinence and pelvic organ prolapse. Obstet Gynecol 1997; 89:423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/47/4857/abstract/26\">",
"      Nichols CM, Gill EJ, Nguyen T, et al. Anal sphincter injury in women with pelvic floor disorders. Obstet Gynecol 2004; 104:690.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/47/4857/abstract/27\">",
"      Roberts RO, Jacobsen SJ, Rhodes T, et al. Urinary incontinence in a community-based cohort: prevalence and healthcare-seeking. J Am Geriatr Soc 1998; 46:467.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/47/4857/abstract/28\">",
"      Swift SE, Herring M. Comparison of pelvic organ prolapse in the dorsal lithotomy compared with the standing position. Obstet Gynecol 1998; 91:961.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/47/4857/abstract/29\">",
"      Barber MD, Lambers A, Visco AG, Bump RC. Effect of patient position on clinical evaluation of pelvic organ prolapse. Obstet Gynecol 2000; 96:18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/47/4857/abstract/30\">",
"      Bump RC, Mattiasson A, B&oslash; K, et al. The standardization of terminology of female pelvic organ prolapse and pelvic floor dysfunction. Am J Obstet Gynecol 1996; 175:10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/47/4857/abstract/31\">",
"      Bump RC, Norton PA. Epidemiology and natural history of pelvic floor dysfunction. Obstet Gynecol Clin North Am 1998; 25:723.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/47/4857/abstract/32\">",
"      Burrows LJ, Sewell C, Leffler KS, Cundiff GW. The accuracy of clinical evaluation of posterior vaginal wall defects. Int Urogynecol J Pelvic Floor Dysfunct 2003; 14:160.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/47/4857/abstract/33\">",
"      Barnett JL, Hasler WL, Camilleri M. American Gastroenterological Association medical position statement on anorectal testing techniques. American Gastroenterological Association. Gastroenterology 1999; 116:732.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/47/4857/abstract/34\">",
"      Greenberg T, Kelvin FM, Maglinte DD. Barium trapping in rectoceles: are we trapped by the wrong definition? Abdom Imaging 2001; 26:587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/47/4857/abstract/35\">",
"      Savoye-Collet C, Savoye G, Koning E, et al. Defecography in symptomatic older women living at home. Age Ageing 2003; 32:347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/47/4857/abstract/36\">",
"      Van Laarhoven CJ, Kamm MA, Bartram CI, et al. Relationship between anatomic and symptomatic long-term results after rectocele repair for impaired defecation. Dis Colon Rectum 1999; 42:204.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/47/4857/abstract/37\">",
"      Maher, CF, Qatwneh, A, Baessler, K, Schluter, P. Midline rectovaginal fascial plication for repair of rectocele and obstructed defecation. Obstet Gynecol 2004; 106:713.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/47/4857/abstract/38\">",
"      Cundiff GW, Weidner AC, Visco AG, et al. An anatomic and functional assessment of the discrete defect rectocele repair. Am J Obstet Gynecol 1998; 179:1451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/47/4857/abstract/39\">",
"      Singh K, Cortes E, Reid WM. Evaluation of the fascial technique for surgical repair of isolated posterior vaginal wall prolapse. Obstet Gynecol 2003; 101:320.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/47/4857/abstract/40\">",
"      Kenton K, Shott S, Brubaker L. Outcome after rectovaginal fascia reattachment for rectocele repair. Am J Obstet Gynecol 1999; 181:1360.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/47/4857/abstract/41\">",
"      Porter WE, Steele A, Walsh P, et al. The anatomic and functional outcomes of defect-specific rectocele repairs. Am J Obstet Gynecol 1999; 181:1353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/47/4857/abstract/42\">",
"      Paraiso MF, Barber MD, Muir TW, Walters MD. Rectocele repair: a randomized trial of three surgical techniques including graft augmentation. Am J Obstet Gynecol 2006; 195:1762.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/47/4857/abstract/43\">",
"      Handa VL, Garrett E, Hendrix S, et al. Progression and remission of pelvic organ prolapse: a longitudinal study of menopausal women. Am J Obstet Gynecol 2004; 190:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/47/4857/abstract/44\">",
"      Bradley, C, Zimmerman, MB, Oi, Y, Nygaard, IE. The natural history of pelvic organ prolapse in older women: A 4-year longitudinal study (abstract). Int J Urogynecol 2006; 17 (Suppl 3):S364.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/47/4857/abstract/45\">",
"      Cundiff GW, Weidner AC, Visco AG, et al. A survey of pessary use by members of the American urogynecologic society. Obstet Gynecol 2000; 95:931.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/47/4857/abstract/46\">",
"      Clemons JL, Aguilar VC, Tillinghast TA, et al. Risk factors associated with an unsuccessful pessary fitting trial in women with pelvic organ prolapse. Am J Obstet Gynecol 2004; 190:345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/47/4857/abstract/47\">",
"      Clemons JL, Aguilar VC, Tillinghast TA, et al. Patient satisfaction and changes in prolapse and urinary symptoms in women who were fitted successfully with a pessary for pelvic organ prolapse. Am J Obstet Gynecol 2004; 190:1025.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/47/4857/abstract/48\">",
"      Heit M, Rosenquist C, Culligan P, et al. Predicting treatment choice for patients with pelvic organ prolapse. Obstet Gynecol 2003; 101:1279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/47/4857/abstract/49\">",
"      Jarvis SK, Hallam TK, Lujic S, et al. Peri-operative physiotherapy improves outcomes for women undergoing incontinence and or prolapse surgery: results of a randomised controlled trial. Aust N Z J Obstet Gynaecol 2005; 45:300.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8076 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1002-222.190.118.195-07BE0D3610-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_47_4857=[""].join("\n");
var outline_f4_47_4857=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H25\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      RISK FACTORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Vaginal childbirth",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Pelvic surgery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Elevated intra-abdominal pressure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Collagen abnormality",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Advancing age",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Increasing body mass index",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      CLINICAL MANIFESTATIONS AND DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      History",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Physical examination",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Anal sphincter",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Associated urinary incontinence",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      DIAGNOSTIC EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Imaging",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Defecography",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Contrast studies of bowel",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Magnetic resonance imaging",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Ancillary testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Expectant management",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Pessary",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Pelvic floor muscle training",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"OBGYN/8076\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/8076|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?16/24/16769\" title=\"figure 1A\">",
"      Stage 1 prolapse",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?13/53/14161\" title=\"figure 1B\">",
"      Stage 2 prolapse",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?26/4/26693\" title=\"figure 2\">",
"      Delancey levels pelvic support 2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?7/22/7520\" title=\"figure 3\">",
"      Tx post vaginal wall def 9",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/29/34263?source=related_link\">",
"      Delayed surgical management of the disrupted anal sphincter",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/22/13673?source=related_link\">",
"      Etiology and evaluation of chronic constipation in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/59/22458?source=related_link\">",
"      Fecal incontinence in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/57/30616?source=related_link\">",
"      Management of chronic constipation in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/19/12602?source=related_link\">",
"      Overview of hysterectomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/18/19753?source=related_link\">",
"      Pelvic floor disorders associated with pregnancy and childbirth",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/46/8937?source=related_link\">",
"      Pelvic organ prolapse in women: Diagnostic evaluation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/24/44424?source=related_link\">",
"      Surgical management of posterior vaginal defects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/7/17530?source=related_link\">",
"      Vaginal pessary treatment of prolapse and incontinence",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f4_47_4858="Epidermolysis bullosa acquisita";
var content_f4_47_4858=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Epidermolysis bullosa acquisita",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/47/4858/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/47/4858/contributors\">",
"     David T Woodley, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/47/4858/contributors\">",
"     Mei Chen, Ph.D.",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/47/4858/contributors\">",
"     Gene Kim, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/47/4858/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/47/4858/contributors\">",
"     John J Zone, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/47/4858/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/47/4858/contributors\">",
"     Abena O Ofori, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?4/47/4858/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 27, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H4624987\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Epidermolysis bullosa acquisita (EBA) is a rare, sporadic, subepithelial, mucocutaneous blistering disease that usually develops in adulthood. EBA is classically described as a mechanobullous disorder characterized by skin fragility, noninflammatory tense bullae, milia, and scarring. Alternatively, EBA can present as an inflammatory bullous eruption reminiscent of bullous pemphigoid or other subepithelial autoimmune blistering diseases.",
"   </p>",
"   <p>",
"    The pathogenesis of EBA involves the production of antibodies against type VII collagen, a major component of anchoring fibrils in the basement membrane zones of skin and mucosa (",
"    <a class=\"graphic graphic_figure graphicRef67891 \" href=\"UTD.htm?3/63/4086\">",
"     figure 1",
"    </a>",
"    ). The immune-mediated disruption of the anchoring fibrils likely contributes to cleavage within the basement membrane zone and clinical blistering.",
"   </p>",
"   <p>",
"    The pathogenesis, clinical manifestations, and management of EBA will be discussed here. Hereditary epidermolysis bullosa is reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/28/28106?source=see_link\">",
"     \"Epidemiology, pathogenesis, and clinical features of epidermolysis bullosa\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/21/39255?source=see_link\">",
"     \"Diagnosis of epidermolysis bullosa\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/63/3066?source=see_link\">",
"     \"Overview of the management of epidermolysis bullosa\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H479445424\">",
"    <span class=\"h1\">",
"     TERMINOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although the name &ldquo;epidermolysis bullosa acquisita&rdquo; arose from the original view of EBA as a disorder reminiscent of recessive dystrophic epidermolysis bullosa (RDEB), EBA and epidermolysis bullosa are distinct diseases. RDEB is a hereditary disease that results from mutations in the COL7A1 gene that encodes type VII collagen. In contrast to EBA, RDEB usually first presents in infancy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/21/39255?source=see_link\">",
"     \"Diagnosis of epidermolysis bullosa\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H316625826\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;EBA is a rare disorder of uncertain incidence. Although pediatric cases have been reported, adults are most commonly affected [",
"    <a class=\"abstract\" href=\"UTD.htm?4/47/4858/abstract/1-4\">",
"     1-4",
"    </a>",
"    ]. Increased risks for EBA based upon gender, ethnicity, or geographic location have not been definitively established.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H316622104\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although the inciting factors for EBA are unknown, evidence indicates that an autoimmune process that involves the production and deposition of antibodies against type VII collagen, a major component of anchoring fibrils (adhesion structures in the dermal-epithelial junction [DEJ]) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/47/4858/abstract/5,6\">",
"     5,6",
"    </a>",
"    ], likely contributes to the development of clinical disease (",
"    <a class=\"graphic graphic_figure graphicRef67891 \" href=\"UTD.htm?3/63/4086\">",
"     figure 1",
"    </a>",
"    ). This concept is based upon several observations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Direct immunofluorescence (DIF) microscopy of perilesional skin from patients with EBA reveals antibody deposition at the basement membrane zone [",
"      <a class=\"abstract\" href=\"UTD.htm?4/47/4858/abstract/7-9\">",
"       7-9",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Antibodies against type VII collagen can be detected in serum from patients with EBA [",
"      <a class=\"abstract\" href=\"UTD.htm?4/47/4858/abstract/10\">",
"       10",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Immunoelectron microscopy demonstrates antibody deposition in the lamina densa area of the basement membrane zone, a site consistent with the location of anchoring fibrils [",
"      <a class=\"abstract\" href=\"UTD.htm?4/47/4858/abstract/10\">",
"       10",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Decreased numbers of normal anchoring fibrils are present in the DEJ in EBA [",
"      <a class=\"abstract\" href=\"UTD.htm?4/47/4858/abstract/11,12\">",
"       11,12",
"      </a>",
"      ], a finding consistent with skin fragility and epidermal blistering.",
"     </li>",
"     <li>",
"      Animal models indicate that passive transfer of antibodies against type VII collagen can induce clinical features consistent with EBA (see",
"      <a class=\"local\" href=\"#H47068462\">",
"       'Pathogenic mechanism'",
"      </a>",
"      below)",
"     </li>",
"     <li>",
"      Serum levels of type VII collagen antibodies detected by ELISA correlate with the severity of skin lesions [",
"      <a class=\"abstract\" href=\"UTD.htm?4/47/4858/abstract/13\">",
"       13",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Patients with bullous systemic lupus erythematosus, which is also associated with antibodies against type VII collagen, develop subepidermal (either sub-lamina lucida or sub-lamina densa) blistering [",
"      <a class=\"abstract\" href=\"UTD.htm?4/47/4858/abstract/14\">",
"       14",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The role of type VII collagen in the DEJ and the mechanism through which antibodies against this protein might contribute to EBA are reviewed in greater detail below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H47068455\">",
"    <span class=\"h2\">",
"     Type VII collagen",
"    </span>",
"    &nbsp;&mdash;&nbsp;Type VII collagen is composed of three identical alpha chains, each consisting of a 145 kDa central collagenous triple-helical segment characterized by repeating Gly-X-Y amino acid sequences. The triple-helical segment is flanked by a large 145 kDa amino-terminal, noncollagenous domain (NC1) and a 34 kDa carboxyl-terminal noncollagenous domain (NC2) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/47/4858/abstract/5,6,15\">",
"     5,6,15",
"    </a>",
"    ]. The major antigenic epitopes of type VII collagen are located within the NC1 domain; thus, the type VII collagen antibodies detected in patients with EBA most frequently recognize epitopes within this site [",
"    <a class=\"abstract\" href=\"UTD.htm?4/47/4858/abstract/16\">",
"     16",
"    </a>",
"    ]. Less often, antibodies against the triple-helical domain or the NC2 domain are present [",
"    <a class=\"abstract\" href=\"UTD.htm?4/47/4858/abstract/1,17-21\">",
"     1,17-21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The NC1 domain may play an important role in maintaining the structural integrity of the DEJ. The NC1 domain contains subdomains with partial homology to adhesive proteins (cartilage matrix protein, fibronectin type III domains, and A domains of von Willebrand factor) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/47/4858/abstract/22\">",
"     22",
"    </a>",
"    ]. This feature may contribute to the ability of anchoring fibrils to stabilize the attachment of the basement membrane zone to the underlying dermis.",
"   </p>",
"   <p>",
"    Additional support for the importance of the NC1 domain in the maintenance of the structural integrity of the DEJ comes from our study of a recombinant NC1 protein [",
"    <a class=\"abstract\" href=\"UTD.htm?4/47/4858/abstract/23\">",
"     23",
"    </a>",
"    ]. In the study, we found that a recombinant NC1 protein was capable of binding to components of the basement membrane zone and dermal extracellular matrix, including fibronectin, laminin 5, type I collagen, and type IV collagen.",
"   </p>",
"   <p>",
"    To date, a definitive link between the epitope specificity of autoantibodies in EBA (ie, NC1 domain, NC2 domain, or the triple helical domain) and specific clinical subtypes of EBA has not been identified (see",
"    <a class=\"local\" href=\"#H4624835\">",
"     'Clinical manifestations'",
"    </a>",
"    below). The results of a series of five patients with EBA who were evaluated with immunoelectron microscopy suggested that antibodies to the triple helical domain may be associated with inflammatory subtypes of EBA; however, additional studies are necessary to determine whether this conclusion is valid [",
"    <a class=\"abstract\" href=\"UTD.htm?4/47/4858/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H47068462\">",
"    <span class=\"h2\">",
"     Pathogenic mechanism",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because it is conceivable that antibody formation against components of the DEJ could occur as a secondary event following skin injury, studies have been performed to determine whether the type VII collagen antibodies detected in EBA are pathogenic. Strong support for the pathogenicity of these antibodies is derived from passive transfer studies in animals [",
"    <a class=\"abstract\" href=\"UTD.htm?4/47/4858/abstract/24-26\">",
"     24-26",
"    </a>",
"    ]. As an example, after intradermal injection of rabbit serum containing high titers of antibodies against the NC1 domain of human type VII collagen, hairless immunocompetent mice had deposits of anti-NC1 antibodies and complement at the DEJ and developed subepithelial blistering and nail dystrophy reminiscent of human EBA [",
"    <a class=\"abstract\" href=\"UTD.htm?4/47/4858/abstract/24\">",
"     24",
"    </a>",
"    ]. Furthermore, mice injected with human EBA autoantibodies affinity-purified against an NC1 column have developed a blistering disease with clinical, immunohistological, and ultrastructural features akin to human EBA [",
"    <a class=\"abstract\" href=\"UTD.htm?4/47/4858/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Several theories on the mechanism through which the production and deposition of antibodies against type VII collagen could lead to mucocutaneous blistering in humans have been proposed. These include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Autoantibody deposition on the NC1 domain of anchoring fibrils may compromise the function of type VII collagen by disturbing its interactions with other basement membrane or upper dermal components, such as type IV collagen, laminin 5, and fibronectin [",
"      <a class=\"abstract\" href=\"UTD.htm?4/47/4858/abstract/23,27\">",
"       23,27",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Autoantibodies may interfere with the anti-parallel dimer formation of type VII collagen, thereby inhibiting anchoring fibril assembly [",
"      <a class=\"abstract\" href=\"UTD.htm?4/47/4858/abstract/19\">",
"       19",
"      </a>",
"      ]. This could result in defective adherence of the lamina densa to the dermis.",
"     </li>",
"     <li>",
"      Antibody-induced complement fixation may lead to tissue inflammation and damage at the DEJ and subsequent blister formation. This mechanism is most likely to occur in the inflammatory bullous pemphigoid-like subtype of EBA [",
"      <a class=\"abstract\" href=\"UTD.htm?4/47/4858/abstract/28\">",
"       28",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H4624835\">",
"       'Clinical manifestations'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Additional study is necessary to confirm the pathogenic mechanism of EBA.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H316626301\">",
"    <span class=\"h2\">",
"     Genetic factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Genetics may play a role in the risk for EBA. In a study of 29 patients with EBA, the frequency of HLA-DR2 was increased when compared to healthy controls [",
"    <a class=\"abstract\" href=\"UTD.htm?4/47/4858/abstract/29\">",
"     29",
"    </a>",
"    ]. In theory, this allele could influence autoimmunity to type VII collagen in anchoring fibrils or could serve as a marker for another gene that is in linkage disequilibrium with HLA-DR2.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4624835\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;EBA was initially described as a subepithelial, noninflammatory mucocutaneous bullous disease associated with skin fragility, a presentation that is now referred to as classical EBA. However, the subsequent identification of autoantibodies against type VII collagen as a diagnostic feature led to the recognition of a broader spectrum of clinical manifestations. In addition to the classical, noninflammatory presentation of EBA, EBA may manifest as an inflammatory blistering disorder characterized by features that resemble bullous pemphigoid, mucous membrane (cicatricial) pemphigoid, linear IgA bullous dermatosis, or Brunsting-Perry pemphigoid. The two most common presentations of EBA are the classical and bullous pemphigoid-like subtypes. The presence of antibodies against type VII collagen distinguishes EBA from the true forms of other autoimmune blistering diseases.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H479445731\">",
"    <span class=\"h2\">",
"     Classical (noninflammatory) EBA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with classical EBA present with skin fragility and the formation of noninflammatory tense vesicles and bullae that rupture, leaving erosions (",
"    <a class=\"graphic graphic_picture graphicRef62505 graphicRef83259 \" href=\"UTD.htm?32/1/32793\">",
"     picture 1A-B",
"    </a>",
"    ). The most common locations for lesion development are sites that are repeatedly subject to minor trauma, such as the hands, feet, elbows, knees, and lower back. The blisters often heal with scarring and small epidermal inclusion cysts referred to as milia (",
"    <a class=\"graphic graphic_picture graphicRef86482 \" href=\"UTD.htm?16/37/16982\">",
"     picture 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Mucosal involvement is common in both classical and inflammatory EBA, and can be subclinical or may manifest as erosions or adhesions on the oral, nasal, ocular, pharyngeal, laryngeal, or anogenital mucosa [",
"    <a class=\"abstract\" href=\"UTD.htm?4/47/4858/abstract/30\">",
"     30",
"    </a>",
"    ]. In one series of 12 patients with EBA, mucosal involvement was present in 11 patients [",
"    <a class=\"abstract\" href=\"UTD.htm?4/47/4858/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Alopecia, nail loss, fibrosis of the hands and fingers (leading to a mitten-like deformity), and esophageal stenosis may occur in patients with severe disease [",
"    <a class=\"abstract\" href=\"UTD.htm?4/47/4858/abstract/18,30,32-34\">",
"     18,30,32-34",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H479445739\">",
"    <span class=\"h2\">",
"     Inflammatory EBA",
"    </span>",
"    &nbsp;&mdash;&nbsp;As noted above, the inflammatory subtypes of EBA resemble other autoimmune subepithelial blistering diseases. In contrast to classical EBA, skin fragility is not a typical feature.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Bullous pemphigoid",
"      </strong>",
"      -",
"      <strong>",
"       like EBA",
"      </strong>",
"      &ndash;",
"      <strong>",
"      </strong>",
"      Bullous pemphigoid-like EBA shares clinical features with bullous pemphigoid, the most common autoimmune subepithelial blistering disease (",
"      <a class=\"graphic graphic_picture graphicRef72866 \" href=\"UTD.htm?26/16/26885\">",
"       picture 3",
"      </a>",
"      ). Rather than the noninflammatory lesions of classic EBA, these patients present with tense bullae that are surrounded by inflamed or urticarial skin [",
"      <a class=\"abstract\" href=\"UTD.htm?4/47/4858/abstract/28,35\">",
"       28,35",
"      </a>",
"      ]. Similar to bullous pemphigoid, the lesions are widespread with a predilection for the trunk, extremities, and skin folds. Larger areas of skin that demonstrate only erythema or urticarial plaques without bullae may also be present. Pruritus is common. Scarring and milia are not prominent findings. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/11/22714?source=see_link&amp;anchor=H53290498#H53290498\">",
"       \"Clinical features and diagnosis of bullous pemphigoid and mucous membrane pemphigoid\", section on 'Bullous pemphigoid'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Mucous membrane pemphigoid-like EBA",
"      </strong>",
"      &ndash;",
"      <strong>",
"      </strong>",
"      EBA may present as a mucosal-predominant disorder with clinical findings that resemble mucous membrane pemphigoid (",
"      <a class=\"graphic graphic_picture graphicRef63997 \" href=\"UTD.htm?37/49/38674\">",
"       picture 4",
"      </a>",
"      ). The primary disease manifestations in these patients are erosions and scarring on the mucosal surfaces of the mouth, upper esophagus, conjunctiva, anus, or vagina [",
"      <a class=\"abstract\" href=\"UTD.htm?4/47/4858/abstract/36\">",
"       36",
"      </a>",
"      ]. Our experience with mucous membrane pemphigoid-like EBA has included a patient who developed scarring and strictures of the urethra and the larynx that led to impaired urination and vocalization. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/11/22714?source=see_link&amp;anchor=H53290512#H53290512\">",
"       \"Clinical features and diagnosis of bullous pemphigoid and mucous membrane pemphigoid\", section on 'Mucous membrane pemphigoid'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       IgA bullous dermatosis",
"      </strong>",
"      -",
"      <strong>",
"       like EBA",
"      </strong>",
"      &ndash; IgA bullous dermatosis-like EBA has clinical, histological, and direct immunofluorescence (DIF) findings that resemble IgA-mediated bullous dermatoses [",
"      <a class=\"abstract\" href=\"UTD.htm?4/47/4858/abstract/2,37,38\">",
"       2,37,38",
"      </a>",
"      ]. Affected patients may present with the annular arrangement of vesicles and bullae characteristic of linear IgA bullous dermatosis or with the grouped vesicles characteristic of dermatitis herpetiformis (",
"      <a class=\"graphic graphic_picture graphicRef56434 \" href=\"UTD.htm?15/62/16359\">",
"       picture 5",
"      </a>",
"      ). Concomitant mucosal involvement is common. &nbsp;(See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?14/36/14922?source=see_link&amp;anchor=H28759738#H28759738\">",
"       \"Linear IgA bullous dermatosis\", section on 'Clinical manifestations'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Brunsting-Perry pemphigoid-like EBA",
"      </strong>",
"      &ndash; The Brunsting-Perry pemphigoid-like variant of EBA resembles Brunsting-Perry pemphigoid, a rare subepithelial blistering disorder characterized by bullae that primarily appear on the head and neck and tend to heal with scarring (",
"      <a class=\"graphic graphic_picture graphicRef54769 \" href=\"UTD.htm?5/47/5876\">",
"       picture 6",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?4/47/4858/abstract/39-41\">",
"       39-41",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/11/22714?source=see_link&amp;anchor=H12467264#H12467264\">",
"       \"Clinical features and diagnosis of bullous pemphigoid and mucous membrane pemphigoid\", section on 'Brunsting-Perry pemphigoid'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H978033474\">",
"    <span class=\"h2\">",
"     Children",
"    </span>",
"    &nbsp;&mdash;&nbsp;EBA rarely occurs in children, but also appears to manifest with various clinical presentations in this population. One retrospective study found that among 14 children with EBA, five presented with bullous pemphigoid-like disease, five with linear IgA bullous dermatosis-like disease, and four with classical EBA [",
"    <a class=\"abstract\" href=\"UTD.htm?4/47/4858/abstract/2\">",
"     2",
"    </a>",
"    ]. Mucosal involvement was common, occurring in 11 children.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H316626856\">",
"    <span class=\"h1\">",
"     ASSOCIATED DISORDERS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The concurrent existence of EBA and various systemic diseases, such as inflammatory bowel disease (IBD), systemic lupus erythematosus, amyloidosis, thyroiditis, multiple endocrinopathy syndrome, rheumatoid arthritis, pulmonary fibrosis, chronic lymphocytic leukemia, thymoma, and diabetes has been anecdotally reported [",
"    <a class=\"abstract\" href=\"UTD.htm?4/47/4858/abstract/42\">",
"     42",
"    </a>",
"    ]. Clinical experience with over 60 patients from several academic centers in the United States suggests that IBD is the systemic disease most frequently seen in association with EBA [",
"    <a class=\"abstract\" href=\"UTD.htm?4/47/4858/abstract/16,43\">",
"     16,43",
"    </a>",
"    ]. The presence of type VII collagen in the human colon and the detection of autoantibodies against type VII collagen in some patients with IBD support a potential link between these diseases [",
"    <a class=\"abstract\" href=\"UTD.htm?4/47/4858/abstract/44-46\">",
"     44-46",
"    </a>",
"    ]. Additional studies are necessary to confirm and explore the relationship of EBA to IBD and other diseases.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H316627112\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Since EBA shares clinical, pathological, and immunohistological features with other subepithelial blistering disorders, the diagnosis of this disease can be challenging. Once an initial evaluation indicates the presence of an autoimmune subepithelial blistering disease and reveals findings consistent with EBA, additional tests may be used to confirm the diagnosis. (See",
"    <a class=\"local\" href=\"#H306466132\">",
"     'Differential diagnosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H306460340\">",
"    <span class=\"h2\">",
"     Initial evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;An evaluation for EBA is triggered by clinical findings that suggest an autoimmune blistering disease, such as the unexplained onset of multifocal cutaneous blistering",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    mucosal erosions. As for other subepithelial blistering diseases, the initial evaluation should include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       A thorough patient history and full skin examination that includes an assessment of the distribution and morphology of skin lesions",
"      </strong>",
"      &ndash; This evaluation helps to narrow the differential diagnosis. As an example, a diagnosis of classical EBA should be strongly considered in adults who present with consistent clinical features (eg, skin fragility and trauma-induced tense bullae that result in milia and scars) and lack a family history of hereditary blistering disease. Due to the various morphologies of EBA, the possibility of EBA should still be considered when clinical features suggest another subepithelial blistering disorder. (See",
"      <a class=\"local\" href=\"#H4624835\">",
"       'Clinical manifestations'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H306466132\">",
"       'Differential diagnosis'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      <strong>",
"       Tissue biopsies for routine histopathology and direct immunofluorescence (DIF) microscopy",
"      </strong>",
"      &ndash;",
"      <strong>",
"      </strong>",
"      A tissue biopsy of",
"      <strong>",
"       lesional",
"      </strong>",
"      skin or mucosa should be obtained for routine histological examination to determine the site of blistering within the skin (eg, intraepithelial versus subepithelial). A biopsy of",
"      <strong>",
"       perilesional",
"      </strong>",
"      skin or mucosa for DIF microscopy should also be performed to evaluate for autoantibody deposition. A 4 mm punch biopsy is typically utilized to obtain each of the necessary tissue specimens. The specimen for DIF should",
"      <strong>",
"       not",
"      </strong>",
"      be placed in formalin. Skin biopsy procedures for the evaluation of blistering diseases are discussed in greater detail separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?13/54/14186?source=see_link&amp;anchor=H4714350#H4714350\">",
"       \"Approach to the patient with cutaneous blisters\", section on 'Skin biopsy'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Immunofluorescence on basement membrane zone-split skin",
"      </strong>",
"      &ndash;",
"      <strong>",
"      </strong>",
"      When clinical, histological, and DIF findings are consistent with an autoimmune subepithelial blistering disorder, immunofluorescence on skin artificially split within the basement membrane zone is useful for ruling out bullous pemphigoid and linear IgA bullous dermatosis, thereby narrowing the differential diagnosis to EBA and a few other rare diseases. (See",
"      <a class=\"local\" href=\"#H1140904728\">",
"       'Immunofluorescence on basement membrane zone-split skin'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H306460423\">",
"    <span class=\"h3\">",
"     Histopathology",
"    </span>",
"    &nbsp;&mdash;&nbsp;The histopathological findings in EBA vary with the stage of lesion development and the clinical subtype. Early lesions typically show vacuolar alteration along the dermal-epithelial junction (DEJ) with subjacent papillary dermal edema. In more developed lesions, there is a frank subepithelial blister (",
"    <a class=\"graphic graphic_picture graphicRef86757 \" href=\"UTD.htm?4/58/5026\">",
"     picture 7",
"    </a>",
"    ). Dermal fibrosis may be present in older lesions, a finding that correlates with the clinical development of scarring [",
"    <a class=\"abstract\" href=\"UTD.htm?4/47/4858/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The intensity of inflammation in the dermis differs among the clinical subtypes. Classical EBA is characterized by a sparse lymphocytic infiltrate in the superficial dermis [",
"    <a class=\"abstract\" href=\"UTD.htm?4/47/4858/abstract/48\">",
"     48",
"    </a>",
"    ]. In contrast, inflammatory subtypes of EBA develop a heavy perivascular, perifollicular,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    interstitial infiltrate in the upper dermis. The infiltrate may be rich in neutrophils or may be a mixed infiltrate that also includes variable numbers of mononuclear cells and eosinophils. (See",
"    <a class=\"local\" href=\"#H4624835\">",
"     'Clinical manifestations'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H306460508\">",
"    <span class=\"h3\">",
"     Direct immunofluorescence",
"    </span>",
"    &nbsp;&mdash;&nbsp;DIF shows deposition of immunoreactants in nearly all cases [",
"    <a class=\"abstract\" href=\"UTD.htm?4/47/4858/abstract/34,49,50\">",
"     34,49,50",
"    </a>",
"    ]. The classic DIF findings in EBA are linear deposits of IgG and complement at the DEJ [",
"    <a class=\"abstract\" href=\"UTD.htm?4/47/4858/abstract/48,51\">",
"     48,51",
"    </a>",
"    ]. Deposition of IgA, IgM, Factor B, and properdin may also be detected.",
"   </p>",
"   <p>",
"    Because linear deposition of IgG and complement at the DEJ may be seen in multiple autoimmune subepithelial blistering disorders, the DIF findings do not provide a definitive diagnosis. In addition, the key DIF finding in linear IgA bullous dermatosis-like EBA, which consists of linear deposition of IgA along the DEJ, is identical to that in linear IgA bullous dermatosis [",
"    <a class=\"abstract\" href=\"UTD.htm?4/47/4858/abstract/37,52\">",
"     37,52",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/36/14922?source=see_link&amp;anchor=H829103#H829103\">",
"     \"Linear IgA bullous dermatosis\", section on 'Direct immunofluorescence'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The pattern of the antibody deposition at the DEJ may offer additional clues for diagnosis. A study of skin biopsies from 157 patients with subepithelial blistering diseases found that a u-serrated pattern is most often seen in EBA and bullous systemic lupus erythematosus, whereas an n-serrated pattern is more typical of bullous pemphigoid, mucous membrane pemphigoid, and linear IgA bullous dermatosis [",
"    <a class=\"abstract\" href=\"UTD.htm?4/47/4858/abstract/53\">",
"     53",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1140904728\">",
"    <span class=\"h3\">",
"     Immunofluorescence on basement membrane zone-split skin",
"    </span>",
"    &nbsp;&mdash;&nbsp;The basement membrane zone-split skin technique involves the artificial induction of cleavage within the lamina lucida of the basement membrane zone by incubation in 1M sodium chloride (salt-split skin) or 20 mM ethylenediaminetetraacetic acid (EDTA). Subsequent visualization of the location of autoantibody binding in reference to the site of cleavage is utilized to narrow the differential diagnosis. This technique may be performed utilizing perilesional tissue (DIF on basement membrane zone-split skin) or serum from the patient and a human skin substrate (indirect immunofluorescence [IIF] on basement membrane zone-split skin).",
"   </p>",
"   <p>",
"    Antibody binding to only the dermal side of basement membrane zone-split skin (floor of blister) is consistent with EBA, which contrasts with bullous pemphigoid, which presents with linear deposits of IgG on the epidermal side of salt-split skin (roof of blister) or to both the epidermal and dermal side of the split. Immunofluorescence on basement membrane zone-split skin is also useful for distinguishing linear IgA bullous dermatosis-like EBA from the more common form of linear IgA bullous dermatosis which is characterized by epidermal binding on basement membrane zone-split skin. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/11/22714?source=see_link&amp;anchor=H20007006#H20007006\">",
"     \"Clinical features and diagnosis of bullous pemphigoid and mucous membrane pemphigoid\", section on 'Diagnosis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/36/14922?source=see_link&amp;anchor=H28759781#H28759781\">",
"     \"Linear IgA bullous dermatosis\", section on 'Diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A downfall of IIF on basement membrane zone-split skin is that the test may be negative in patients with low levels of circulating type VII collagen antibodies [",
"    <a class=\"abstract\" href=\"UTD.htm?4/47/4858/abstract/32,54\">",
"     32,54",
"    </a>",
"    ]. Although IIF on salt-split skin was positive and showed dermal staining in all 10 patients with EBA in one series [",
"    <a class=\"abstract\" href=\"UTD.htm?4/47/4858/abstract/55\">",
"     55",
"    </a>",
"    ], in a separate series of five patients with EBA, IIF on basement membrane zone-split skin was positive in only three patients [",
"    <a class=\"abstract\" href=\"UTD.htm?4/47/4858/abstract/54\">",
"     54",
"    </a>",
"    ]. In these patients with low levels of circulating type VII collagen antibodies, the enzyme-linked immunosorbent assay (ELISA) will also likely be negative. It is also important to note that although immunofluorescence on salt-split skin that shows antibody binding to only the dermal side of split skin supports a diagnosis of EBA, it does not rule out the possibility of several rare subepithelial blistering disorders. (See",
"    <a class=\"local\" href=\"#H1267771\">",
"     'Additional studies'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1267771\">",
"    <span class=\"h3\">",
"     Additional studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Additional studies may be useful to support a diagnosis of EBA in the setting of a negative IIF and may aid in the differentiation of EBA from other subepithelial blistering disorders. Examples of test options include [",
"    <a class=\"abstract\" href=\"UTD.htm?4/47/4858/abstract/16\">",
"     16",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Transmission electron microscopy",
"      </strong>",
"      &ndash;",
"      <strong>",
"      </strong>",
"      This test is readily available in many hospitals and can be used to identify a reduction in anchoring fibrils in the DEJ. It also can demonstrate amorphous material beneath the lamina densa that may represent immunoglobulin deposits on anchoring fibrils.",
"     </li>",
"     <li>",
"      <strong>",
"       Enzyme-linked immunosorbent assay (ELISA)",
"      </strong>",
"      &ndash;",
"      <strong>",
"      </strong>",
"      ELISA based upon the full length protein of type VII collagen is a commercially available test that can be used to identify antibodies that bind to type VII collagen [",
"      <a class=\"abstract\" href=\"UTD.htm?4/47/4858/abstract/56,57\">",
"       56,57",
"      </a>",
"      ]. However, if the circulating antibodies are absent, the ELISA is likely to be negative.",
"     </li>",
"     <li>",
"      <strong>",
"       Direct or indirect immunoelectron microscopy (IEM)",
"      </strong>",
"      &ndash; These ultrastructural tests are generally used in the research setting. IEM can identify the location of antibody deposits in perilesional tissue (direct IEM) or the location where antibodies in patient serum bind within a human skin substrate (indirect IEM). Antibody deposition in the sublamina densa zone (the site of anchoring fibrils) is consistent with EBA. IEM is considered the",
"      <strong>",
"       gold standard",
"      </strong>",
"      for diagnosis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Examples of other studies that have been used in research settings to aid in the diagnosis of EBA include immunoblotting (demonstrates a 290 kDa band that represents the alpha chain of type VII collagen &plusmn; a 145 kDa band that represents the NC1 domain) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/47/4858/abstract/16\">",
"     16",
"    </a>",
"    ] and fluorescent overlay antigen mapping (FOAM) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/47/4858/abstract/58,59\">",
"     58,59",
"    </a>",
"    ]. FOAM uses computer analysis to compare the location of immunoglobulin deposits in perilesional skin to the sites where monoclonal antibodies to various components of the basement membrane zone bind. In EBA, antibody deposits are localized below the lamina densa.",
"   </p>",
"   <p>",
"    Specialized testing is also necessary to distinguish EBA from rare subepithelial blistering diseases with similar findings on basement membrane zone-split skin immunofluorescence, including bullous systemic lupus erythematosus, anti-laminin 332 (laminin",
"    <span class=\"nowrap\">",
"     5/epiligrin)",
"    </span>",
"    mucous membrane pemphigoid [",
"    <a class=\"abstract\" href=\"UTD.htm?4/47/4858/abstract/60\">",
"     60",
"    </a>",
"    ], anti-p105 pemphigoid [",
"    <a class=\"abstract\" href=\"UTD.htm?4/47/4858/abstract/61\">",
"     61",
"    </a>",
"    ], and anti-laminin 311",
"    <span class=\"nowrap\">",
"     (p200/laminin",
"    </span>",
"    gamma 1) pemphigoid [",
"    <a class=\"abstract\" href=\"UTD.htm?4/47/4858/abstract/62\">",
"     62",
"    </a>",
"    ]. Bullous systemic lupus erythematosus occurs in patients with systemic lupus erythematosus, and therefore can be ruled out when evidence for underlying systemic lupus erythematosus is absent. ELISA testing for type VII collagen antibodies or IEM can be used to distinguish EBA from the other rare subepithelial blistering disorders. As noted above, the availability of IEM is primarily limited to research environments.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H306466132\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multiple disorders share clinical features with EBA. Some of the disorders most commonly mistaken for EBA are reviewed below:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Bullous pemphigoid",
"      </strong>",
"      &ndash; The inflammatory, urticarial plaques and tense blisters of BP may also occur in inflammatory EBA (",
"      <a class=\"graphic graphic_picture graphicRef72866 \" href=\"UTD.htm?26/16/26885\">",
"       picture 3",
"      </a>",
"      ). Immunofluorescence on basement membrane zone-split skin is useful for differentiating these diagnoses. (See",
"      <a class=\"local\" href=\"#H1140904728\">",
"       'Immunofluorescence on basement membrane zone-split skin'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/11/22714?source=see_link\">",
"       \"Clinical features and diagnosis of bullous pemphigoid and mucous membrane pemphigoid\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Linear IgA bullous dermatosis",
"      </strong>",
"      &ndash; Linear IgA bullous dermatosis is a subepithelial blistering disorder that occurs in children and adults. An annular configuration of blisters is common (",
"      <a class=\"graphic graphic_picture graphicRef56434 \" href=\"UTD.htm?15/62/16359\">",
"       picture 5",
"      </a>",
"      ). Immunofluorescence on basement membrane zone-split skin is useful for distinguishing linear IgA bullous dermatosis from the linear IgA bullous dermatosis-like form of EBA. (See",
"      <a class=\"local\" href=\"#H1140904728\">",
"       'Immunofluorescence on basement membrane zone-split skin'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?14/36/14922?source=see_link\">",
"       \"Linear IgA bullous dermatosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Porphyria cutanea tarda",
"      </strong>",
"      &ndash; Porphyria cutanea tarda is an inherited or acquired metabolic disorder that presents with photodistributed, noninflammatory vesicles, bullae, crusts, and milia (",
"      <a class=\"graphic graphic_picture graphicRef74528 graphicRef78547 \" href=\"UTD.htm?25/16/25863\">",
"       picture 8A-B",
"      </a>",
"      ). The dorsal hands and forearms are common sites for involvement. Associated clinical findings include hyperpigmentation, facial hypertrichosis, and localized sclerodermoid plaques. Porphyria cutanea tarda is diagnosed through the detection of elevated levels of porphyrins in plasma or urine. In addition, direct immunofluorescence (DIF) microscopy typically reveals deposition of IgG around dermal blood vessels [",
"      <a class=\"abstract\" href=\"UTD.htm?4/47/4858/abstract/63\">",
"       63",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/50/28458?source=see_link\">",
"       \"Porphyria cutanea tarda and hepatoerythropoietic porphyria\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Bullous systemic lupus erythematosus",
"      </strong>",
"      &ndash; Bullous systemic lupus erythematosus is a rare subepithelial blistering disorder that occurs in the setting of systemic lupus erythematosus (",
"      <a class=\"graphic graphic_picture graphicRef86216 \" href=\"UTD.htm?21/21/21845\">",
"       picture 9",
"      </a>",
"      ). As with EBA, antibodies to type VII collagen have been implicated in the pathogenesis of bullous systemic lupus erythematosus. The presence of an underlying diagnosis of systemic lupus erythematosus in a patient with immunofluorescence findings similar to those in EBA suggests the possibility of this diagnosis.",
"     </li>",
"     <li>",
"      <strong>",
"       Recessive dystrophic epidermolysis bullosa",
"      </strong>",
"      &ndash; Recessive dystrophic epidermolysis bullosa is a rare, inherited blistering disorder characterized by the congenital absence of type VII collagen. Patients first present in infancy. Severe skin fragility and generalized blisters that resolve with scarring and milia formation are characteristic (",
"      <a class=\"graphic graphic_picture graphicRef68938 \" href=\"UTD.htm?36/38/37475\">",
"       picture 10",
"      </a>",
"      ). Fusion of the digits of the hands and feet (mitten deformity) is common. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/28/28106?source=see_link\">",
"       \"Epidemiology, pathogenesis, and clinical features of epidermolysis bullosa\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/28/28106?source=see_link&amp;anchor=H2900750#H2900750\">",
"       \"Epidemiology, pathogenesis, and clinical features of epidermolysis bullosa\", section on 'Dystrophic epidermolysis bullosa'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H306466449\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;EBA is notoriously difficult to treat; disease refractory to multiple interventions is common. Randomized therapeutic trials of this rare disorder are lacking and the optimal approach to treatment remains unclear [",
"    <a class=\"abstract\" href=\"UTD.htm?4/47/4858/abstract/64\">",
"     64",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H306467843\">",
"    <span class=\"h2\">",
"     General measures",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to pharmacologic therapy, efforts to minimize disease severity are often beneficial in patients with EBA. These include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Avoidance of incidental and iatrogenic trauma to the skin",
"     </li>",
"     <li>",
"      Gentle cleansing of skin during bathing and avoidance of vigorous scrubbing and harsh soaps",
"     </li>",
"     <li>",
"      Education of patients regarding signs of cutaneous infection to promote early recognition and treatment",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    For wound care, we typically use hydrogel or semiocclusive hydrocolloid dressings on new, clean wounds. For lower extremity wounds, we often apply a silver impregnated dressing that is changed every 48 hours to minimize the risk for infection. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/63/27642?source=see_link\">",
"     \"Basic principles of wound management\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with mucosal involvement usually require multidisciplinary management to minimize consequences of the disease. Ocular disease may result in conjunctival scarring and blindness. Thus, patients with ocular involvement should be managed jointly with an ophthalmologist to assist with following the response to treatment and the use of adjunctive topical therapies. Symptoms of dysphagia or diarrhea are an indication for a referral to gastroenterology to evaluate for the presence of esophageal strictures or inflammatory bowel disease, respectively. Last, patients with oral involvement may benefit from joint management with a dentist who is familiar with the care of patients with autoimmune blistering diseases [",
"    <a class=\"abstract\" href=\"UTD.htm?4/47/4858/abstract/65\">",
"     65",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H306466456\">",
"    <span class=\"h2\">",
"     Approach to treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;The preferred first-line treatments for EBA are agents that both have appeared to be effective based upon the limited available data and are generally well-tolerated.",
"   </p>",
"   <p>",
"    Although systemic glucocorticoids are often utilized in EBA, clinical experience suggests that classical EBA may be less likely to respond to systemic glucocorticoids than inflammatory subtypes of EBA, and that overall, systemic glucocorticoids are less effective for EBA than for other subepithelial blistering diseases [",
"    <a class=\"abstract\" href=\"UTD.htm?4/47/4858/abstract/16,66\">",
"     16,66",
"    </a>",
"    ]. The long-term side effects of systemic glucocorticoid therapy are an additional concern. Thus, we prefer a different approach to initial therapy.",
"   </p>",
"   <p>",
"    In our practice, the initial treatment for most patients consists of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/13/32983?source=see_link\">",
"     colchicine",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/59/32688?source=see_link\">",
"     dapsone",
"    </a>",
"    , both of which have been reported to be effective when administered in combination with systemic glucocorticoids; monotherapy with colchicine has also been reported as effective in several patients [",
"    <a class=\"abstract\" href=\"UTD.htm?4/47/4858/abstract/66\">",
"     66",
"    </a>",
"    ]. If satisfactory improvement is not attained with colchicine or dapsone monotherapy, we combine these agents. If this is not effective, we consider treatments for refractory disease, most often utilizing",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    (particularly for patients with classical EBA) or a trial of the addition of a short course of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    to colchicine and dapsone therapy. (See",
"    <a class=\"local\" href=\"#H306466477\">",
"     'Refractory disease'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    In severe cases in which acute improvement is needed, treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    may be initiated at the start of treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/13/32983?source=see_link\">",
"     colchicine",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/59/32688?source=see_link\">",
"     dapsone",
"    </a>",
"    to attempt to accelerate improvement of disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H978032645\">",
"    <span class=\"h3\">",
"     Colchicine",
"    </span>",
"    &nbsp;&mdash;&nbsp;Typical doses of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/13/32983?source=see_link\">",
"     colchicine",
"    </a>",
"    for EBA in adults range from 0.5 to 3 mg per day, with the maximum dose typically limited by the development of dose-related gastrointestinal adverse effects. In our experience, tolerance to the drug is improved when the dose is increased gradually.",
"   </p>",
"   <p>",
"    In adults, we typically begin",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/13/32983?source=see_link\">",
"     colchicine",
"    </a>",
"    at 0.5 mg per day and increase by 0.5 mg per week until diarrhea occurs, up to a maximum dose of 6 mg per day (maximum of 3 mg per day in elderly patients and patients with renal or hepatic impairment). We then reduce the dose to a level that was tolerated without diarrhea. In our experience, most adults are able to tolerate a daily dose of 2 to 3 mg per day. Due to the high likelihood of gastrointestinal adverse effects, we usually avoid the use of colchicine in EBA patients who also have inflammatory bowel disease [",
"    <a class=\"abstract\" href=\"UTD.htm?4/47/4858/abstract/67,68\">",
"     67,68",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H316626856\">",
"     'Associated disorders'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H978032652\">",
"    <span class=\"h3\">",
"     Dapsone",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/59/32688?source=see_link\">",
"     dapsone",
"    </a>",
"    and systemic glucocorticoids has been associated with clinical improvement in adults and children with EBA [",
"    <a class=\"abstract\" href=\"UTD.htm?4/47/4858/abstract/69,70\">",
"     69,70",
"    </a>",
"    ]. Dapsone is typically given as 1 to 2",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day [",
"    <a class=\"abstract\" href=\"UTD.htm?4/47/4858/abstract/66\">",
"     66",
"    </a>",
"    ], beginning with a low dose (eg, 25 mg in adults) and increasing as tolerated.",
"   </p>",
"   <p>",
"    Hemolytic anemia is a common side effect of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/59/32688?source=see_link\">",
"     dapsone",
"    </a>",
"    therapy that occurs to some degree in all patients, resulting in a mild, typically asymptomatic drop in hemoglobin. Individuals with glucose-6-phosphate deficiency have an increased risk for severe hemolytic anemia. Thus, we test for G6PD deficiency prior to initiating therapy with this agent.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H306466477\">",
"    <span class=\"h2\">",
"     Refractory disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who fail to respond well to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/13/32983?source=see_link\">",
"     colchicine",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/59/32688?source=see_link\">",
"     dapsone",
"    </a>",
"    require more aggressive therapy. Treatments that may be of benefit in this population include immunosuppressants, intravenous immunoglobulin (IVIG), and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    . The high costs and requirements for infusion of IVIG and rituximab limit the use of these agents for some patients.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Immunosuppressants",
"      </strong>",
"      &ndash; Although the efficacy of systemic glucocorticoids for EBA is inconsistent, a trial of the addition of a short course of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/13/32983?source=see_link\">",
"       colchicine",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/59/32688?source=see_link\">",
"       dapsone",
"      </a>",
"      may be performed in an attempt to augment improvement. Prednisone is administered in doses of 0.5 to 1.5",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day, with the doses on the lower end of this range used for less severe disease. Prednisone is subsequently tapered as tolerated, with an ideal goal of limiting the course of systemic glucocorticoid therapy to six weeks [",
"      <a class=\"abstract\" href=\"UTD.htm?4/47/4858/abstract/66\">",
"       66",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Case reports have documented clinical improvement with immunosuppressive therapy such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"       cyclosporine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"       azathioprine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      , and mycophenolic acid [",
"      <a class=\"abstract\" href=\"UTD.htm?4/47/4858/abstract/66\">",
"       66",
"      </a>",
"      ]. However, clinical experience suggests the benefit of these agents is particularly limited in patients with the classical presentation of EBA. Patients with the inflammatory, bullous pemphigoid-like presentation may be more likely to respond to these therapies.",
"     </li>",
"     <li>",
"      <strong>",
"       Intravenous immunoglobulin",
"      </strong>",
"      &ndash; Intravenous immunoglobulin (IVIG) has been utilized for the treatment of pemphigus vulgaris and other autoimmune diseases. Multiple case reports suggest that the periodic administration of IVIG alone or in combination with other agents is also effective for improving the clinical manifestations of EBA [",
"      <a class=\"abstract\" href=\"UTD.htm?4/47/4858/abstract/71-74\">",
"       71-74",
"      </a>",
"      ]. In a 2011 review of published reports, 14 of 15 patients given IVIG as monotherapy or in conjunction with other therapies achieved clinical improvement [",
"      <a class=\"abstract\" href=\"UTD.htm?4/47/4858/abstract/66\">",
"       66",
"      </a>",
"      ]. Multiple cycles of IVIG were typically given; each cycle usually consisted of a total of 1.5 to 2",
"      <span class=\"nowrap\">",
"       g/kg",
"      </span>",
"      of IVIG given over the course of three to five days.",
"      <br/>",
"      <br/>",
"      Side effects of IVIG are usually mild and transient; however, serious adverse effects occasionally occur. The adverse effects of IVIG are reviewed separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/32/38409?source=see_link\">",
"       \"Intravenous immune globulin: Adverse effects\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"       Rituximab",
"      </a>",
"      <strong>",
"      </strong>",
"      &ndash; Rituximab, a monoclonal antibody against CD20 that depletes B lymphocytes, has been given in combination with immunosuppressants or immunoadsorption for refractory EBA in small numbers of patients with favorable results, including patients with the classical variant of EBA [",
"      <a class=\"abstract\" href=\"UTD.htm?4/47/4858/abstract/75-79\">",
"       75-79",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Caution must be used with rituximab as potential side effects include life threatening infections, pancytopenia, severe mucocutaneous reactions, and bowel obstruction, among others. One EBA patient treated with rituximab developed a fatal",
"      <em>",
"       Pseudomonas",
"      </em>",
"      pneumonia [",
"      <a class=\"abstract\" href=\"UTD.htm?4/47/4858/abstract/80\">",
"       80",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/40/21130?source=see_link\">",
"       \"Rituximab and other B cell targeted therapies for rheumatoid arthritis\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H306466505\">",
"    <span class=\"h2\">",
"     Other therapies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other treatments that have been reported to be effective in individual patients with refractory EBA include daclizumab [",
"    <a class=\"abstract\" href=\"UTD.htm?4/47/4858/abstract/81\">",
"     81",
"    </a>",
"    ], plasmapheresis [",
"    <a class=\"abstract\" href=\"UTD.htm?4/47/4858/abstract/82\">",
"     82",
"    </a>",
"    ], and extracorporeal photophoresis [",
"    <a class=\"abstract\" href=\"UTD.htm?4/47/4858/abstract/83,84\">",
"     83,84",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H306466512\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although the course of EBA varies, the disease most commonly has a prolonged course, persisting for years. Mucosal involvement can lead to long-term consequences, such as blindness and esophageal strictures. Uncontrolled cutaneous involvement may lead to joint contractures [",
"    <a class=\"abstract\" href=\"UTD.htm?4/47/4858/abstract/85\">",
"     85",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A cure for EBA does not exist. Thus, the goal of treatment is suppression of disease. In a retrospective study of 30 patients with EBA, all of whom were initially treated with a combination of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/25/31129?source=see_link\">",
"     methylprednisolone",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/59/32688?source=see_link\">",
"     dapsone",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/13/32983?source=see_link\">",
"     colchicine",
"    </a>",
"    (six who did not respond were subsequently treated with other immunosuppressants), 8 of 24 patients (33 percent) achieved complete remission and 5 of 24 (21 percent) achieved partial remission within one year [",
"    <a class=\"abstract\" href=\"UTD.htm?4/47/4858/abstract/86\">",
"     86",
"    </a>",
"    ]. The overall prognosis and response to treatment may be less favorable in adults than in children [",
"    <a class=\"abstract\" href=\"UTD.htm?4/47/4858/abstract/2,87\">",
"     2,87",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H306466519\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Epidermolysis bullosa acquisita (EBA) is a rare subepithelial blistering disorder that primarily affects adults. EBA is a disease distinct from hereditary epidermolysis bullosa. (See",
"      <a class=\"local\" href=\"#H316625826\">",
"       'Epidemiology'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H479445424\">",
"       'Terminology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      EBA is an autoimmune disease characterized by the production of antibodies against type VII collagen, a major component of anchoring fibrils in the dermal-epithelial junction (",
"      <a class=\"graphic graphic_figure graphicRef67891 \" href=\"UTD.htm?3/63/4086\">",
"       figure 1",
"      </a>",
"      ). Immune-mediated disruption of the anchoring fibrils likely contributes to the clinical development of blistering. (See",
"      <a class=\"local\" href=\"#H316622104\">",
"       'Pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      EBA is characterized by several clinical presentations. The most common presentations are classical EBA and bullous pemphigoid-like EBA. Classical EBA presents as a mechanobullous disorder associated with skin fragility and noninflammatory tense bullae, with a predilection for acral areas (",
"      <a class=\"graphic graphic_picture graphicRef62505 graphicRef83259 \" href=\"UTD.htm?32/1/32793\">",
"       picture 1A-B",
"      </a>",
"      ). Bullae often heal with milia and scarring (",
"      <a class=\"graphic graphic_picture graphicRef86482 \" href=\"UTD.htm?16/37/16982\">",
"       picture 2",
"      </a>",
"      ). Bullous pemphigoid-like EBA is an inflammatory form of EBA that is characterized by urticarial plaques and widespread inflammatory bullae. (See",
"      <a class=\"local\" href=\"#H4624835\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Anecdotal reports document the occurrence of EBA in association with multiple other systemic diseases. The most common disorder seen in association with EBA is inflammatory bowel disease. (See",
"      <a class=\"local\" href=\"#H316626856\">",
"       'Associated disorders'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The approach to the diagnosis of EBA resembles that for other autoimmune subepithelial blistering disorders. The initial evaluation includes a patient history, full skin examination, and skin biopsies for hematoxylin and eosin staining and direct immunofluorescence. Immunofluorescence on basement membrane zone-split skin provides valuable clues for further narrowing of the differential diagnosis. (See",
"      <a class=\"local\" href=\"#H316627112\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Although the clinical evaluation, biopsies, and immunofluorescence studies provide evidence to support a diagnosis of EBA, they do not rule out the possibility of several other rare subepithelial blistering diseases. (See",
"      <a class=\"local\" href=\"#H1267771\">",
"       'Additional studies'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Data are limited on the treatment options for EBA. Thus, the optimal approach to treatment has not been established. For patients with EBA we suggest",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/13/32983?source=see_link\">",
"       colchicine",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/59/32688?source=see_link\">",
"       dapsone",
"      </a>",
"      as initial treatment (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). If treatment is not effective, these agents may be used simultaneously.",
"     </li>",
"     <li>",
"      EBA that is refractory to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/13/32983?source=see_link\">",
"       colchicine",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/59/32688?source=see_link\">",
"       dapsone",
"      </a>",
"      requires more aggressive therapy. Agents that may have efficacy for refractory EBA include immunosuppressants, intravenous immunoglobulin, and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      . (See",
"      <a class=\"local\" href=\"#H306466477\">",
"       'Refractory disease'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/47/4858/abstract/1\">",
"      Schmidt E, H&ouml;pfner B, Chen M, et al. Childhood epidermolysis bullosa acquisita: a novel variant with reactivity to all three structural domains of type VII collagen. Br J Dermatol 2002; 147:592.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/47/4858/abstract/2\">",
"      Callot-Mellot C, Bodemer C, Caux F, et al. Epidermolysis bullosa acquisita in childhood. Arch Dermatol 1997; 133:1122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/47/4858/abstract/3\">",
"      Arpey CJ, Elewski BE, Moritz DK, Gammon WR. Childhood epidermolysis bullosa acquisita. Report of three cases and review of literature. J Am Acad Dermatol 1991; 24:706.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/47/4858/abstract/4\">",
"      Mayuzumi M, Akiyama M, Nishie W, et al. Childhood epidermolysis bullosa acquisita with autoantibodies against the noncollagenous 1 and 2 domains of type VII collagen: case report and review of the literature. Br J Dermatol 2006; 155:1048.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/47/4858/abstract/5\">",
"      Burgeson RE. Type VII collagen, anchoring fibrils, and epidermolysis bullosa. J Invest Dermatol 1993; 101:252.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/47/4858/abstract/6\">",
"      Sakai LY, Keene DR, Morris NP, Burgeson RE. Type VII collagen is a major structural component of anchoring fibrils. J Cell Biol 1986; 103:1577.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/47/4858/abstract/7\">",
"      Lapiere JC, Woodley DT, Parente MG, et al. Epitope mapping of type VII collagen. Identification of discrete peptide sequences recognized by sera from patients with acquired epidermolysis bullosa. J Clin Invest 1993; 92:1831.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/47/4858/abstract/8\">",
"      Gammon WR, Briggaman RA. Epidermolysis bullosa acquisita and bullous systemic lupus erythematosus. Diseases of autoimmunity to type VII collagen. Dermatol Clin 1993; 11:535.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/47/4858/abstract/9\">",
"      Jones DA, Hunt SW 3rd, Prisayanh PS, et al. Immunodominant autoepitopes of type VII collagen are short, paired peptide sequences within the fibronectin type III homology region of the noncollagenous (NC1) domain. J Invest Dermatol 1995; 104:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/47/4858/abstract/10\">",
"      Woodley DT, Briggaman RA, O'Keefe EJ, et al. Identification of the skin basement-membrane autoantigen in epidermolysis bullosa acquisita. N Engl J Med 1984; 310:1007.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/47/4858/abstract/11\">",
"      Gupta R, Woodley DT, Chen M. Epidermolysis bullosa acquisita. Clin Dermatol 2012; 30:60.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/47/4858/abstract/12\">",
"      Ray TL, Levine JB, Weiss W, Ward PA. Epidermolysis bullosa acquisita and inflammatory bowel disease. J Am Acad Dermatol 1982; 6:242.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/47/4858/abstract/13\">",
"      Kim JH, Kim YH, Kim S, et al. Serum levels of anti-type VII collagen antibodies detected by enzyme-linked immunosorbent assay in patients with epidermolysis bullosa acquisita are correlated with the severity of skin lesions. J Eur Acad Dermatol Venereol 2013; 27:e224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/47/4858/abstract/14\">",
"      Sebaratnam DF, Murrell DF. Bullous systemic lupus erythematosus. Dermatol Clin 2011; 29:649.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/47/4858/abstract/15\">",
"      Christiano AM, Greenspan DS, Lee S, Uitto J. Cloning of human type VII collagen. Complete primary sequence of the alpha 1(VII) chain and identification of intragenic polymorphisms. J Biol Chem 1994; 269:20256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/47/4858/abstract/16\">",
"      Chen M, Kim GH, Prakash L, Woodley DT. Epidermolysis bullosa acquisita: autoimmunity to anchoring fibril collagen. Autoimmunity 2012; 45:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/47/4858/abstract/17\">",
"      Fukumoto T, Umekawa T, Higuchi M, et al. Childhood epidermolysis bullosa acquisita with autoantibodies against all 3 structural domains of type VII collagen. J Am Acad Dermatol 2004; 50:480.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/47/4858/abstract/18\">",
"      Tanaka H, Ishida-Yamamoto A, Hashimoto T, et al. A novel variant of acquired epidermolysis bullosa with autoantibodies against the central triple-helical domain of type VII collagen. Lab Invest 1997; 77:623.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/47/4858/abstract/19\">",
"      Chen M, Keene DR, Costa FK, et al. The carboxyl terminus of type VII collagen mediates antiparallel dimer formation and constitutes a new antigenic epitope for epidermolysis Bullosa acquisita autoantibodies. J Biol Chem 2001; 276:21649.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/47/4858/abstract/20\">",
"      Ishii N, Yoshida M, Hisamatsu Y, et al. Epidermolysis bullosa acquisita sera react with distinct epitopes on the NC1 and NC2 domains of type VII collagen: study using immunoblotting of domain-specific recombinant proteins and postembedding immunoelectron microscopy. Br J Dermatol 2004; 150:843.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/47/4858/abstract/21\">",
"      Ishii N, Yoshida M, Ishida-Yamamoto A, et al. Some epidermolysis bullosa acquisita sera react with epitopes within the triple-helical collagenous domain as indicated by immunoelectron microscopy. Br J Dermatol 2009; 160:1090.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/47/4858/abstract/22\">",
"      Christiano AM, Rosenbaum LM, Chung-Honet LC, et al. The large non-collagenous domain (NC-1) of type VII collagen is amino-terminal and chimeric. Homology to cartilage matrix protein, the type III domains of fibronectin and the A domains of von Willebrand factor. Hum Mol Genet 1992; 1:475.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/47/4858/abstract/23\">",
"      Chen M, Marinkovich MP, Veis A, et al. Interactions of the amino-terminal noncollagenous (NC1) domain of type VII collagen with extracellular matrix components. A potential role in epidermal-dermal adherence in human skin. J Biol Chem 1997; 272:14516.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/47/4858/abstract/24\">",
"      Woodley DT, Chang C, Saadat P, et al. Evidence that anti-type VII collagen antibodies are pathogenic and responsible for the clinical, histological, and immunological features of epidermolysis bullosa acquisita. J Invest Dermatol 2005; 124:958.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/47/4858/abstract/25\">",
"      Sitaru C, Mihai S, Otto C, et al. Induction of dermal-epidermal separation in mice by passive transfer of antibodies specific to type VII collagen. J Clin Invest 2005; 115:870.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/47/4858/abstract/26\">",
"      Woodley DT, Ram R, Doostan A, et al. Induction of epidermolysis bullosa acquisita in mice by passive transfer of autoantibodies from patients. J Invest Dermatol 2006; 126:1323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/47/4858/abstract/27\">",
"      Chen M, Marinkovich MP, Jones JC, et al. NC1 domain of type VII collagen binds to the beta3 chain of laminin 5 via a unique subdomain within the fibronectin-like repeats. J Invest Dermatol 1999; 112:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/47/4858/abstract/28\">",
"      Gammon WR, Briggaman RA, Woodley DT, et al. Epidermolysis bullosa acquisita--a pemphigoid-like disease. J Am Acad Dermatol 1984; 11:820.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/47/4858/abstract/29\">",
"      Gammon WR, Heise ER, Burke WA, et al. Increased frequency of HLA-DR2 in patients with autoantibodies to epidermolysis bullosa acquisita antigen: evidence that the expression of autoimmunity to type VII collagen is HLA class II allele associated. J Invest Dermatol 1988; 91:228.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/47/4858/abstract/30\">",
"      Luke MC, Darling TN, Hsu R, et al. Mucosal morbidity in patients with epidermolysis bullosa acquisita. Arch Dermatol 1999; 135:954.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/47/4858/abstract/31\">",
"      Delgado L, Aoki V, Santi C, et al. Clinical and immunopathological evaluation of epidermolysis bullosa acquisita. Clin Exp Dermatol 2011; 36:12.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/47/4858/abstract/32\">",
"      Hoang-Xuan T, Robin H, Heller M, et al. Epidermolysis bullosa acquisita diagnosed by direct immunoelectron microscopy of the conjunctiva. Ophthalmology 1997; 104:1414.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/47/4858/abstract/33\">",
"      Shipman AR, Agero AL, Cook I, et al. Epidermolysis bullosa acquisita requiring multiple oesophageal dilatations. Clin Exp Dermatol 2008; 33:787.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/47/4858/abstract/34\">",
"      Medenica-Mojsilovi�� L, Fenske NA, Espinoza CG. Epidermolysis bullosa acquisita. Direct immunofluorescence and ultrastructural studies. Am J Dermatopathol 1987; 9:324.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/47/4858/abstract/35\">",
"      Gammon WR, Briggaman RA, Wheeler CE Jr. Epidermolysis bullosa acquisita presenting as an inflammatory bullous disease. J Am Acad Dermatol 1982; 7:382.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/47/4858/abstract/36\">",
"      Dahl MG. Epidermolysis bullosa acquisita--a sign of cicatricial pemphigoid? Br J Dermatol 1979; 101:475.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/47/4858/abstract/37\">",
"      Hashimoto T, Ishiko A, Shimizu H, et al. A case of linear IgA bullous dermatosis with IgA anti-type VII collagen autoantibodies. Br J Dermatol 1996; 134:336.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/47/4858/abstract/38\">",
"      Rusenko KW, Gammon WR, Briggaman RA. Type VII collagen is the antigen recognized by IgA anti-sub lamina densa autoantibodies. J Invest Dermatol 1989; 92:510.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/47/4858/abstract/39\">",
"      Choi GS, Lee ES, Kim SC, Lee S. Epidermolysis bullosa acquisita localized to the face. J Dermatol 1998; 25:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/47/4858/abstract/40\">",
"      Kushniruk W. The immunopathology of epidermolysis bullosa acquisita. Can Med Assoc J 1973; 108:1143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/47/4858/abstract/41\">",
"      Kurzhals G, Stolz W, Meurer M, et al. Acquired epidermolysis bullosa with the clinical feature of Brunsting-Perry cicatricial bullous pemphigoid. Arch Dermatol 1991; 127:391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/47/4858/abstract/42\">",
"      Roenigk HH Jr, Ryan JG, Bergfeld WF. Epidermolysis bullosa acquisita. Report of three cases and review of all published cases. Arch Dermatol 1971; 103:1.",
"     </a>",
"    </li>",
"    <li>",
"     Chan LS, Woodley DT. Pemphigoid: Bullous and cicatricial. In: Current Therapy in Allergy, Immunology and Rhematology, 5th ed, Lichtenstein LM, Fauci AS (Eds), Mosby, St Louis 1996. p.93.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/47/4858/abstract/44\">",
"      Chen M, O'Toole EA, Sanghavi J, et al. The epidermolysis bullosa acquisita antigen (type VII collagen) is present in human colon and patients with crohn's disease have autoantibodies to type VII collagen. J Invest Dermatol 2002; 118:1059.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/47/4858/abstract/45\">",
"      Ishii N, Recke A, Mihai S, et al. Autoantibody-induced intestinal inflammation and weight loss in experimental epidermolysis bullosa acquisita. J Pathol 2011; 224:234.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/47/4858/abstract/46\">",
"      Licarete E, Ganz S, Recknagel MJ, et al. Prevalence of collagen VII-specific autoantibodies in patients with autoimmune and inflammatory diseases. BMC Immunol 2012; 13:16.",
"     </a>",
"    </li>",
"    <li>",
"     Ackerman AB, Chongchitnant N, Sanchez J, et al. Histologic diagnosis of inflammatory skin diseases: an algorithmic method based on pattern analysis, 2nd ed, Williams &amp; Wilkins, Baltimore, MD 1997.",
"    </li>",
"    <li>",
"     Weedon D. The vesicobullous reaction pattern. In: Weedon's Skin Pathology, 3rd ed, Elsevier Limited, 2010. p.123.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/47/4858/abstract/49\">",
"      Palestine RF, Kossard S, Dicken CH. Epidermolysis bullosa acquisita: a heterogeneous disease. J Am Acad Dermatol 1981; 5:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/47/4858/abstract/50\">",
"      Smoller BR, Woodley DT. Differences in direct immunofluorescence staining patterns in epidermolysis bullosa acquisita and bullous pemphigoid. J Am Acad Dermatol 1992; 27:674.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/47/4858/abstract/51\">",
"      Yaoita H, Briggaman RA, Lawley TJ, et al. Epidermolysis bullosa acquisita: ultrastructural and immunological studies. J Invest Dermatol 1981; 76:288.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/47/4858/abstract/52\">",
"      Bauer JW, Schaeppi H, Metze D, et al. Ocular involvement in IgA-epidermolysis bullosa acquisita. Br J Dermatol 1999; 141:887.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/47/4858/abstract/53\">",
"      Vodegel RM, Jonkman MF, Pas HH, de Jong MC. U-serrated immunodeposition pattern differentiates type VII collagen targeting bullous diseases from other subepidermal bullous autoimmune diseases. Br J Dermatol 2004; 151:112.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/47/4858/abstract/54\">",
"      Wozniak K, Kazama T, Kowalewski C. A practical technique for differentiation of subepidermal bullous diseases: localization of in vivo-bound IgG by laser scanning confocal microscopy. Arch Dermatol 2003; 139:1007.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/47/4858/abstract/55\">",
"      Ghohestani RF, Nicolas JF, Rousselle P, Claudy AL. Diagnostic value of indirect immunofluorescence on sodium chloride-split skin in differential diagnosis of subepidermal autoimmune bullous dermatoses. Arch Dermatol 1997; 133:1102.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/47/4858/abstract/56\">",
"      Chen M, Chan LS, Cai X, et al. Development of an ELISA for rapid detection of anti-type VII collagen autoantibodies in epidermolysis bullosa acquisita. J Invest Dermatol 1997; 108:68.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/47/4858/abstract/57\">",
"      Saleh MA, Ishii K, Kim YJ, et al. Development of NC1 and NC2 domains of type VII collagen ELISA for the diagnosis and analysis of the time course of epidermolysis bullosa acquisita patients. J Dermatol Sci 2011; 62:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/47/4858/abstract/58\">",
"      Wozniak K, Hashimoto T, Ishii N, et al. Fluorescence overlay antigen mapping using laser scanning confocal microscopy differentiates linear IgA bullous dermatosis from epidermolysis bullosa acquisita mediated by IgA. Br J Dermatol 2013; 168:634.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/47/4858/abstract/59\">",
"      Kazama T, Yamamoto Y, Hashimoto T, et al. Application of confocal laser scanning microscopy to differential diagnosis of bullous pemphigoid and epidermolysis bullosa acquisita. Br J Dermatol 1998; 138:593.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/47/4858/abstract/60\">",
"      Domloge-Hultsch N, Anhalt GJ, Gammon WR, et al. Antiepiligrin cicatricial pemphigoid. A subepithelial bullous disorder. Arch Dermatol 1994; 130:1521.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/47/4858/abstract/61\">",
"      Chan LS, Fine JD, Briggaman RA, et al. Identification and partial characterization of a novel 105-kDalton lower lamina lucida autoantigen associated with a novel immune-mediated subepidermal blistering disease. J Invest Dermatol 1993; 101:262.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/47/4858/abstract/62\">",
"      Mascar&oacute; JM Jr, Zillikens D, Giudice GJ, et al. A subepidermal bullous eruption associated with IgG autoantibodies to a 200 kd dermal antigen: the first case report from the United States. J Am Acad Dermatol 2000; 42:309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/47/4858/abstract/63\">",
"      Epstein JH, Tuffanelli DL, Epstein WL. Cutaneous changes in the porphyrias. A microscopic study. Arch Dermatol 1973; 107:689.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/47/4858/abstract/64\">",
"      Kirtschig G, Murrell D, Wojnarowska F, Khumalo N. Interventions for mucous membrane pemphigoid and epidermolysis bullosa acquisita. Cochrane Database Syst Rev 2003; :CD004056.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/47/4858/abstract/65\">",
"      Intong LR, Murrell DF. Management of epidermolysis bullosa acquisita. Dermatol Clin 2011; 29:643.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/47/4858/abstract/66\">",
"      G&uuml;rcan HM, Ahmed AR. Current concepts in the treatment of epidermolysis bullosa acquisita. Expert Opin Pharmacother 2011; 12:1259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/47/4858/abstract/67\">",
"      Cunningham BB, Kirchmann TT, Woodley D. Colchicine for epidermolysis bullosa acquisita. J Am Acad Dermatol 1996; 34:781.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/47/4858/abstract/68\">",
"      Megahed M, Scharffetter-Kochanek K. Epidermolysis bullosa acquisita--successful treatment with colchicine. Arch Dermatol Res 1994; 286:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/47/4858/abstract/69\">",
"      Hughes AP, Callen JP. Epidermolysis bullosa acquisita responsive to dapsone therapy. J Cutan Med Surg 2001; 5:397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/47/4858/abstract/70\">",
"      Miyake H, Morishima Y, Komai R, et al. Epidermolysis bullosa acquisita: correlation of IgE levels with disease activity under successful betamethasone/dapsone combination therapy. Acta Derm Venereol 2001; 81:429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/47/4858/abstract/71\">",
"      Caldwell JB, Yancey KB, Engler RJ, James WD. Epidermolysis bullosa acquisita: efficacy of high-dose intravenous immunoglobulins. J Am Acad Dermatol 1994; 31:827.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/47/4858/abstract/72\">",
"      Kofler H, Wambacher-Gasser B, Topar G, et al. Intravenous immunoglobulin treatment in therapy-resistant epidermolysis bullosa acquisita. J Am Acad Dermatol 1997; 36:331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/47/4858/abstract/73\">",
"      Meier F, S&ouml;nnichsen K, Schaumburg-Lever G, et al. Epidermolysis bullosa acquisita: efficacy of high-dose intravenous immunoglobulins. J Am Acad Dermatol 1993; 29:334.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/47/4858/abstract/74\">",
"      Mohr C, Sunderk&ouml;tter C, Hildebrand A, et al. Successful treatment of epidermolysis bullosa acquisita using intravenous immunoglobulins. Br J Dermatol 1995; 132:824.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/47/4858/abstract/75\">",
"      Sadler E, Schafleitner B, Lanschuetzer C, et al. Treatment-resistant classical epidermolysis bullosa acquisita responding to rituximab. Br J Dermatol 2007; 157:417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/47/4858/abstract/76\">",
"      Crichlow SM, Mortimer NJ, Harman KE. A successful therapeutic trial of rituximab in the treatment of a patient with recalcitrant, high-titre epidermolysis bullosa acquisita. Br J Dermatol 2007; 156:194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/47/4858/abstract/77\">",
"      Saha M, Cutler T, Bhogal B, et al. Refractory epidermolysis bullosa acquisita: successful treatment with rituximab. Clin Exp Dermatol 2009; 34:e979.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/47/4858/abstract/78\">",
"      Schmidt E, Benoit S, Br&ouml;cker EB, et al. Successful adjuvant treatment of recalcitrant epidermolysis bullosa acquisita with anti-CD20 antibody rituximab. Arch Dermatol 2006; 142:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/47/4858/abstract/79\">",
"      Niedermeier A, Eming R, Pf&uuml;tze M, et al. Clinical response of severe mechanobullous epidermolysis bullosa acquisita to combined treatment with immunoadsorption and rituximab (anti-CD20 monoclonal antibodies). Arch Dermatol 2007; 143:192.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/47/4858/abstract/80\">",
"      Mercader P, Rodenas JM, Pe&ntilde;a A, Mascaro JM Jr. Fatal Pseudomona pneumonia following rituximab therapy in a patient with epidermolysis bullosa acquisita. J Eur Acad Dermatol Venereol 2007; 21:1141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/47/4858/abstract/81\">",
"      Egan CA, Brown M, White JD, Yancey KB. Treatment of epidermolysis bullosa acquisita with the humanized anti-Tac mAb daclizumab. Clin Immunol 2001; 101:146.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/47/4858/abstract/82\">",
"      Furue M, Iwata M, Yoon HI, et al. Epidermolysis bullosa acquisita: clinical response to plasma exchange therapy and circulating anti-basement membrane zone antibody titer. J Am Acad Dermatol 1986; 14:873.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/47/4858/abstract/83\">",
"      Miller JL, Stricklin GP, Fine JD, et al. Remission of severe epidermolysis bullosa acquisita induced by extracorporeal photochemotherapy. Br J Dermatol 1995; 133:467.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/47/4858/abstract/84\">",
"      Gordon KB, Chan LS, Woodley DT. Treatment of refractory epidermolysis bullosa acquisita with extracorporeal photochemotherapy. Br J Dermatol 1997; 136:415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/47/4858/abstract/85\">",
"      Lehman JS, Camilleri MJ, Gibson LE. Epidermolysis bullosa acquisita: concise review and practical considerations. Int J Dermatol 2009; 48:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/47/4858/abstract/86\">",
"      Kim JH, Kim YH, Kim SC. Epidermolysis bullosa acquisita: a retrospective clinical analysis of 30 cases. Acta Derm Venereol 2011; 91:307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/47/4858/abstract/87\">",
"      Edwards S, Wakelin SH, Wojnarowska F, et al. Bullous pemphigoid and epidermolysis bullosa acquisita: presentation, prognosis, and immunopathology in 11 children. Pediatr Dermatol 1998; 15:184.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 15299 Version 2.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-122.72.76.133-9F69235DB9-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_47_4858=[""].join("\n");
var outline_f4_47_4858=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H306466519\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4624987\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H479445424\">",
"      TERMINOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H316625826\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H316622104\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H47068455\">",
"      Type VII collagen",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H47068462\">",
"      Pathogenic mechanism",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H316626301\">",
"      Genetic factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4624835\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H479445731\">",
"      Classical (noninflammatory) EBA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H479445739\">",
"      Inflammatory EBA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H978033474\">",
"      Children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H316626856\">",
"      ASSOCIATED DISORDERS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H316627112\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H306460340\">",
"      Initial evaluation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H306460423\">",
"      - Histopathology",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H306460508\">",
"      - Direct immunofluorescence",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1140904728\">",
"      - Immunofluorescence on basement membrane zone-split skin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1267771\">",
"      - Additional studies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H306466132\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H306466449\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H306467843\">",
"      General measures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H306466456\">",
"      Approach to treatment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H978032645\">",
"      - Colchicine",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H978032652\">",
"      - Dapsone",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H306466477\">",
"      Refractory disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H306466505\">",
"      Other therapies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H306466512\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H306466519\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DERM/15299\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DERM/15299|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?3/63/4086\" title=\"figure 1\">",
"      Epidermal basement membrane zone",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DERM/15299|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?21/36/22085\" title=\"picture 1A\">",
"      Epidermolysis bullosa acquisita",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?11/40/11909\" title=\"picture 1B\">",
"      Epidermolysis bullosa acquisita hand",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?16/37/16982\" title=\"picture 2\">",
"      Epidermolysis bullosa acquisita scarring",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?26/16/26885\" title=\"picture 3\">",
"      Bullous pemphigoid multiple lesions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?37/49/38674\" title=\"picture 4\">",
"      Mucous membrane pemphigoid palate",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?15/62/16359\" title=\"picture 5\">",
"      Linear IgA bullous dermatosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?5/47/5876\" title=\"picture 6\">",
"      Brunsting-Perry pemphigoid",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?4/58/5026\" title=\"picture 7\">",
"      Epidermolysis bullosa acquisita histopathology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?13/30/13794\" title=\"picture 8A\">",
"      Porphyria cutanea tarda",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?13/47/14066\" title=\"picture 8B\">",
"      Porphyria cutanea tarda 2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?21/21/21845\" title=\"picture 9\">",
"      Bullous lupus erythematosus chest",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?36/38/37475\" title=\"picture 10\">",
"      Dystrophic epidermolysis bullosa",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/54/14186?source=related_link\">",
"      Approach to the patient with cutaneous blisters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/63/27642?source=related_link\">",
"      Basic principles of wound management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/11/22714?source=related_link\">",
"      Clinical features and diagnosis of bullous pemphigoid and mucous membrane pemphigoid",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/21/39255?source=related_link\">",
"      Diagnosis of epidermolysis bullosa",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/28/28106?source=related_link\">",
"      Epidemiology, pathogenesis, and clinical features of epidermolysis bullosa",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/32/38409?source=related_link\">",
"      Intravenous immune globulin: Adverse effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/36/14922?source=related_link\">",
"      Linear IgA bullous dermatosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/63/3066?source=related_link\">",
"      Overview of the management of epidermolysis bullosa",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/50/28458?source=related_link\">",
"      Porphyria cutanea tarda and hepatoerythropoietic porphyria",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/40/21130?source=related_link\">",
"      Rituximab and other B cell targeted therapies for rheumatoid arthritis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f4_47_4859="Causes of lymphedema";
var content_f4_47_4859=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F64677&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F64677&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Causes of lymphedema",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Primary lymphedema",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Congenital",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Precox (adolescence)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Tarda (adulthood)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Secondary lymphedema",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Malignancy",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Recurrent cellulitis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Connective tissue disease",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Infection (filariasis)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Contact dermatitis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Lymphatic damage (surgery, radiation therapy, burns, etc)",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_47_4859=[""].join("\n");
var outline_f4_47_4859=null;
var title_f4_47_4860="Pretreatment for patients with prior RCM reactions";
var content_f4_47_4860=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F59096&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F59096&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Pretreatment for patients with previous adverse reactions to radiocontrast media",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Non-urgent pretreatment:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Glucocorticoid-preferred:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Adult: Oral prednisone 50 mg at 13, 7, and 1 hour prior to procedure.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Pediatric: Prednisone 0.5 to 0.7 mg/kg oral (maximum 50 mg per dose) at 13, 7, and 1 hour prior to procedure.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Glucocorticoid-alternate: (oral administration not possible)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Adult: IV methylprednisolone 40 mg at 13, 7, and 1 hour prior to procedure.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Pediatric: Methylprednisolone 0.5 mg/kg IV (maximum 40 mg per dose) at 13, 7, and 1 hour prior to procedure.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <strong>",
"         AND",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        H1 antihistamine:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Adult: Diphenhydramine 50 mg oral, IM, or IV 1 hour prior to procedure.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Pediatric: Diphenhydramine 1.25 mg/kg oral, IM, or IV (maximum 50 mg) 1 hour prior to procedure.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Emergency pretreatment:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Methylprednisolone 40 mg IV every 4 hours until contrast study required plus diphenhydramine 50 mg IV 1 hour prior to contrast injection (pediatric doses as above).*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Lower/iso-osmolar RCM should be recommended",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Emergency therapy for a recurrent hypersensitivity reaction should be available",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     RCM: radiocontrast media.",
"     <br/>",
"     * Glucocorticoids have not been shown to be effective when given less than 4 to 6 hours prior to contrast injection.",
"    </div>",
"    <div class=\"reference\">",
"     American College of Radiology, \"Manual on Contrast Media, Version 8.0\", &copy; 2012.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_47_4860=[""].join("\n");
var outline_f4_47_4860=null;
var title_f4_47_4861="Monitoring the HL survivor for long-term complications";
var content_f4_47_4861=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F85763&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F85763&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Monitoring the Hodgkin lymphoma (HL) survivor for long-term complications",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"2\">",
"        Cancer screening",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"2\">",
"        HL survivors should be advised of their increased risk of developing a malignancy following treatment, encouraged to participate in routine age-appropriate cancer surveillance, and to report any concerning symptoms to their physician.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Breast cancer",
"       </td>",
"       <td>",
"        Starting at age 40 years (or if chest irradiated, eight years after radiation or age 25, whichever is later):",
"        <ul>",
"         <li>",
"          Annual screening mammogram",
"         </li>",
"         <li>",
"          Consider annual breast MRI in addition to mammogram for women who received radiation to the chest between the age of 10 and 35 years",
"         </li>",
"         <li>",
"          Consider referral to high-risk breast clinic for discussion of chemoprevention",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Lung cancer",
"       </td>",
"       <td>",
"        <ul>",
"         <li>",
"          Consider annual low-dose spiral computed tomography scan starting five years after diagnosis for those with a significant smoking history",
"         </li>",
"         <li>",
"          Smoking cessation",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Skin cancer",
"       </td>",
"       <td>",
"        <ul>",
"         <li>",
"          Annual complete skin examination",
"         </li>",
"         <li>",
"          Sun safety practice",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Colon cancer",
"       </td>",
"       <td>",
"        <ul>",
"         <li>",
"          Begin colorectal cancer screening 10 years earlier than for the general population",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"2\">",
"        Cardiovascular health",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"2\">",
"        Screening and counseling techniques are similar to those used for other high risk populations. At a minimum, patients should be instructed not to ignore persistent troubling symptoms and to bring such symptoms to the attention of their physician without delay.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Cardiac disease",
"       </td>",
"       <td>",
"        <ul>",
"         <li>",
"          Referral to cardiologist for baseline evaluation after treatment",
"         </li>",
"         <li>",
"          Resting and stress echocardiogram (frequency depending on baseline findings and existence of other cardiac risk factors)",
"         </li>",
"         <li>",
"          Traditional risk factors should be minimized (eg, smoking, obesity, hyperlipidemia, hypertension)",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Non-coronary vascular disease",
"       </td>",
"       <td>",
"        <ul>",
"         <li>",
"          Annual examination for carotid bruits; obtain carotid ultrasound if suspicious clinical findings",
"         </li>",
"         <li>",
"          Traditional risk factors should be minimized (eg, smoking, obesity, hyperlipidemia, hypertension)",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"2\">",
"        Endocrine assessment",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Infertility",
"       </td>",
"       <td>",
"        <ul>",
"         <li>",
"          Referral to reproductive endocrinologist as needed",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Hypothyroidism",
"       </td>",
"       <td>",
"        <ul>",
"         <li>",
"          Annual thyroid examination and thyroid function tests (ie, TSH) for HL survivors whose treatment included radiation to the neck or mediastinum",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"2\">",
"        Neurologic and psychiatric evaluation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"2\">",
"        Annual evaluation should include a discussion of psychiatric health including an assessment of symptoms of depression.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_47_4861=[""].join("\n");
var outline_f4_47_4861=null;
var title_f4_47_4862="Mechanisms of drugs for angioedema";
var content_f4_47_4862=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F82805&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F82805&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 475px\">",
"   <div class=\"ttl\">",
"    Drug therapy for angioedema: Mechanisms of action",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 455px; height: 379px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The renin-angiotensin (AT)-bradykinin (BK) system and sites of drug action.",
"    <br>",
"     <font color=\"#ff0000\">",
"      Red",
"     </font>",
"     text: drugs.",
"     <br>",
"      <font color=\"#0000ff\">",
"       Blue",
"      </font>",
"      text: enzymes.",
"      <div class=\"footnotes\">",
"       ACE: angiotensin-converting enzyme; ARB: angiotensin II receptor blocker.",
"      </div>",
"      <div class=\"reference\">",
"       <p>",
"        Reproduced with permission from: Hurst M, Empson M. Oral angioedema secondary to ACE inhibitors, a frequently overlooked association: case report and review. N Z Med J 2006; 119:U1930. Copyright &copy; 2006 New Zealand Medical Association.",
"       </p>",
"      </div>",
"     </br>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_47_4862=[""].join("\n");
var outline_f4_47_4862=null;
var title_f4_47_4863="Mortality metoprolol HF";
var content_f4_47_4863=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F78949%7ECARD%2F76232&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F78949%7ECARD%2F76232&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Metoprolol reduces mortality in patients with heart failure",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 386px; height: 363px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The MERIT-HF trial randomly assigned 3991 patients with NYHA class II to IV heart failure who were treated with digoxin, angiotensin converting enzyme inhibitors, and digoxin to metoprolol CR/XL or placebo. Kaplan-Meier curves show a significant reduction in total mortality at 12 months with metoprolol (7.2 versus 11 percent for placebo, p = 0.006).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: The MERIT-HF Study Group, Lancet 1999; 353:2001.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Spironolactone reduces mortality in heart failure",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 387px; height: 346px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Kaplan-Meier analysis of survival among 1663 patients with advanced heart failure in the RALES trial shows that spironolactone reduces mortality by 30 percent (35 versus 46 percent for placebo, p &lt;0.001).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Pitt B, Zannad F, Remme WJ, et al. N Engl J Med 1999; 341:709.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_47_4863=[""].join("\n");
var outline_f4_47_4863=null;
